var images_info;if (!images_info) images_info =[]; images_info["85"]={"85471":{"type":"graphic_picture","displayName":"Buruli ulcer edematous lesion","title":"Edematous lesion of Buruli ulcer","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Edematous lesion of Buruli ulcer</div><div class=\"cntnt\"><img style=\"width:576px; height:218px;\" src=\"images/ID/85471_Buruli_ulcer_edemat_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Tjip van der Werf, MD, PhD.</div><div id=\"graphicVersion\">Graphic 85471 Version 1.0</div></div></div>"},"85510":{"type":"graphic_picture","displayName":"Nail psoriasis onycholysis","title":"Nail psoriasis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nail psoriasis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85510_Nail_psorias_onycholysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onycholysis with erythema of the nail bed and splinter hemorrhages in a patient with nail psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85510 Version 4.0</div></div></div>"},"85511":{"type":"graphic_picture","displayName":"Parakeratosis pustulosa","title":"Parakeratosis pustulosa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Parakeratosis pustulosa</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/85511_Parakeratosis_pustulosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85511 Version 3.0</div></div></div>"},"85512":{"type":"graphic_diagnosticimage","displayName":"TB enteritis - Barium enema","title":"Tuberculous enteritis – Barium enema","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Tuberculous enteritis&nbsp;– Barium enema</div><div class=\"cntnt\"><img style=\"width:573px; height:532px;\" src=\"images/RADIOL/85512_Barium_enema_TB_enteritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double contrast barium enema demonstrates ileocecal valve region. The cecum is fibrotic and contracted (arrow), the ileocecal valve is irregular, narrowed, gaping, and incompetent (small arrowhead), and the terminal ileum appears to empty directly into the ascending colon (Stierlin's sign; region of small arrowhead). Note the diffuse ulcerations in the ascending colon (large arrowheads) and the lymphoid follicles in the terminal ileum (triple arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg RL. An atlas of differential diagnosis, 4th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85512 Version 3.0</div></div></div>"},"85527":{"type":"graphic_table","displayName":"Major clinical manifestations of GD at presentation","title":"Major clinical manifestations of Gaucher disease (all types) at presentation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major clinical manifestations of Gaucher disease (all types) at presentation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical manifestation</td> <td class=\"subtitle1\">Frequency<br /> (percent at presentation)</td> </tr> <tr> <td>Splenomegaly</td> <td class=\"centered\">85</td> </tr> <tr> <td>Hepatomegaly</td> <td class=\"centered\">63</td> </tr> <tr> <td>Thrombocytopenia</td> <td class=\"centered\">68</td> </tr> <tr> <td>Anemia</td> <td class=\"centered\">34</td> </tr> <tr> <td>Bleeding</td> <td class=\"centered\">Common<br /> (percent not reported)</td> </tr> <tr> <td>Osteopenia</td> <td class=\"centered\">55</td> </tr> <tr> <td>Bone pain</td> <td class=\"centered\">33</td> </tr> <tr> <td>Pathologic fractures</td> <td class=\"centered\">7</td> </tr> <tr> <td>Bone crisis</td> <td class=\"centered\">7</td> </tr> <tr> <td>Growth retardation</td> <td class=\"centered\">36</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Charrow J, Andersson HC, Kaplan P, et al. The Gaucher Registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000; 160:2835.</div><div id=\"graphicVersion\">Graphic 85527 Version 2.0</div></div></div>"},"85528":{"type":"graphic_picture","displayName":"Trachyonychia - twenty nail dystrophy","title":"Trachyonychia (twenty nail dystrophy)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Trachyonychia (twenty nail dystrophy)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85528_Trachyon_twenty_nail_dyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85528 Version 3.0</div></div></div>"},"85529":{"type":"graphic_diagnosticimage","displayName":"Radiograph of pt with dialysis-related amyloidosis","title":"Radiograph of patient with dialysis-related amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of patient with dialysis-related amyloidosis</div><div class=\"cntnt\"><img style=\"width:366px; height:343px;\" src=\"images/NEPH/85529_Radio_pt_dial_amyloid.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Provided by Robert E Cronin, MD.</div><div id=\"graphicVersion\">Graphic 85529 Version 4.0</div></div></div>"},"85530":{"type":"graphic_diagnosticimage","displayName":"MRI cluster of breast cysts","title":"MRI cluster of breast cysts","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">MRI cluster of breast cysts</div><div class=\"cntnt\"><img style=\"width:582px; height:382px;\" src=\"images/RADIOL/85530_MRI_cluster_breast_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The T2 weighted MRI image of the breast (A) reveals hyperintense, small clustered cysts (arrow), and larger isolated cysts (double arrow). The cysts do not show enhancement on the T1-weighted fat saturated post contrast sequence (B).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 85530 Version 3.0</div></div></div>"},"85531":{"type":"graphic_diagnosticimage","displayName":"Breast MRI intraductal papilloma","title":"Breast MRI intraductal papilloma","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Breast MRI intraductal papilloma</div><div class=\"cntnt\"><img style=\"width:597px; height:285px;\" src=\"images/RADIOL/85531_Br_MRI_intraduct_papilloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T1-weighted precontrast image (A) demonstrates a dilated duct containing proteinaceous or hemorrhagic debris (arrow). Following IV contrast, an enhancing mass is seen contiguous to the dilated duct (B; arrowhead). This was biopsied under MR guidance and shown to represent an intraductal papilloma.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; IV: intravenous; MR: magnetic resonance.</div><div class=\"graphic_reference\">Courtesy of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 85531 Version 3.0</div></div></div>"},"85533":{"type":"graphic_figure","displayName":"Safety packing list","title":"Safety packing list","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Safety packing list</div><div class=\"cntnt\"><img style=\"width:542px; height:628px;\" src=\"images/PC/85533_Safety_packing_list.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* It is best not to use a card or phone that you shared with an abuser because he or she may be able to use them to find you.</div><div class=\"graphic_reference\">Reproduced from: US Department of Health and Human Services Office on Women's Health. Violence Against Women: Safety planning for abusive situations. Available at: <A style=\"FONT-STYLE: italic\" href=\"http://www.womenshealth.gov/\" target=_blank>http://www.womenshealth.gov</A>. (Accessed June 25, 2012).</div><div id=\"graphicVersion\">Graphic 85533 Version 1.0</div></div></div>"},"85541":{"type":"graphic_figure","displayName":"Single port laparosc set-up","title":"Laparoendoscopic single-site surgery: Multichannel ports and instruments","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoendoscopic single-site surgery: Multichannel ports and instruments</div><div class=\"cntnt\"><img style=\"width:360px; height:504px;\" src=\"images/OBGYN/85541_Single_port_laparosc_set.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laparoendoscopic single-site (single port) surgery ports and instruments.</div><div class=\"graphic_reference\">Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography &#169; 2012. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 85541 Version 1.0</div></div></div>"},"85543":{"type":"graphic_figure","displayName":"PAH prognosis","title":"Prognosis according to the REVEAL pulmonary arterial hypertension (PAH) risk score","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Prognosis according to the REVEAL pulmonary arterial hypertension (PAH) risk score</div><div class=\"cntnt\"><img style=\"width:576px; height:787px;\" src=\"images/PULM/85543_PAH_prognosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">REVEAL Registry PAH risk score calculator. Calculated risk scores can range from 0 (lowest risk) to 22 (highest risk). If N-terminal proBNP is available and BNP is not, listed cut points are replaced with &lt;300 pg/mL and &gt;1500 pg/mL.<br />For a given risk score, the one-year survival is the following: 1 to 7 (95 percent), 8 (92 percent), 9 (89 percent), 10 to 11 (72 percent), and &ge;12 (66 percent).</div><div class=\"graphic_footnotes\">PAH: pulmonary arterial hypertension; WHO: World Health Organization; APAH: associated pulmonary arterial hypertension; CTD: connective tissue disease; POPH: portopulmonary hypertension; FPAH: familial pulmonary arterial hypertension; NYHA: New York Heart Association; SBP: systolic blood pressure; HR: heart rate; BPM: beats per minute; BNP: brain natriuretic peptide; DLCO: diffusing capacity of lung for carbon monoxide; mRAP: mean right atrial pressure; PVR: pulmonary vascular resistance; REVEAL Registry: Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management.</div><div class=\"graphic_reference\">From: Benza RL, Gomber-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in Patients newly diagnosed with pulmonary arterial hypertension. Chest 2012; 141:354. Copyright &copy; 2012. Reproduced with permission from the American College of Chest Physicians.</div><div id=\"graphicVersion\">Graphic 85543 Version 10.0</div></div></div>"},"85544":{"type":"graphic_figure","displayName":"Transvaginal mesh kits second generation","title":"Examples of second-generation transvaginal mesh kits","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Examples of second-generation transvaginal mesh kits</div><div class=\"cntnt\"><img style=\"width:512px; height:399px;\" src=\"images/OBGYN/85544_Transvagmeshsecgen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of second-generation transvaginal mesh kits for surgical treatment of pelvic organ prolapse, Elevate (A-C) and Uphold (D).</div><div class=\"graphic_reference\">Panels A-C: Images Courtesy of American Medical Systems, Inc. Minnetonka, Minnesota USA. <br />Panel D: Image Courtesy of Boston Scientific Corporation. Opinions expressed are those of the author alone and not of Boston Scientific.</div><div id=\"graphicVersion\">Graphic 85544 Version 3.0</div></div></div>"},"85546":{"type":"graphic_figure","displayName":"Insertion-removal of contraceptive vaginal ring","title":"Insertion and removal of the contraceptive vaginal ring","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Insertion and removal of the contraceptive vaginal ring</div><div class=\"cntnt\"><img style=\"width:520px; height:697px;\" src=\"images/OBGYN/85546_Insertion-of-contraceptive-vaginal-ring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A and B illustrate insertion of the contraceptive vaginal ring. C shows removal.</div><div id=\"graphicVersion\">Graphic 85546 Version 1.0</div></div></div>"},"85548":{"type":"graphic_table","displayName":"Nail questionnaire","title":"Key questions for the patient with abnormal nails","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key questions for the patient with abnormal nails</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>What do you think is the cause of your nail problem?</td> </tr> <tr> <td>Were you born with this problem? If no, when did this problem begin?</td> </tr> <tr> <td>Which nails were affected first?</td> </tr> <tr> <td>Which nails are affected now?</td> </tr> <tr> <td>How has your nail condition progressed?</td> </tr> <tr> <td>Using general terms, describe your nails (hard, soft, brittle, etc).</td> </tr> <tr> <td>Have you ever traumatized any of the involved nails?</td> </tr> <tr> <td>Do you do anything to affect your nails or the tips of your fingers or toes?</td> </tr> <tr> <td>Do any of your hobbies affect or traumatize your nails (ie, tennis, jogging, basketball, racquetball, painting, playing the piano, etc)?</td> </tr> <tr> <td>What is your occupation?</td> </tr> <tr> <td>Have you done any of the following: Picked at your nails, bit or sucked on your nails, torn your nails off, worn tight or pointed-toe shoes, or pushed the cuticle back? If yes, when and how often?</td> </tr> <tr> <td>Have you ever had ingrown nails?</td> </tr> <tr> <td>Are your hands in water often?</td> </tr> <tr> <td>Do your nails ever come in contact with any chemicals or irritants such as strong soaps, detergents, hair color/straightening chemicals, or dyes? </td> </tr> <tr> <td>What nail cosmetics or conditioners do you use (ie, base coat, top coat, enamel, nail strengtheners, nail hardeners, cuticle treatment, gloss, nail conditioners, etc)?</td> </tr> <tr> <td>Do you go to a manicurist/pedicurist? How often? What do you usually have done to your nails?</td> </tr> <tr> <td>Have you ever had any of the following: Sculptured nails, false/artificial nails, gel nails, nail tips, nail wraps, acrylic nails, etc? If so, how often and when was the last time?</td> </tr> <tr> <td>What instruments do you use when caring for your nails?</td> </tr> <tr> <td>How do you use your nail care instruments?</td> </tr> <tr> <td>How often do you use your nail care instruments?</td> </tr> <tr> <td>Have you recently experienced swelling around the cuticles?</td> </tr> <tr> <td>What treatments have you tried for your nail problem? Please list all pills, topical treatments, and surgical treatments and the dates.</td> </tr> <tr> <td>Do you currently have, or have you ever had, any other skin or hair problems (ie, lichen planus, psoriasis, alopecia areata, ringworm, jock itch, athlete's foot, vaginal yeast infection or other yeast infection, etc)?</td> </tr> <tr> <td>Do you currently have, or have you ever had, any other medical problems (ie, diabetes mellitus, heart trouble, lung issues or difficulty breathing, kidney problems, thyroid problems, gastrointestinal disorders, lower extremity swelling, etc)?</td> </tr> <tr> <td>Is there any chance that you could be pregnant?</td> </tr> <tr> <td>What prescription and nonprescription medications have you taken during the last year? Please include vitamins and herbal supplements.</td> </tr> <tr> <td>Do you have any drug allergies?</td> </tr> <tr> <td>Does anyone in your family have any of the following: Nail problems, thyroid problems, diabetes, hair and skin problems (ie, psoriasis, lichen planus, fungus, etc)?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 85548 Version 2.0</div></div></div>"},"85551":{"type":"graphic_figure","displayName":"Median BMI percentiles in patients with cystic fibrosis","title":"Median BMI percentiles in patients with cystic fibrosis, 1992 through 2012","html":"<div class=\"graphic\"><div style=\"width: 649px\" class=\"figure\"><div class=\"ttl\">Median BMI percentiles in patients with cystic fibrosis, 1992 through 2012</div><div class=\"cntnt\"><img style=\"width:629px; height:285px;\" src=\"images/PEDS/85551_Mdn_BMI_prcnt_ptnt_cyst_fbr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this figure, the \"goal\" is defined as a body mass index (BMI) greater than the 50th percentile for age and gender, using the growth reference from the Centers for Disease Control (CDC).</div><div class=\"graphic_reference\">Reproduced with permission from: Cystic Fibrosis Foundation Patient Registry: 2012 Annual Data Report, Bethesda, MD. Copyright &copy; 2013 Cystic Fibrosis Foundation.</div><div id=\"graphicVersion\">Graphic 85551 Version 2.0</div></div></div>"},"85552":{"type":"graphic_figure","displayName":"FEV1 vs BMI percentile in children with cystic fibrosis","title":"FEV<SUB>1</SUB> versus BMI percentile in children with cystic fibrosis, 6 to 19 years of age","html":"<div class=\"graphic\"><div style=\"width: 768px\" class=\"figure\"><div class=\"ttl\">FEV<SUB>1</SUB> versus BMI percentile in children with cystic fibrosis, 6 to 19 years of age</div><div class=\"cntnt\"><img style=\"width:748px; height:326px;\" src=\"images/PEDS/85552_FEV1_BMI_prcntl_CF_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For children, nutritional goals are BMI percentile meeting or exceeding the 50th percentile for age and gender.</div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in one second; BMI: body mass index.</div><div class=\"graphic_reference\">Reproduced with permission from: Cystic Fibrosis Foundation Patient Registry: 2015 Annual Data Report, Bethesda, MD. Copyright &#169; 2016 Cystic Fibrosis Foundation.</div><div id=\"graphicVersion\">Graphic 85552 Version 4.0</div></div></div>"},"85553":{"type":"graphic_table","displayName":"Vitamin D recommendations for individuals with CF","title":"Recommendations for vitamin D intake and treatment for children and adults with cystic fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for vitamin D intake and treatment for children and adults with cystic fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Routine dosing* of vitamin D3 (units)</td> <td class=\"subtitle1\">Step 1<sup>&#182;</sup><br /> dose increases (units)</td> <td class=\"subtitle1\">Step 2<sup>&#916;</sup><br /> dose titration maximum (units)</td> <td class=\"subtitle1\">Step 3<sup>&#9674;</sup></td> </tr> <tr> <td><strong>0 to 12 months</strong></td> <td>400 to 500</td> <td>800 to 1000</td> <td>2000</td> <td>Refer</td> </tr> <tr> <td><strong>1 to 10 years</strong></td> <td>800 to 1000</td> <td>1600 to 3000</td> <td>4000</td> <td>Refer</td> </tr> <tr> <td><strong>11 to 18 years</strong></td> <td>800 to 2000</td> <td>1600 to 6000</td> <td>10,000</td> <td>Refer</td> </tr> <tr> <td><strong>Over 18 years</strong></td> <td>800 to 2000</td> <td>1600 to 6000</td> <td>10,000</td> <td>Refer</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Stepwise approach to vitamin D replacement and monitoring, as recommended by the&nbsp;CFF. Target serum 25-hydroxyvitamin D (25OHD) levels are at least 30 ng/mL (75 nmol/L). Serum 25OHD levels should be checked at least annually (preferably near the end of winter), and approximately three months after a change in vitamin D dose.</div><div class=\"graphic_footnotes\">CF: cystic fibrosis; CFF: Cystic Fibrosis Foundation.<br />* Routine dosing of vitamin D3 (cholecalciferol) is achieved with use of CF-specific multivitamins.<br />¶ Step 1: If serum 25OHD is less than 30 ng/mL (or &lt;75 nmol/L), with good adherence to supplements, increase to step 1 dose as shown.<br />Δ Step 2: If serum 25OHD is 10 to 20 ng/mL (or 25 to 50 nmol/L), with good adherence to supplements, or if unable to achieve a serum 25OHD level of at least 30 ng/mL after treatment with step&nbsp;1 doses, increase dose and titrate as needed, up to the maximum dose shown.<br /><FONT class=lozenge>◊</FONT> Step 3: If serum 25OHD is less than 10 ng/mL (or &lt;25 nmol/L), with good adherence to supplements, or if unable to achieve a serum 25OHD level of at least 30 ng/mL after treatment with step 2 doses, refer to a specialist with expertise in vitamin D therapy.</div><div class=\"graphic_reference\">Modified with permission from: Tangpricha V, Kelly A, Stephenson K, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: Evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab 2012; 97:1082. Copyright &copy; 2012 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 85553 Version 3.0</div></div></div>"},"85570":{"type":"graphic_algorithm","displayName":"Approach to gluten challenge","title":"Approach to gluten challenge","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Approach to gluten challenge</div><div class=\"cntnt\"><img style=\"width:593px; height:437px;\" src=\"images/GAST/85570_Approach_gluten_challenge.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An approach to gluten challenge for the diagnosis or exclusion of celiac disease in patients maintained on a gluten-free diet without prior definitive diagnostic testing.</div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.<br />* Tissue transglutaminase, endomysium, and/or deamidated gliadin peptide antibody serology.<br />&para; Normal or nondiagnostic histology in a patient with positive serology while maintaining a gluten-free diet requires gluten challenge and repeat biopsy for definitive diagnosis or exclusion of celiac disease.<br />&Delta; Those with positive celiac serology but a normal biopsy have potential celiac disease and should be evaluated and monitored further depending upon their clinical circumstances.<br /><span class=\"lozenge\">&loz;</span> In one study of subjects receiving a gluten challenge for 14 days, Marsh III histology was seen in 68 percent, positive celiac serology in 75 percent, and either Marsh III histology or positive serology in 90 percent. Thus, a two-week gluten challenge may yield false-negative results in 10 percent of patients. The added diagnostic sensitivity of extending the challenge to eight weeks is unknown.<br />&sect; Celiac serology antibody concentrations may continue to rise after a gluten challenge ends. In one study, positive tissue transglutaminase serology was seen in 25 percent of subjects and positive deamidated gliadin peptide serology in 30 percent at the end of a 14-day gluten challenge; 50 percent had at least one positive serology on day 14. Positivity rates rose to 55 percent and 45 percent, respectively, 14 days later, despite the fact that subjects had resumed a gluten-free diet; 75 percent had at least one positive serology on day 28, 14 days after the gluten challenge ended.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: American Journal of Gastroenterology. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: Diagnosis and management of celiac disease. Am J Gastroenterol 2013; 108:656. Copyright &copy; 2013. <a href=\"http://www.nature.com/ajg\" target=\"_blank\">www.nature.com/ajg</a>.</div><div id=\"graphicVersion\">Graphic 85570 Version 4.0</div></div></div>"},"85571":{"type":"graphic_figure","displayName":"Arcades and vasa recta of the small intestines","title":"Arcades and vasa recta of the small intestines","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Arcades and vasa recta of the small intestines</div><div class=\"cntnt\"><img style=\"width:561px; height:629px;\" src=\"images/SURG/85571_Arcades_vasa_recta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The superior mesenteric artery gives rise to the arcuate system that supplies the vasa recta of the small intestine. The arcades are simple and primary in the upper jejunum but increase in complexity in the more distal portions of the intestine. The vasa recta arise from the most peripheral arcades, and do not intercommunicate.</div><div id=\"graphicVersion\">Graphic 85571 Version 4.0</div></div></div>"},"85572":{"type":"graphic_table","displayName":"Dental anxiety scale revised","title":"Dental Anxiety Scale - Revised","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dental Anxiety Scale - Revised</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Item 1.</td> </tr> <tr> <td>If you had to go to the dentist tomorrow for a checkup, how would you feel about it?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol> <li>I would look forward to it as a reasonably enjoyable experience. </li> <li>I wouldn't care one way or the other. </li> <li>I would be a little uneasy about it. </li> <li>I would be afraid that it would be unpleasant and painful. </li> <li>I would be very frightened of what the dentist would do. </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Item 2.</td> </tr> <tr> <td>When you are waiting in the dentist's office for your turn in the chair, how do you feel?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol> <li>Relaxed. </li> <li>A little uneasy. </li> <li>Tense. </li> <li>Anxious. </li> <li>So anxious that I sometimes break out in a sweat or almost feel physically sick. </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Item 3.</td> </tr> <tr> <td>When you are in the dentist's chair waiting while the dentist gets the drill ready to begin working on your teeth, how do you feel?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol> <li>Relaxed. </li> <li>A little uneasy. </li> <li>Tense. </li> <li>Anxious. </li> <li>So anxious that I sometimes break out in a sweat or almost feel physically sick. </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Item 4.</td> </tr> <tr> <td>Imagine you are in the dentist's chair to have your teeth cleaned. While you are waiting and the dentist or hygienist is getting out the instruments which will be used to scrape your teeth around your gums, how do you feel?</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Relaxed. </li> <li>A little uneasy. </li> <li>Tense. </li> <li>Anxious. </li> <li>So anxious that I sometimes break out in a sweat or almost feel physically sick. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The scale is scored by summing the scores on the four items (range: 4 to 20). Scores of 13 to 14 indicate an anxious patient. Scores of 15 or higher indicate a highly anxious patient.</div><div class=\"graphic_reference\">Reprinted with permission from the Journal of Dental Hygiene. Ronis DL, Hansen CH, Antonakas CL. Equivalence of the original and revised dental anxiety scales. J Dent Hyg 1995; 69:270. Copyright &copy; 1995.</div><div id=\"graphicVersion\">Graphic 85572 Version 2.0</div></div></div>"},"85573":{"type":"graphic_table","displayName":"Claustrophobia miniscreen","title":"Claustrophobia miniscreen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Claustrophobia miniscreen</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Not at all anxious</td> <td class=\"subtitle1\">Slightly anxious</td> <td class=\"subtitle1\">Moderately anxious</td> <td class=\"subtitle1\">Very anxious</td> <td class=\"subtitle1\">Extremely anxious</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Restriction items</td> </tr> <tr> <td class=\"indent1\">1. Tied up with hands behind back for 15 minutes</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">2. Standing for 15 minutes in a straightjacket</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">3. Having your legs tied to an immovable chair</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Suffocation items</td> </tr> <tr> <td class=\"indent1\">1. Working under a sink for 15 minutes</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">2. Standing in an elevator on the ground floor with the doors closed</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">3. Lying on a bottom bunk bed</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Please indicate the degree to which you would feel anxious in each of the following situations by circling the most appropriate number.</div><div class=\"graphic_reference\">Nephrology, dialysis, transplantation, Claustrophobia and the magnetic resonance imaging procedure, Vol. 21, 1998, p. 255, McIsaac HK, Thordarson DS, Shafron R, et al, Copyright © 1998 Plenum Publishing Corporation. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 85573 Version 2.0</div></div></div>"},"85576":{"type":"graphic_picture","displayName":"Pyoderma gangrenosum - Ulcer PI","title":"Pyoderma gangrenosum sore","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Pyoderma gangrenosum sore</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/PI/85576_Pyoderma_gangrenos_ulcer_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pyoderma gangrenosum can form a large open sore. The edges can look purple.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85576 Version 4.0</div></div></div>"},"85578":{"type":"graphic_picture","displayName":"Nail anatomy","title":"Nail anatomy","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Nail anatomy</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/85578_Nail_anatomy_2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85578 Version 2.0</div></div></div>"},"85579":{"type":"graphic_picture","displayName":"Subungual onychomycosis","title":"Distal subungual onychomycosis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Distal subungual onychomycosis</div><div class=\"cntnt\"><img style=\"width:540px; height:504px;\" src=\"images/DERM/85579_Subungual_onychomycosis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85579 Version 2.0</div></div></div>"},"85580":{"type":"graphic_picture","displayName":"Blistering distal dactylitis","title":"Blistering distal dactylitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Blistering distal dactylitis</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/85580_Blist_distal_dacyt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85580 Version 3.0</div></div></div>"},"85581":{"type":"graphic_picture","displayName":"Blistering distal dactylitis 2","title":"Blistering distal dactylitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Blistering distal dactylitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85581_Blist_distal_dactyl_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85581 Version 4.0</div></div></div>"},"85582":{"type":"graphic_picture","displayName":"Blistering distal dactylitis 3","title":"Blistering distal dactylitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Blistering distal dactylitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85582_Blist_dist_dact_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85582 Version 3.0</div></div></div>"},"85584":{"type":"graphic_picture","displayName":"Pseudomonas nail","title":"Nail infection from <EM>Pseudomonas aeruginosa</EM> (green nail syndrome)","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Nail infection from <EM>Pseudomonas aeruginosa</EM> (green nail syndrome)</div><div class=\"cntnt\"><img style=\"width:523px; height:540px;\" src=\"images/DERM/85584_Pseudomonas_nail.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85584 Version 2.0</div></div></div>"},"85585":{"type":"graphic_picture","displayName":"Microcystic adnexal carcinoma perineural invasion","title":"Microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Microcystic adnexal carcinoma</div><div class=\"cntnt\"><img style=\"width:540px; height:357px;\" src=\"images/DERM/85585_Micro_adnex_carc_perineural.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perineural and intraneural invasion in microcystic adnexal carcinoma (center). Extensive perineural invasion is a hallmark of microcystic adnexal carcinoma. Invasion of muscle tissue is also present (bottom right).</div><div id=\"graphicVersion\">Graphic 85585 Version 1.0</div></div></div>"},"85586":{"type":"graphic_picture","displayName":"Microcystic adnexal carcinoma keratin cysts","title":"Microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Microcystic adnexal carcinoma</div><div class=\"cntnt\"><img style=\"width:540px; height:356px;\" src=\"images/DERM/85586_Micr_adn_carc_keratin_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Keratin-filled cysts are present in the superficial dermis. Nests and cords composed of tumor cells are also present in the dermis.</div><div id=\"graphicVersion\">Graphic 85586 Version 1.0</div></div></div>"},"85587":{"type":"graphic_picture","displayName":"Microcystic adnexal carcinoma tumor cells","title":"Microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Microcystic adnexal carcinoma</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/85587_Microcys_adnex_carcin_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nests and cords of tumor cells of microcystic adnexal carcinoma are present in the dermis. Note the lack of epidermal involvement.</div><div id=\"graphicVersion\">Graphic 85587 Version 1.0</div></div></div>"},"85588":{"type":"graphic_picture","displayName":"Microcystic adnexal carcinoma light microscopy","title":"Microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Microcystic adnexal carcinoma</div><div class=\"cntnt\"><img style=\"width:540px; height:358px;\" src=\"images/DERM/85588_Microcys_adnex_carcin_light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small aggregates of tumor cells are present within a hyalinized stroma.</div><div id=\"graphicVersion\">Graphic 85588 Version 1.0</div></div></div>"},"85589":{"type":"graphic_picture","displayName":"Microcystic adnexal carcinoma invading bone","title":"Microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Microcystic adnexal carcinoma</div><div class=\"cntnt\"><img style=\"width:576px; height:379px;\" src=\"images/DERM/85589_Micro_adnex_carcin_inv_bone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microcystic adnexal carcinoma can invade and destroy bone.</div><div id=\"graphicVersion\">Graphic 85589 Version 1.0</div></div></div>"},"85590":{"type":"graphic_picture","displayName":"Microcystic adnexal carcinoma CEA stain","title":"Microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Microcystic adnexal carcinoma</div><div class=\"cntnt\"><img style=\"width:576px; height:381px;\" src=\"images/DERM/85590_Microcys_adnexal_carcin_CEA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microcystic adnexal carcinoma staining positively for carcinoembryonic antigen (CEA).</div><div id=\"graphicVersion\">Graphic 85590 Version 2.0</div></div></div>"},"85593":{"type":"graphic_table","displayName":"AS susceptibility genes","title":"Contribution to heritability of ankylosing spondylitis of confirmed susceptibility genes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contribution to heritability of ankylosing spondylitis of confirmed susceptibility genes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene name or chromosomal region</td> <td class=\"subtitle1\">Most highly associated SNP</td> <td class=\"subtitle1\">Odds ratio</td> <td class=\"subtitle1\">Overall contribution to AS heritability (percent)</td> </tr> <tr> <td><em>HLA-B27</em></td> <td>rs4349859</td> <td>90.4</td> <td>23.3</td> </tr> <tr> <td><em>IL23R</em></td> <td>rs11209026</td> <td>1.90</td> <td>0.31</td> </tr> <tr> <td><em>LTBR-TNFRSF1A</em></td> <td>rs11616188</td> <td>1.38</td> <td>0.075</td> </tr> <tr> <td>2p15</td> <td>rs10865331</td> <td>1.36</td> <td>0.54</td> </tr> <tr> <td><em>ERAP1</em></td> <td>rs30187</td> <td>1.35</td> <td>0.34</td> </tr> <tr> <td><em>KIF21B</em></td> <td>rs2297909</td> <td>1.25</td> <td>0.25</td> </tr> <tr> <td>21q22</td> <td>rs378108</td> <td>1.25</td> <td>0.035</td> </tr> <tr> <td><em>TBKBP1</em></td> <td>rs8070463</td> <td>1.24</td> <td>0.054</td> </tr> <tr> <td><em>ANTXR2</em></td> <td>rs4389526</td> <td>1.21</td> <td>0.054</td> </tr> <tr> <td><em>PTGER4</em></td> <td>rs10440635</td> <td>1.20</td> <td>0.052</td> </tr> <tr> <td><em>RUNX3</em></td> <td>rs11249215</td> <td>1.19</td> <td>0.12</td> </tr> <tr> <td><em>IL12B</em></td> <td>rs6556416</td> <td>1.18</td> <td>0.11</td> </tr> <tr> <td><em>CARD9</em></td> <td>rs10781500</td> <td>1.18</td> <td>0.034</td> </tr> <tr class=\"divider_bottom\"> <td><em>IL1R2</em></td> <td>rs2310173</td> <td>1.18</td> <td>0.12</td> </tr> <tr> <td colspan=\"3\" align=\"right\"><strong>Total:</strong></td> <td><strong>25.39</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: The estimated heritability contribution of <EM>IL23R </EM>was increased to 0.35 in a 2013 publication<SUP>[1]</SUP>.</div><div class=\"graphic_footnotes\">SNP: single nucleotide polymorphism.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>International Genetics of Ankylosing Spondylitis Consortium (IGAS), Cortes A, Hadler J, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 2013; 45:730.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reprinted by permission from: Macmillan Publishers Ltd: Nature Reviews Rheumatology. Reveille JD. Genetics of spondyloarthritis - beyond the MHC. Nat Rev Rheumatol 2012; 8:296. Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 85593 Version 6.0</div></div></div>"},"85594":{"type":"graphic_picture","displayName":"Acquired ungual fibrokeratoma","title":"Acquired ungual fibrokeratoma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Acquired ungual fibrokeratoma</div><div class=\"cntnt\"><img style=\"width:540px; height:521px;\" src=\"images/DERM/85594_Acq_ungual_fibrokeratoma.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85594 Version 1.0</div></div></div>"},"85596":{"type":"graphic_picture","displayName":"CobraPLA","title":"CobraPLA","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">CobraPLA</div><div class=\"cntnt\"><img style=\"width:503px; height:504px;\" src=\"images/EM/85596_CobraPLA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This device consists of a ventilation tube with a flexible \"cobra\"-shaped head at its distal end and a ventilation port at its proximal end.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &#169; 2012 Pulmodyne, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85596 Version 2.0</div></div></div>"},"85597":{"type":"graphic_picture","displayName":"Subungual fibroma","title":"Subungual fibroma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Subungual fibroma</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/85597_Subungual_fibroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85597 Version 3.0</div></div></div>"},"85598":{"type":"graphic_picture","displayName":"Nail fibroma","title":"Nail fibroma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nail fibroma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85598_Nail_fibroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85598 Version 3.0</div></div></div>"},"85599":{"type":"graphic_picture","displayName":"Koenen tumor","title":"Periungual fibroma in tuberous sclerosis (Koenen tumor)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Periungual fibroma in tuberous sclerosis (Koenen tumor)</div><div class=\"cntnt\"><img style=\"width:504px; height:391px;\" src=\"images/DERM/85599_Koenen_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85599 Version 1.0</div></div></div>"},"85600":{"type":"graphic_picture","displayName":"Onychomatricoma","title":"Onychomatricoma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Onychomatricoma</div><div class=\"cntnt\"><img style=\"width:540px; height:477px;\" src=\"images/DERM/85600_Onychomatricoma.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85600 Version 2.0</div></div></div>"},"85601":{"type":"graphic_picture","displayName":"Onychomatricoma pincer nail","title":"Pincer nail deformity secondary to onychomatricoma","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Pincer nail deformity secondary to onychomatricoma</div><div class=\"cntnt\"><img style=\"width:463px; height:540px;\" src=\"images/DERM/85601_Onychomatricoma_pincer_nail.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85601 Version 1.0</div></div></div>"},"85602":{"type":"graphic_picture","displayName":"Digital myxoid cyst","title":"Digital myxoid (mucous) cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Digital myxoid (mucous) cyst</div><div class=\"cntnt\"><img style=\"width:395px; height:540px;\" src=\"images/DERM/85602_Digital_myxoid_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A&nbsp;clear, viscous, jelly-like material can be expressed from a myxoid cyst after puncturing it with a sterile needle.&nbsp;&nbsp;&nbsp;</div><div id=\"graphicVersion\">Graphic 85602 Version 4.0</div></div></div>"},"85603":{"type":"graphic_picture","displayName":"Digital myxoid cyst nail plate depression","title":"Longitudinal depression of the nail plate caused by a digital myxoid (mucous) cyst","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Longitudinal depression of the nail plate caused by a digital myxoid (mucous) cyst</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/85603_Dig_myxoid_cyst_nail_plate.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85603 Version 3.0</div></div></div>"},"85604":{"type":"graphic_picture","displayName":"Pyogenic granuloma periungual","title":"Periungual pyogenic granuloma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Periungual pyogenic granuloma</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/85604_Pyogenic_granul_periungual.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85604 Version 1.0</div></div></div>"},"85605":{"type":"graphic_picture","displayName":"Subungual exostosis","title":"Subungual exostosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subungual exostosis</div><div class=\"cntnt\"><img style=\"width:444px; height:515px;\" src=\"images/DERM/85605_Subungual_exostosis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85605 Version 2.0</div></div></div>"},"85606":{"type":"graphic_picture","displayName":"Squamous cell carcinoma nail","title":"Invasive squamous cell carcinoma of the nail","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Invasive squamous cell carcinoma of the nail</div><div class=\"cntnt\"><img style=\"width:540px; height:530px;\" src=\"images/DERM/85606_Squam_cell_carcinoma_nail.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85606 Version 2.0</div></div></div>"},"85607":{"type":"graphic_picture","displayName":"Squamous cell carcinoma erythronychia","title":"Longitudinal erythronychia secondary to squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal erythronychia secondary to squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:433px; height:540px;\" src=\"images/DERM/85607_Squam_cell_carcin_erythrony.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85607 Version 2.0</div></div></div>"},"85608":{"type":"graphic_picture","displayName":"Periungual Bowen","title":"Periungual Bowen disease (squamous cell carcinoma in situ)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Periungual Bowen disease (squamous cell carcinoma in situ)</div><div class=\"cntnt\"><img style=\"width:504px; height:354px;\" src=\"images/DERM/85608_Periungual_bowen.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85608 Version 2.0</div></div></div>"},"85609":{"type":"graphic_picture","displayName":"Periungual Bowen 2","title":"Periungual Bowen disease (squamous cell carcinoma in situ)","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Periungual Bowen disease (squamous cell carcinoma in situ)</div><div class=\"cntnt\"><img style=\"width:468px; height:504px;\" src=\"images/DERM/85609_Periungual_bowen_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85609 Version 2.0</div></div></div>"},"85611":{"type":"graphic_picture","displayName":"Melanoma nail dystrophy","title":"Nail melanoma in situ","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Nail melanoma in situ</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/85611_Melanoma_nail_dystrophy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85611 Version 2.0</div></div></div>"},"85612":{"type":"graphic_picture","displayName":"Nail melanoma Hutchinson sign","title":"Nail melanoma with the Hutchinson sign","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Nail melanoma with the Hutchinson sign</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/85612_Nail_melan_Hutchinson_sign.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85612 Version 1.0</div></div></div>"},"85613":{"type":"graphic_picture","displayName":"Longitudinal melanonychia pseudo Hutchinson","title":"Nail matrix nevus with pseudo-Hutchinson sign","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Nail matrix nevus with pseudo-Hutchinson sign</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/DERM/85613_Long_melanon_pseu_hutch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The darkly pigmented band is visible through the thin, transparent cuticle (\"pseudo-Hutchinson sign\") in this child with a congenital nail matrix nevus.</div><div id=\"graphicVersion\">Graphic 85613 Version 3.0</div></div></div>"},"85614":{"type":"graphic_table","displayName":"Pseudo-Hutchinson sign causes","title":"Conditions associated with pseudo-Hutchinson sign","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with pseudo-Hutchinson sign</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Benign</td> </tr> <tr> <td>Physiologic melanonychia in dark-skinned individuals</td> </tr> <tr> <td>Lauzier-Hunziker syndrome</td> </tr> <tr> <td>Peutz-Jeghers syndrome</td> </tr> <tr> <td>Radiation therapy</td> </tr> <tr> <td>Malnutrition</td> </tr> <tr> <td>Minocycline-induced dyschromia</td> </tr> <tr> <td>AIDS</td> </tr> <tr> <td>Congenital nevus</td> </tr> <tr> <td>Chronic trauma</td> </tr> <tr> <td>Subungual hematoma</td> </tr> <tr> <td>Illusory - pigmentation within the nail bed and/or matrix seen through the transparency of the cuticle</td> </tr> <tr> <td class=\"subtitle1_single\">Malignant nonmelanoma</td> </tr> <tr> <td>Bowen disease</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Andr&eacute; J, Lateur N. Pigmented nail disorders. Dermatol Clin 2006; 24:329.</div><div id=\"graphicVersion\">Graphic 85614 Version 2.0</div></div></div>"},"85615":{"type":"graphic_table","displayName":"Causes of longitudinal melanonychia 2","title":"Longitudinal melanonychia: Conditions associated with melanocytic activation and hyperplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Longitudinal melanonychia: Conditions associated with melanocytic activation and hyperplasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Melanocytic activation</td> </tr> <tr> <td class=\"subtitle2_left\">Physiologic causes</td> </tr> <tr> <td class=\"indent1\">Racial melanonychia</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"subtitle2_left\">Local and regional causes</td> </tr> <tr> <td class=\"indent1\">Repeated local trauma from poor footwear or overriding toes</td> </tr> <tr> <td class=\"indent1\">Onychotillomania</td> </tr> <tr> <td class=\"indent1\">Nail biting</td> </tr> <tr> <td class=\"indent1\">Occupational trauma</td> </tr> <tr> <td class=\"indent1\">Carpal tunnel syndrome</td> </tr> <tr> <td class=\"subtitle2_left\">Dermatologic causes</td> </tr> <tr> <td class=\"indent1\">Psoriasis</td> </tr> <tr> <td class=\"indent1\">Lichen planus</td> </tr> <tr> <td class=\"indent1\">Amyloidosis</td> </tr> <tr> <td class=\"indent1\">Chronic radiation dermatitis</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Localized scleroderma</td> </tr> <tr> <td class=\"indent1\">Chronic paronychia</td> </tr> <tr> <td class=\"indent1\">Onychomycosis</td> </tr> <tr> <td class=\"indent1\">Onychomatricoma</td> </tr> <tr> <td class=\"indent1\">Bowen disease</td> </tr> <tr> <td class=\"indent1\">Myxoid pseudocyst</td> </tr> <tr> <td class=\"indent1\">Basal cell carcinoma</td> </tr> <tr> <td class=\"indent1\">Subungual fibrous histiocytoma</td> </tr> <tr> <td class=\"indent1\">Verruca vulgaris</td> </tr> <tr> <td class=\"subtitle2_left\">Systemic causes</td> </tr> <tr> <td class=\"indent1\">Endocrine disorders (Addison disease, Cushing syndrome, Nelson syndrome, hyperthyroidism, acromegaly)</td> </tr> <tr> <td class=\"indent1\">Alcaptonuria</td> </tr> <tr> <td class=\"indent1\">Nutritional disorders </td> </tr> <tr> <td class=\"indent1\">Hemosiderosis</td> </tr> <tr> <td class=\"indent1\">Hyperbilirubinemia</td> </tr> <tr> <td class=\"indent1\">Porphyria</td> </tr> <tr> <td class=\"indent1\">Graft versus host disease (lichen planus-type changes accompanied by longitudinal melanonychia)</td> </tr> <tr> <td class=\"indent1\">AIDS</td> </tr> <tr> <td class=\"subtitle2_left\">Iatrogenic causes</td> </tr> <tr> <td class=\"indent1\">Phototherapy</td> </tr> <tr> <td class=\"indent1\">X-ray exposure</td> </tr> <tr> <td class=\"indent1\">Electron beam therapy</td> </tr> <tr> <td class=\"indent1\">Drug intake</td> </tr> <tr> <td class=\"subtitle2_left\">Syndromes</td> </tr> <tr> <td class=\"indent1\">Laugier-Hunziker syndrome</td> </tr> <tr> <td class=\"indent1\">Peutz-Jegher syndrome</td> </tr> <tr> <td class=\"indent1\">Touraine syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Melanocytic hyperplasia</td> </tr> <tr> <td class=\"subtitle2_left\">Lentigo</td> </tr> <tr> <td class=\"subtitle2_left\">Nevus</td> </tr> <tr> <td class=\"indent1\">Congenital nevi</td> </tr> <tr> <td class=\"indent1\">Acquired nevi</td> </tr> <tr> <td class=\"subtitle2_left\">Nail apparatus in-situ and invasive melanoma</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Andr&eacute; J, Lateur N. Pigmented nail disorders. Dermatol Clin 2006; 24:329.</div><div id=\"graphicVersion\">Graphic 85615 Version 2.0</div></div></div>"},"85616":{"type":"graphic_figure","displayName":"Anatomy of the nail apparatus","title":"Anatomy of the nail apparatus","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Anatomy of the nail apparatus</div><div class=\"cntnt\"><img style=\"width:491px; height:598px;\" src=\"images/DERM/85616_Nail-anatomy-3.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85616 Version 2.0</div></div></div>"},"85617":{"type":"graphic_figure","displayName":"Nail growth","title":"Nail growth: Direction of matrix cell differentiation and movement","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Nail growth: Direction of matrix cell differentiation and movement</div><div class=\"cntnt\"><img style=\"width:507px; height:461px;\" src=\"images/DERM/85617_Nail-growth.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85617 Version 2.0</div></div></div>"},"85618":{"type":"graphic_picture","displayName":"Nail melanoma dermoscopy","title":"Dermoscopy of nail melanoma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of nail melanoma</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/85618_Nail_melanoma_dermoscopy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85618 Version 1.0</div></div></div>"},"85619":{"type":"graphic_picture","displayName":"Lichen planus nail pterygium","title":"Lichen planus of the nails, permanent nail dystrophy leading to pterygium and anonychia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Lichen planus of the nails, permanent nail dystrophy leading to pterygium and anonychia</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/85619_Lichen_planus_nail_pterig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Permanent nail dystrophy resulting in anonychia and&nbsp;pterygium (extension and adherence of the proximal nail fold to the nail bed secondary to scarring of the nail matrix).</div><div id=\"graphicVersion\">Graphic 85619 Version 3.0</div></div></div>"},"85620":{"type":"graphic_picture","displayName":"Lichen planus trachyonychia","title":"Trachyonychia induced by lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Trachyonychia induced by lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85620_Lichen_plan_trachyonychia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85620 Version 4.0</div></div></div>"},"85621":{"type":"graphic_picture","displayName":"Nail lichen planus longitudinal fissuring","title":"Longitudinal nail fissuring caused by lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Longitudinal nail fissuring caused by lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85621_Nail_lich_plan_long_fis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85621 Version 5.0</div></div></div>"},"85628":{"type":"graphic_picture","displayName":"Secondary C-cell hyperplasia","title":"Secondary C-cell hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Secondary C-cell hyperplasia</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ENDO/85628_Second_C_cell_hyperplas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Secondary C-cell hyperplasia. The follicular boundaries are intact.</div><div class=\"graphic_reference\">Courtesy of Cornelis J Lips, MD, PhD.</div><div id=\"graphicVersion\">Graphic 85628 Version 2.0</div></div></div>"},"85629":{"type":"graphic_picture","displayName":"Pheo in adrenal gland","title":"Pheochromocytoma in an accessory adrenal gland: Surgical specimen","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pheochromocytoma in an accessory adrenal gland: Surgical specimen</div><div class=\"cntnt\"><img style=\"width:504px; height:454px;\" src=\"images/ENDO/85629_Peo_adrenal_gland.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multicentric pheochromocytoma of the left adrenal gland together with a small pheochromocytoma in an accessory adrenal gland 8 mm in diameter. The bean-shaped structure is the left semilunar celiac ganglion.</div><div class=\"graphic_reference\">Courtesy of Cornelis J Lips, MD, PhD.</div><div id=\"graphicVersion\">Graphic 85629 Version 2.0</div></div></div>"},"85631":{"type":"graphic_picture","displayName":"MSU crystals in a gout flare","title":"Monosodium urate crystals","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Monosodium urate crystals</div><div class=\"cntnt\"><img style=\"width:499px; height:335px;\" src=\"images/RHEUM/85631_MSUcrystalsacutegout.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Synovial fluid from a patient with acute gouty arthritis, when viewed with compensated polarized microscopy, reveals needle-shaped, birefringent crystals. These monosodium urate crystals are bright yellow when aligned with the axis of the compensator.</div><div class=\"graphic_reference\">Courtesy of H Ralph Schumacher, MD.</div><div id=\"graphicVersion\">Graphic 85631 Version 3.0</div></div></div>"},"85632":{"type":"graphic_picture","displayName":"CPPD crystal","title":"Calcium pyrophosphate crystals in synovial fluid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Calcium pyrophosphate crystals in synovial fluid</div><div class=\"cntnt\"><img style=\"width:504px; height:364px;\" src=\"images/RHEUM/85632_CPPD_crystal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An intracellular calcium pyrophosphate crystal is shown, which is pale blue when aligned with the axis of the compensator on polarized light microscopic examination. Note the rhomboid shape of the calcium-pyrophosphate crystal.</div><div class=\"graphic_reference\">Courtesy of H Ralph Schumacher, MD, and Tim Jansen, MD.</div><div id=\"graphicVersion\">Graphic 85632 Version 1.0</div></div></div>"},"85635":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of gout of the metacarpophalangeal joint","title":"Ultrasound of gout of the metacarpophalangeal joint","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ultrasound of&nbsp;gout of the metacarpophalangeal joint</div><div class=\"cntnt\"><img style=\"width:504px; height:200px;\" src=\"images/RHEUM/85635_Ultrasound_MCP_gout.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This longitudinal dorsal ultrasound scan of the second MCP joint shows thickened synovium with hyperechoic deposits (arrow) indicative of urate crystal deposition. The double contour sign at the metacarpal head (arrowhead) represents crystal deposition on the articular cartilage surface. The findings in this 56-year-old man with polyarthritis are consistent with gout.</div><div class=\"graphic_footnotes\">MCP: metacarpophalangeal.</div><div class=\"graphic_reference\">Copyright © 2017 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 85635 Version 17.0</div></div></div>"},"85644":{"type":"graphic_picture","displayName":"Sweet syndrome plaques on forehead","title":"Sweet syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sweet syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85644_Sweet_synd_plaque_forehd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, edematous plaques are present on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85644 Version 3.0</div></div></div>"},"85645":{"type":"graphic_picture","displayName":"Sweet syndrome plaques on arm","title":"Sweet syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sweet syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85645_Sweet_synd_plaque_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plaques with a pustular component are present on the upper extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85645 Version 3.0</div></div></div>"},"85646":{"type":"graphic_picture","displayName":"Sweet syndrome plaques on legs","title":"Sweet syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sweet syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85646_Sweet_synd_plaque_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory plaques are present on the extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85646 Version 3.0</div></div></div>"},"85647":{"type":"graphic_picture","displayName":"Sweet syndrome in childhood","title":"Sweet syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sweet syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85647_Sweet_synd_childhood.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple inflammatory plaques are present on the face and upper extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85647 Version 3.0</div></div></div>"},"85653":{"type":"graphic_table","displayName":"Classification of MTC","title":"Classification of MTC","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of MTC</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td>Hereditary&nbsp;MTC (germline<em> RET</em> mutation present)</td> <td>25%</td> </tr> <tr> <td class=\"sublist1_start\">Sporadic MTC (no germline <em>RET </em>mutation identified)</td> <td class=\"sublist_other_start\">75%</td> </tr> <tr> <td class=\"sublist1_start\">Sporadic MTC (no germline <em>RET </em>mutation identified)</td> <td class=\"sublist_other_start\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">&#8226; No somatic <em>RET </em>mutations found</td> <td>35%</td> </tr> <tr> <td class=\"indent1\">&#8226; Somatic <em>RET </em>mutations found</td> <td>65%</td> </tr> <tr> <td class=\"indent2\">- Exon 16, codon 918</td> <td>60%</td> </tr> <tr> <td class=\"indent2\">- Exon 11, codon 630, 634</td> <td>21%</td> </tr> <tr> <td class=\"indent2\">- Exon 10, codon 609, 620</td> <td>9%</td> </tr> <tr> <td class=\"indent2\">- Exon 15, codon 891</td> <td>9%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MTC: medullary thyroid cancer.</div><div id=\"graphicVersion\">Graphic 85653 Version 4.0</div></div></div>"},"85654":{"type":"graphic_table","displayName":"Mgmt acute infusion rxns - I","title":"Administration of infliximab: Guidelines for drug administration and the recognition and initial approach to infusion reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Administration of infliximab: Guidelines for drug administration and the recognition and initial approach to infusion reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Description</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\">Intravenous (IV) administration of infliximab, a tumor necrosis factor-alpha antagonist biologic therapy. Infliximab, a chimeric antibody, is administered in the form of periodic infusions (zero, two, and&nbsp;six weeks and, depending on the subsequent course of the disease, every&nbsp;six to&nbsp;eight weeks thereafter).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Contraindications to treatment</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Known hypersensitivity to the drug or murine proteins</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Active systemic or localized infections</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">History of infection related to a prosthesis that remains in place</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Infection with human immunodeficiency virus</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Active infection with hepatitis B virus</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Congestive heart failure classified on the New York Heart Association scale as functional class III/IV</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">History of demyelinating disease</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">History of cancer (except when there has been no recurrence in the preceding&nbsp;five years and in the case of patients with basal cell carcinoma)</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Patients with a history of systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Live vaccines should not be administered during treatment: yellow fever, German measles, measles, polio, or bacillus Calmette-Gu&#233;rin (BCG)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Patient care during IV administration of infliximab</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Objectives</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">To prepare patients physically and psychologically so that they undergo treatment in the best possible conditions</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">To ensure the patient's safety throughout the infusion process</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">To prevent treatment-related problems and ensure prompt detection of any such problems</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Preparation of the patient before the procedure</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Ascertain what the patient knows about the treatment they are about to receive</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Patients may eat breakfast or lunch and take their usual medication unless they have a history of moderate to severe infusion reactions (risk of vomiting)</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Make the patient comfortable in a seat or bed, depending on the preference and physical state of each individual</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Check whether the patient's chart includes an order for laboratory testing before the procedure, and whether premedication has been prescribed</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">Personnel: nursing staff</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Procedure</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Personnel: nursing staff</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">Materials:<br /> <ul> <li>Esmarch bandage </li> <li>Cotton </li> <li>Antiseptic </li> <li>20 G catheter </li> <li>Catheter securement dressings </li> <li>Pump </li> <li>Filter (pore size &#8804;1.2 microns) </li> <li>Infusion pump </li> <li>10 mL syringe </li> <li>21 G needle </li> <li>10 mL of double-distilled water for each vial of infliximab </li> <li>Infliximab (store in refrigerator at between 2 and 8&#176;C) </li> <li>250 mL of 0.9% saline solution </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Implement laboratory testing order, if any, prior to infusion. Administer prescribed premedication, if any. This can only be diphenhydramine or hydrocortisone.</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Check arterial blood pressure, heart rate, respiratory rate, and temperature at the start and after completion of infusion and whenever required by the patient's physical condition</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Preparation of the drug</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">Aseptic technique</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">Reconstitute each 100 mg vial of infliximab with 10 mm of double-distilled water</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">Aim the double-distilled water against the side of the vial to prevent foaming</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">Ensure that the contents of the vial have dissolved completely, but avoid prolonged and energetic movements</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">Allow the solution to stand for&nbsp;five minutes</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">The solution should be colorless to slightly yellowish and may contain translucent particles (protein)<br /> <ul> <li>The solution should not be administered if it is inappropriately colored or contains visible opaque particles </li> </ul> </td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">From the bottle of saline solution, withdraw a volume of saline equal to the volume of infliximab solution to be used in order to obtain a final volume of 250 mL and a concentration of between 0.4 and 4 mg/ml</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">The solution must be infused within&nbsp;three hours of reconstitution</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">Never dissolve infliximab in dextrose solution</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">Cannulate the venous line</td> </tr> <tr> <td class=\"sublist2\" colspan=\"3\">Administer the drug using a volumetric infusion pump<br /> <ul> <li>The first, second, third, and fourth infusions should be administered over&nbsp;two hours (125 mL/hour) </li> <li>Starting with the fifth infusion, the dose can be infused in&nbsp;one hour (250 mL/hour) </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Assess response to treatment; if the patient does not present any anomalous symptoms, he or she can be discharged and return to normal daily activity</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">Patients must be instructed to telephone their clinician or the nursing staff if they experience any reaction symptoms after the infusion</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Observations</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">Infusion time can be modified by the clinician responsible for the patient</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Description of problems related to the procedure and remedial action</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Acute infusion reactions</td> </tr> <tr> <td class=\"subtitle3\">Mild in the presence of</td> <td class=\"subtitle3\">Moderate in the presence of</td> <td class=\"subtitle3\">Severe in the presence of</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\"> <ul> <li>Headache </li> <li>Diaphoresis </li> <li>Throat irritation </li> <li>Lumbar pain </li> <li>Hyperemia </li> <li>Nausea </li> <li>Palpitations </li> <li>Itching </li> <li>Cutaneous eruption </li> <li>Flushing </li> <li>Vertigo </li> <li>Vomiting </li> </ul> </td> <td class=\"sublist1\">The same symptoms as mild reactions and <ul> <li>Dysphagia </li> <li>Hypotension or hypertension (&#177; 20 mmHg with respect to baseline) </li> <li>Chest pain or tightness </li> <li>Edema of the face, hands, or lips </li> <li>Suffocating sensation </li> <li>Hyperemia (accompanied by a sensation of heat or fever) </li> <li>Hyperthermia (&#60;39&#176;C) </li> <li>Palpitations, tachycardia </li> <li>Urticaria </li> </ul> </td> <td class=\"sublist1\">The same symptoms as moderate reactions and <ul> <li>Severe hypotension or hypertension (&#177; 40 mmHg with respect to baseline) </li> <li>Hyperthermia and chills (&#8805;39&#176;C) </li> <li>Swelling of the larynx or pharynx with stridor </li> <li>Dyspnea </li> <li>Severe bronchospasm </li> <li>Convulsive seizure </li> <li>Clinically significant chest pain </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Action to be taken:<br /> <ul> <li>Stop the infusion </li> <li>Monitor blood pressure, heart rate, respiratory rate, and temperature </li> <li>Notify the treating clinician </li> <li>If the reaction does not resolve, follow appropriate procedures for management of&nbsp;an acute reaction to infusion of infliximab </li> <li>If extravasation occurs, stop the infusion immediately, notify the treating clinician, attempt to aspirate the extravasated fluid with a 10 to 20 mL syringe, withdraw the IV line, mark the affected area, and follow the hospital's treatment protocol covering such events </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Important points</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">To ensure early detection of infusion reactions, monitor the patient's response to treatment</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">Ensure that the intravenous line is open</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Assessment indicators</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">The nursing record should include details of the results of vital signs monitoring before and after treatment</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">The nursing record should provide details of the assessment of tolerance to treatment, that is, the occurrence or absence of incidents</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Records</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">The following information&nbsp;should be recorded:<br /> <ul> <li>Vital signs </li> <li>The assessment and preparation of the patient prior to treatment </li> <li>Incidents (presence or absence) related to the procedure </li> <li>Assessment of the patient's condition after treatment </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Puig Sanz L, S&aacute;ez E, Lozano MJ, et al. [Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Espa&ntilde;ol de Psoriasis de la Academia Espa&ntilde;ola de Dermatolog&iacute;a y Venereolog&iacute;a ]. Actas Dermosifiliogr 2009; 100:103. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85654 Version 3.0</div></div></div>"},"85655":{"type":"graphic_algorithm","displayName":"Mgmt acute infusion rxns - II","title":"Procedure to be followed in the case of an acute reaction to infliximab infusion","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Procedure to be followed in the case of an acute reaction to infliximab infusion</div><div class=\"cntnt\"><img style=\"width:597px; height:556px;\" src=\"images/RHEUM/85655_Mgmt_act_infs_rxns_2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous.</div><div class=\"graphic_reference\">Original figure modified for this publication. Puig Sanz L, S&aacute;ez E, Lozano MJ, et al. (Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Espa&ntilde;ol de Psoriasis de la Academia Espa&ntilde;ola de Dermatolog&iacute;a y Venereolog&iacute;a ). Actas Dermosifiliogr 2009; 100:103. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85655 Version 3.0</div></div></div>"},"85656":{"type":"graphic_figure","displayName":"Suspicion Index tool for NPD-C","title":"Suspicion Index tool for Niemann-Pick disease type C","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Suspicion Index tool for Niemann-Pick disease type C</div><div class=\"cntnt\"><img style=\"width:611px; height:514px;\" src=\"images/NEURO/85656_Susp_index_NPD_C.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Symptoms are scored according to their relative association with positive Niemann-Pick disease type C (NPD-C) diagnosis. The combination of symptoms and the patient's family history together provide the prediction score.</div><div class=\"graphic_reference\">Reproduced with permission from: Wijburg FA, Sedel F, Pineda M, et al. Development of a suspicion index to aid diagnosis of Niemann-Pick disease type C. Neurology 2012; 78:1560. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85656 Version 4.0</div></div></div>"},"85669":{"type":"graphic_table","displayName":"Types of vasculitis PI","title":"Types of vasculitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of vasculitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of vasculitis</td> <td class=\"subtitle1\">Affected body part(s)</td> <td class=\"subtitle1\">People often affected</td> <td class=\"subtitle1\">Symptoms can include</td> </tr> <tr> <td>Takayasu arteritis</td> <td>Aorta (the main artery that gets blood from the heart) </td> <td>Women between 10 and 40. Not common in the United States.</td> <td>Pain and weakness in arms or legs, belly pain after eating</td> </tr> <tr> <td>Giant cell arteritis</td> <td>Aorta, arteries on face and head</td> <td>Older people and people with a condition called \"polymyalgia rheumatica\"</td> <td>Headache, pain in the jaw, trouble seeing clearly or seeing from 1 eye</td> </tr> <tr> <td>Polyarteritis nodosa</td> <td>Kidneys, skin, other body parts</td> <td>People with lupus, rheumatoid arthritis, hepatitis B or C, HIV (human immunodeficiency virus, the virus that causes AIDS), or a cancer called \"hairy cell leukemia\"</td> <td>Tiredness, weight loss, fever, red bumps or purple bumps on skin, numbness or tingling in hands or feet, belly pain</td> </tr> <tr> <td>Kawasaki disease</td> <td>Heart, other body parts</td> <td>Children under 5 years old</td> <td>Fever, swelling, and redness in areas with inflammation</td> </tr> <tr> <td>Primary central nervous system vasculitis</td> <td>Brain and spinal cord</td> <td>Middle-aged adults</td> <td>Headache, confusion, stroke</td> </tr> <tr> <td>Churg-Strauss vasculitis</td> <td>Lungs, nose and sinuses, skin, other body parts</td> <td>People with asthma</td> <td>Asthma, allergies, sores on the skin</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's)</td> <td>Nose, sinuses, lungs, kidneys</td> <td>Older adults</td> <td>Fever, joint pain, weight loss, runny or \"crusty\" nose, ear infections, cough, brown or dark urine</td> </tr> <tr> <td>Henoch-Sch&#246;nlein purpura</td> <td>Skin, kidneys</td> <td>Children between age 3 and 15, but can affect adults</td> <td>Belly and joint pain, skin rash, brown or dark urine</td> </tr> <tr> <td>Cryoglobulinemia</td> <td>Blood</td> <td>People infected with hepatitis C</td> <td>Red or purple skin bumps, tiredness, joint and muscle pain, swollen glands</td> </tr> <tr> <td>Hypersensitivity vasculitis</td> <td>Skin</td> <td>People taking medicines that cause a reaction</td> <td>Red or purple skin bumps or other rash</td> </tr> <tr> <td>Beh&#231;et's disease</td> <td>Mouth, skin, genitals, eyes, other body parts</td> <td>Adults age 20 to 40</td> <td>Sores in mouth or on skin or genitals, eye problems, joint pain and swelling</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Vasculitis is inflammation in the blood vessels. There are many different types that affect different parts of the body. Some types are more serious than others.</div><div id=\"graphicVersion\">Graphic 85669 Version 2.0</div></div></div>"},"85670":{"type":"graphic_table","displayName":"Caries risk assessment form for 0- to 3-year-olds","title":"Caries risk assessment form for 0- to 3-year-olds<SUP>[1,2]</SUP> (for nondental health care providers)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Caries risk assessment form for 0- to 3-year-olds<SUP>[1,2]</SUP> (for nondental health care providers)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"55%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text subtitle2\">Factors</td> <td class=\"highlight_red_text subtitle2\">High risk</td> <td class=\"highlight_yellow_text subtitle2\">Moderate risk</td> <td class=\"highlight_green_text subtitle2\">Protective</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"4\">Biological</td> </tr> <tr> <td class=\"indent1\">Mother/primary caregiver has active cavities</td> <td class=\"centered highlight_red_text\">Yes</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Parent/caregiver has low socioeconomic status</td> <td class=\"centered highlight_red_text\">Yes</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Child has &#62;3 between-meal sugar-containing snacks or beverages per day</td> <td class=\"centered highlight_red_text\">Yes</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Child is put to bed with a bottle containing natural or added sugar</td> <td class=\"centered highlight_red_text\">Yes</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Child has special health care needs</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered highlight_yellow_text\">Yes</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Child is a recent immigrant</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered highlight_yellow_text\">Yes</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Protective</td> </tr> <tr> <td class=\"indent1\">Child receives optimally fluoridated drinking water or fluoride supplements</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered highlight_green_text\">Yes</td> </tr> <tr> <td class=\"indent1\">Child has teeth brushed daily with fluoridated toothpaste</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered highlight_green_text\">Yes</td> </tr> <tr> <td class=\"indent1\">Child receives topical fluoride from health professional</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered highlight_green_text\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Child has dental home/regular dental care</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered highlight_green_text\">Yes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Clinical findings</td> </tr> <tr> <td class=\"indent1\">Child has white spot lesions or enamel defects</td> <td class=\"centered highlight_red_text\">Yes</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Child has visible cavities or fillings</td> <td class=\"centered highlight_red_text\">Yes</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Child has plaque on teeth</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered highlight_yellow_text\">Yes</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"4\">Circling those conditions that apply to a specific patient helps the health care worker and parent understand the factors that contribute to or protect from caries. Risk assessment categorization of low, moderate, or high is based on preponderance of factors for the individual. However, clinical judgment may justify the use of one factor (eg, frequent exposure to sugar-containing snacks or beverages, visible cavities) in determining overall risk.</td> </tr> <tr> <td colspan=\"4\"><strong>Overall assessment of the child's dental caries risk:</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><span class=\"primarybox_left\">&nbsp;</span> <strong>High</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Moderate</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><span class=\"primarybox_left\">&nbsp;</span> <strong>Low</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ramos-Gomez FJ, Crall J, Gansky SA, et al. Caries risk assessment appropriate for the age 1 visit (infants and toddlers). J Calif Dent Assoc 2007; 35:687.</li>&#xD;&#xA;    <li>American Dental Association Councils on Scientific Affairs and Dental Practice. Caries Risk Assessment Form (Ages 0-6). American Dental Association: Chicago, 2008.</li>&#xD;&#xA;</ol>&#xD;&#xA;Copyright &copy; 2013-14 by the American Academy of Pediatric Dentistry and reproduced with their permission.</div><div id=\"graphicVersion\">Graphic 85670 Version 3.0</div></div></div>"},"85671":{"type":"graphic_diagnosticimage","displayName":"CT-OctreoScan panc NET and liver mets","title":"CT/OctreoScan fusion demonstrating pancreatic neuroendocrine tumor (arrow) with radiotracer-avid liver metastases (arrowheads)","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">CT/OctreoScan fusion demonstrating pancreatic neuroendocrine tumor (arrow) with radiotracer-avid liver metastases (arrowheads)</div><div class=\"cntnt\"><img style=\"width:490px; height:385px;\" src=\"images/ONC/85671_CT_Oct_Sc_panc_NET_liv.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Dr. Jonathan R Strosberg.</div><div id=\"graphicVersion\">Graphic 85671 Version 3.0</div></div></div>"},"85672":{"type":"graphic_picture","displayName":"Melanoma subungual amelanotic","title":"Amelanotic subungual melanoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Amelanotic subungual melanoma</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/85672_Melanoma_subung_amelan.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85672 Version 4.0</div></div></div>"},"85673":{"type":"graphic_table","displayName":"Stimulants and antidepressants - palliative care","title":"Management of depression in adult palliative care patients: Pharmacologic therapy with stimulants and antidepressants*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of depression in adult palliative care patients: Pharmacologic therapy with stimulants and antidepressants*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Starting dose</td> <td class=\"subtitle1\">Suggested dose range</td> <td class=\"subtitle1\">Role</td> <td class=\"subtitle1\">Precautions<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Psychostimulants</td> </tr> <tr> <td class=\"indent1\">Methylphenidate (immediate release)</td> <td>2.5 mg orally each morning and noon</td> <td>5 to 10 mg orally each morning and noon</td> <td class=\"divider_bottom\" rowspan=\"3\">Applies to methylphenidate, dextroamphetamine and modafinil: Useful for treatment of depression in patients with life-expectancy of weeks to months, or requiring prompt relief of symptoms, including apathy, cognitive impairment, low energy, anorexia<sup>&#916;</sup>, hypersomnia. Counteracts opioid associated sedation. Onset of action 24 to 48 hours. Titrate dose upward as needed after one to two days.</td> <td class=\"divider_bottom\" rowspan=\"3\">Applies to methylphenidate, dextroamphetamine and modafinil: Insomnia, restlessness, agitation, palpitations, increased blood pressure, anorexia<sup>&#916;</sup>, tremor, dry mouth. Risk of cardiac decompensation in patients with heart disease. Give doses early in the day; some patients may need an additional half dose of methylphenidate in late afternoon.</td> </tr> <tr> <td class=\"indent1\">Dextroamphetamine</td> <td>5 mg each morning</td> <td>5 to 15 mg orally each morning and noon</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Modafinil</td> <td>100 mg each morning</td> <td>200 mg orally each morning</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Selective serotonin reuptake inhibitors (SSRIs)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Citalopram</td> <td>10 mg per day</td> <td>20 to 40 mg per day<sup>&#167;</sup></td> <td rowspan=\"2\">Applies to citalopram and escitalopram: Effective for anxiety, generally well-tolerated, non-sedating, low risk of sleep disturbance or sexual side effects. Comparatively few significant drug interactions.</td> <td>Applies to citalopram: Dose related risk of QT prolongation. Mild discontinuation symptoms may occur absent tapering.</td> </tr> <tr> <td class=\"indent1\">Escitalopram</td> <td>5 mg per day</td> <td>10 to 20 mg per day</td> <td>Applies to escitalopram: Mild discontinuation symptoms may occur absent tapering.</td> </tr> <tr> <td class=\"indent1\">Sertraline</td> <td>25 mg per day</td> <td>50 to 100 mg per day</td> <td>Non-sedating, low risk of insomnia, lacks significant cardiovascular effects.</td> <td>More frequent gastrointestinal symptoms including diarrhea. Variable oral bioavailability. Oral solution contains alcohol. Discontinuation symptoms may occur absent tapering.</td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> <td>10 mg per day</td> <td>20 to 40 mg per day</td> <td>Activating effect may be useful for treatment of depressed patients with low energy or hypersomnia. Tapering upon discontinuation is not needed due to long half-life.</td> <td>Prolonged half-life and active metabolites require weeks to reach steady-state, prolonging time needed to evaluate effect of dose adjustment and complicating wash-out and withdrawal. Less well tolerated than sertraline.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Paroxetine</td> <td>10 mg per day in evening</td> <td>20 to 40 mg per day</td> <td>Sedating; possibly useful for depressed or anxious patients with insomnia.</td> <td>Weakly anticholinergic. May cause constipation, dry mouth or drowsiness. Associated with more severe discontinuation symptoms in absence of tapering.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Serotonin norepinephrine reuptake inhibitors (SNRIs)</td> </tr> <tr> <td class=\"indent1\">Venlafaxine (extended release)</td> <td>37.5 mg per day</td> <td>75 to&nbsp;225 mg&nbsp;per day</td> <td>Activating effect may be useful for treatment of melancholic depressed patients with low energy or hypersomnia. Useful for patients with comorbid painful conditions such as diabetic neuropathy.</td> <td>Insomnia. May cause dose-dependent increases in blood pressure (primarily diastolic) and heart rate. Associated with more severe discontinuation symptoms in absence of tapering.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Duloxetine</td> <td>10 to 20 mg per day</td> <td>20 to 60 mg per day</td> <td>Useful for patients with comorbid painful conditions such as diabetic neuropathy, chemotherapy-induced neuropathy, or chronic pain. Mildly sedating. Low risk of insomnia.</td> <td>Significant drug interactions.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Atypical antidepressants</td> </tr> <tr> <td class=\"indent1\">Bupropion (sustained release)</td> <td>75 mg in morning initially then twice daily</td> <td>150 mg in morning and mid-afternoon (twice daily)</td> <td>Activating effect may be useful for treatment of depressed patients with low energy and apathy. Low risk of cognitive toxicity. Dopaminergic action may be advantageous for depressed patients with Parkinson disease.</td> <td>Avoid in seizure disorders and depressed patients with agitation. Dose-dependent increase in diastolic blood pressure. Insomnia, constipation, dry mouth, dizziness.</td> </tr> <tr> <td class=\"indent1\">Mirtazapine</td> <td>7.5 mg every evening</td> <td>15 to 60 mg every evening</td> <td>Sedating; useful for patients with insomnia or who may benefit from weight gain. Appetite stimulant and anti-nausea effects can be noted within days.</td> <td>Drowsiness, weight gain. Prolonged half-life and active metabolites. Risk of accumulation with renal and/or hepatic insufficiency.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trazodone</td> <td>12.5 to 25 mg taken 30 to 60 minutes before bedtime for hypnotic effect</td> <td>25 to 100 mg taken 30 to 60 minutes before bedtime for hypnotic effect</td> <td>Used in low doses as an adjunct to SSRI for treatment of insomnia.</td> <td>Sedation, orthostatic hypotension, nausea. Residual daytime sedation and cognitive impairment.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Tricyclic antidepressants (TCAs)</td> </tr> <tr> <td class=\"indent1\">Desipramine</td> <td>10 mg every morning</td> <td>25 to 150 mg every&nbsp;morning or in two divided doses</td> <td>Mild stimulant effects may be useful for depressed patients with low energy and hypersomnia who have not responded to first line antidepressants. Useful for patients with comorbid painful conditions such as diabetic neuropathy. Established therapeutic serum concentration 125 to 300 ng/mL.</td> <td rowspan=\"2\">Applies to desipramine and nortriptyline: Not well tolerated in palliative care patients due to anticholinergic effects including dry mouth, delirium, constipation, urinary retention or altered vision. May be fatal in overdose. Can cause arrhythmia or orthostatic hypotension. Significant drug interactions.</td> </tr> <tr> <td class=\"indent1\">Nortriptyline</td> <td>10 mg every evening</td> <td>10 to 100 mg every evening or in two divided doses</td> <td>Mildly sedating. Taken at bedtime for depressed patients with insomnia. May be useful for melancholic, anxious, depressed patients who have not responded to first line antidepressants. Useful for patients with comorbid painful conditions such as diabetic neuropathy. Established therapeutic serum concentration 50 to 150 ng/mL.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The onset of action for psychostimulants is generally faster than that for conventional antidepressants (&lt;24 hours versus 4 to 8 weeks).<br />&para; For additional information on specific side effects, refer to table on Side effects of antidepressant medications.<br />&Delta; Apathetic patients without appetite, who respond to stimulant medications, generally have an improvement in appetite.<br /><span class=\"lozenge\">&loz;</span> In general, SSRIs associated with few drug interactions; easy to titrate, minimal cardiac side effects.<br />&sect; Maximum recommended daily dose of citalopram is 20 mg for patients &gt;60 years of age, with significant hepatic insufficiency, or taking interacting medications that can increase citalopram levels.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kennedy G, Marcus P. Use of antidepressants in older patients with co-morbid medical conditions: guidance from studies of depression in somatic illness. Drugs Aging 2005; 22:273.</li>&#xD;&#xA;    <li>Irwin S, Block, S. Depression. In: Evidence-Based Practice of Palliative Medicine, Goldstein NE, Morrison RS (Eds), Saunders, Philadelphia. In press.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 85673 Version 2.0</div></div></div>"},"85682":{"type":"graphic_figure","displayName":"Calculation of frontal plane axis","title":"Calculation of frontal plane axis","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Calculation of frontal plane axis</div><div class=\"cntnt\"><img style=\"width:546px; height:472px;\" src=\"images/CARD/85682_Calc_front_plane_axis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If the QRS complex is positive in leads I and II, it falls between -30 and 90&deg; and is normal, as indicated by the yellow area. If the QRS complex is negative in I and positive in aVF, there is right axis deviation. If the QRS complex is positive in I and negative in II, there is left axis deviation. If the QRS complex is negative in I and aVF, there is extreme axis deviation.</div><div id=\"graphicVersion\">Graphic 85682 Version 1.0</div></div></div>"},"85684":{"type":"graphic_algorithm","displayName":"Approach to tachycardia ","title":"Approach to tachycardia ","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Approach to tachycardia </div><div class=\"cntnt\"><img style=\"width:525px; height:325px;\" src=\"images/CARD/85684_Approach_tachycardia.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85684 Version 2.0</div></div></div>"},"85685":{"type":"graphic_algorithm","displayName":"Approach to bradycardia","title":"Approach to bradycardia","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Approach to bradycardia</div><div class=\"cntnt\"><img style=\"width:524px; height:336px;\" src=\"images/CARD/85685_Approach_bradycardia.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85685 Version 2.0</div></div></div>"},"85688":{"type":"graphic_table","displayName":"Modified European Heart Rhythm Association symptom scale","title":"Modified European Heart Association symptom scale (modified from Wynn, et al)<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified European Heart Association symptom scale (modified from Wynn, et al)<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Modified EHRA score</td> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">None</td> <td>AF does not cause any symptoms</td> </tr> <tr> <td class=\"centered\">2a</td> <td class=\"centered\">Mild</td> <td>Normal daily activity not affected by symptoms related to AF*</td> </tr> <tr> <td class=\"centered\">2b</td> <td class=\"centered\">Moderate</td> <td>Normal daily activity not affected by symptoms related to AF, but patient troubled by symptoms*</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">Severe</td> <td>Normal daily activity affected by symptoms related to AF</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">Disabling</td> <td>Normal daily activity discontinued</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AF: atrial fibrillation; EHRA: European Heart Rhythm Association.<br />* EHRA class 2a and 2b can be differentiated by evaluating whether patients are functionally affected by their AF symptoms. AF-related symptoms are most commonly fatigue/tiredness and exertional shortness of breath, or less frequently palpitations and chest pain.<sup>[2-6]</sup></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Wynn GJ, Todd DM, Webber M, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace 2014;16:965.</li>&#xD;&#xA;    <li>​Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP, Boriani G. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2014; 35:3365.</li>&#xD;&#xA;    <li>Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events&mdash;European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6.​</li>&#xD;&#xA;    <li>Meinertz T, KirchW, Rosin L, Pittrow D, Willich SN, Kirchhof P, ATRIUM investigators. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol 2011; 100:897.</li>&#xD;&#xA;    <li>Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: Patient characteristics and initial management. Europace 2009; 11:423.</li>&#xD;&#xA;    <li>von Eisenhart Rothe AF, Goette A, Kirchhof P, et al. Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enroled in two large clinical trials. Europace 2014; 16:812.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18(11):1609-1678. By permission of Oxford University Press on behalf of the European Society of Cardiology. Copyright &copy; 2016 Oxford University Press. Available at: <a href=\"http://www.escardio.org/\" spellcheck=\"true\" target=\"_blank\">www.escardio.org/</a>.</div><div id=\"graphicVersion\">Graphic 85688 Version 13.0</div></div></div>"},"85698":{"type":"graphic_table","displayName":"Discussing contraception with adolescents","title":"Specific tips for counseling adolescents about contraception","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Specific tips for counseling adolescents about contraception</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Counseling</td> <td class=\"subtitle1\">Specific examples</td> <td class=\"subtitle1\">Tips</td> </tr> <tr class=\"divider_bottom\"> <td>Assessing pregnancy intention or ambivalence</td> <td> <ul> <li>\"What are your thoughts on pregnancy or delaying pregnancy?\" </li> <li>\"At present, in the next couple years, and long-term?\" </li> <li>\"If you were to be pregnant, would that be a good thing or a problem for you?\" </li> <li>\"Are you interested starting or continuing birth control?\" </li> </ul> </td> <td> <ul> <li>Avoid assuming all adolescents want to contracept </li> <li>Adherence failures may indicate ambivalence or an unstated desire to become pregnant </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Assessing birth control methods and options</td> <td> <ul> <li>\"What birth control do you use now?\" </li> <li>\"What kind of birth control does your partner use?\" </li> <li>\"What birth control have you tried or used in the past?\" </li> <li>\"What did you like or not like about that birth control method(s)?\" </li> <li>\"Was your method(s) easy to do or take?\" </li> </ul> </td> <td> <ul> <li>Don't forget to include boys and men in discussions about pregnancy planning and contraception </li> <li>Women who decline birth control or who are condom-only users should be offered Plan B and prenatal multivitamins (this includes young women who have sex with women) </li> <li>Consider long-acting reversible contraceptives (intrauterine devices and progestin implants) for superior effectiveness and ease of use </li> </ul> </td> </tr> <tr> <td>Assessing side effects, concerns, and next steps</td> <td> <ul> <li>\"Did you have any problems keeping up with your method?\" </li> <li>\"Did you have any side effects that made you concerned?\" </li> <li>\"If you want to try method X, we can always reassess how this is working for you in Y weeks or months.\" </li> </ul> </td> <td> <ul> <li>Thorough counseling and education about normal and abnormal side-effects up front may help patients continue on their method </li> <li>Encourage patients to call or return to clinic with questions or concerns, rather than just discontinuing a method </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 85698 Version 2.0</div></div></div>"},"85699":{"type":"graphic_table","displayName":"Discussing adolescent sexuality ","title":"Suggested examples of developmentally appropriate ways to discuss adolescent sexuality and screen, counsel, and prevent sexually transmitted infections*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested examples of developmentally appropriate ways to discuss adolescent sexuality and screen, counsel, and prevent sexually transmitted infections*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Developmental stage</td> </tr> <tr> <td class=\"subtitle2\">Issue</td> <td class=\"subtitle2\"> <p>Early adolescence</p> 10 to 14 years old</td> <td class=\"subtitle2\"> <p>Middle adolescence</p> 15 to 17 years old</td> <td class=\"subtitle2\"> <p>Late adolescence</p> &#8805;18 years old</td> </tr> <tr class=\"divider_bottom\"> <td>Puberty</td> <td> <p>\"Has your mom/dad talked to you about puberty and the way your body changes as you become a teenager?\"</p> <p>\"Do you have odor from your armpits and/or use deodorant now?\"</p> <p>\"Do you notice that your breasts/penis/testicles or balls are getting bigger?\"</p> <p>\"Have you experienced something coming out of your penis during the night? We call these nocturnal emissions and they are very normal.\"</p> <p>\"Most girls will get some discharge or fluid and mucous that comes out of the vagina, which is normal and related to hormones.\"</p> \"Do you have any concerns about the changes your body is starting to go through?\"</td> <td> <p>\"It looks as if your body is finishing/finished puberty, but that does not mean you have finished all the other tasks and growing of puberty.\"</p> <p>\"Do you have any concerns about your body?\"</p> \"Do you like your body or do you have strong feelings about any particular body parts?\"</td> <td> <p>\"You have completed puberty but still have additional brain, social, and emotional growth ahead.\"</p> <p>\"How do you feel about where you are in your development?\"</p> <p>\"Do you feel confident and competent to make health decisions?\"</p> <p>\"Do you have questions about the social and emotional development that occurs as you leave for school or a job?\"</p> \"As you get older we will start doing regular breast or chest examinations and/or cervical pap screenings to check for or prevent cancer.\" <p>&nbsp;</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Gender</td> <td>\"Most of us learn about being a girl or boy from early on. When you think about your brain and body, do you consider yourself a girl, a boy, somewhere in between? Are you happy and comfortable being a boy or girl, or do you have questions about your gender?\"</td> <td> <p>\"I ask all my patients when they come in for check-ups: 'Do you consider yourself a girl, boy, or somewhere in between? How do you describe your gender?'\" </p> \"There are lots of ways that people experience or express gender. I am open to discussing this or any questions about gender with you.\"</td> <td> <p>\"How do you identify, regarding gender? That is, do you feel or regard yourself as a woman, man, or something in between, or some other way?\"</p> \"Do you have any questions or concerns about your gender?\"</td> </tr> <tr class=\"divider_bottom\"> <td>Sexuality</td> <td> <p>\"Have you and your parent(s) talked about sex and how to make decisions about getting involved in a romantic or sexual relationship?\"</p> <p>\"What have you and your parent(s) talked about so far?\"</p> <p>\"If you were to have a crush or romantic feelings toward someone, would that someone be a girl, boy, both, or neither?\"</p> <p>\"Do you have someone that you like or that you would like to talk to or date?\"</p> <p>\"Do you have any questions about your sexuality?\"</p> </td> <td> <p>\"Are you attracted to girls, boys, or both?\"</p> <p>\"Who have you been romantically and sexually involved with in the past?\"</p> <p>\"Have you ever had sex?\" (See specific questions related to types of sex below.)</p> <p>\"Do you feel safe with your partner(s)?\"</p> <p>\"What do you do for sexually transmitted infection protection?\"</p> <p>\"What do you use for pregnancy prevention?\"</p> \"What do you know or what would you like to know about birth control options?\"</td> <td> <p>\"Are you attracted to women, men, or both?\"</p> <p>\"Who have you been romantically or sexually involved with in the past?\" </p> <p>\"How many sexual partners have you ever had? What types of sexual behaviors have you tried or are currently having?\"</p> \"Does sex feel good and satisfying for you and your partner? Do you have any concerns about orgasm, ejaculation, or your sexual function?\"</td> </tr> <tr class=\"divider_bottom\"> <td>Sexual behaviors</td> <td> <p>\"Do you have any questions about a common way some young people your age are sexually active, such as masturbation or touching yourself?\"</p> <p>\"What sorts of things have you been taught or heard about sex?\"</p> </td> <td>\"What kinds of sex have you had?<br /> <ul> <li>Kissing </li> <li>Petting or touching breasts </li> <li>Touching a penis to masturbate and make it cum </li> <li>Fingering or putting fingers in vagina or anus </li> <li>Putting your mouth on a penis or vagina </li> <li>Having someone put their mouth on your penis or vagina </li> <li>Putting your penis in a vagina or penis in an anus </li> <li>Having someone else put their penis in your anus?\" </li> </ul> </td> <td> <p>\"What kinds of sex and partners do you have?\"</p> <p>\"Some people feel uncomfortable talking about sex. I hope this can be a safe and comfortable place for you to talk about sex.\"</p> \"There is a variety of ways to be sexually active. Do you have any questions about different ways to be sexual or have sex?\"</td> </tr> <tr> <td>STI prevention</td> <td> <p>\"Do you have any questions about how to be safe in a sexual relationship?\"</p> <p>\"What have you heard about ways to protect yourself if you do have sex?\"</p> <p>\"Do you know about condoms? How we use them? How they can help prevent pregnancy and sexually transmitted infections?\"</p> <p>\"What do you know about sexually transmitted infections?\"</p> </td> <td> <p>\"What do you know about sexually transmitted infections?\"</p> <p>\"What do you know about how to protect yourself or a partner from sexually transmitted infections?\"</p> <p>\"Have you ever had: chlamydia, gonorrhea, genital warts, or herpes?\"</p> <p>\"Have you ever been tested for syphilis or HIV?\"</p> <p>\"What have your used or tried in order to prevent sexually transmitted infections?\"</p> <p>\"What has worked for you? What has not worked so well for you in the past?\"</p> \"Would you like testing for sexually transmitted infections today?\"</td> <td> <p>\"Are you currently having sex and/or in a relationship?\"</p> <p>\"Who do you have sex with?\"</p> <p>\"Have you and your partner discussed whether your relationship is monogamous or whether you both will also be having other sex partners?\"</p> <p>\"Are you feeling valued and respected in your relationship? Do you feel safe in your relationship?\"</p> <p>\"What would or could make your relationship better?\"</p> \"Until age 26, we recommend at least annual sexually transmitted infection testing; can we do this today?\"</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">STI: sexually transmitted infection; HIV: human immunodeficiency virus.<br />* This is not meant to be a comprehensive list, but to provide examples of the developmental differences among early, middle, and late adolescents. Questions related to dating violence are discussed in the topics on date rape.</div><div class=\"graphic_reference\">Courtesy of Michelle Forcier, MD, MPH, and Johanna Olson, MD.</div><div id=\"graphicVersion\">Graphic 85699 Version 3.0</div></div></div>"},"85700":{"type":"graphic_table","displayName":"Melanonychia drug induced","title":"Drugs inducing longitudinal melanonychia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs inducing longitudinal melanonychia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Chemotherapeuticals</td> <td class=\"subtitle1\">Others</td> </tr> <tr> <td class=\"centered\"> <p>Bleomycin sulfate</p> <p>Busulfan</p> <p>Cyclophosphamide</p> <p>Dacarbazine</p> <p>Daunorubicin hydrochloride</p> <p>Doxorubicin</p> <p>Etoposide</p> <p>5-fluorouracile</p> <p>Hydroxyurea</p> <p>Imatinib</p> <p>Melphalan hydrochloride</p> <p>Methotrexate</p> <p>Nitrogen mustard</p> <p>Nitrosourea</p> <p>Tegafur</p> </td> <td class=\"centered\"> <p>ACTH</p> <p>Amodiaquine</p> <p>Amorolfine</p> <p>Arsenic</p> <p>Chloroquine</p> <p>Clofazimine</p> <p>Clomipramine</p> <p>Cyclones</p> <p>Fluconazole</p> <p>Fluorides</p> <p>Gold salts</p> <p>Ibuprofen</p> <p>Ketoconazole</p> <p>Lamivudine</p> <p>Mepacrine</p> <p>Mercury</p> <p>MSH</p> <p>Minocycline</p> <p>PCB</p> <p>Phenytoin</p> <p>Phenothiazine</p> <p>Psoralen</p> <p>Roxithromycin</p> <p>Steroids</p> <p>Sulfonamide</p> <p>Thallium</p> <p>Timolol</p> <p>Zidovudine</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Andr&eacute; J, Lateur N. Pigmented nail disorders. Dermatol Clin 2006; 24:329. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85700 Version 1.0</div></div></div>"},"85701":{"type":"graphic_picture","displayName":"Melanonychia ethnic","title":"Ethnic melanonychia commonly seen in dark-skinned individuals","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ethnic melanonychia commonly seen in dark-skinned individuals</div><div class=\"cntnt\"><img style=\"width:347px; height:504px;\" src=\"images/DERM/85701_Melononychia_ethic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple longitudinal melanonychia bands are commonly seen in dark-skinned individuals.</div><div id=\"graphicVersion\">Graphic 85701 Version 2.0</div></div></div>"},"85702":{"type":"graphic_picture","displayName":"Melanonychia hydroxyurea","title":"Melanonychia caused by hydroxyurea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Melanonychia caused by hydroxyurea</div><div class=\"cntnt\"><img style=\"width:362px; height:504px;\" src=\"images/DERM/85702_Melanonychia_hydroxyurea.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85702 Version 1.0</div></div></div>"},"85703":{"type":"graphic_picture","displayName":"Lentigo nail","title":"Lentigo of the nail matrix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lentigo of the nail matrix</div><div class=\"cntnt\"><img style=\"width:360px; height:504px;\" src=\"images/DERM/85703_Lentigo_nail.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85703 Version 2.0</div></div></div>"},"85704":{"type":"graphic_picture","displayName":"Nail nevus child","title":"Nevus of the nail matrix in a child","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Nevus of the nail matrix in a child</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/DERM/85704_Nail_nevus_child.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85704 Version 1.0</div></div></div>"},"85705":{"type":"graphic_picture","displayName":"Onychomadesis","title":"Nail plate detachment from the matrix area (onychomadesis)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nail plate detachment from the matrix area (onychomadesis)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85705_Onychomadesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85705 Version 3.0</div></div></div>"},"85706":{"type":"graphic_picture","displayName":"Beau lines 2","title":"Transverse grooves of the nail plate (Beau lines)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Transverse grooves of the nail plate (Beau lines)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85706_Beau_lines_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85706 Version 3.0</div></div></div>"},"85707":{"type":"graphic_picture","displayName":"Median nail dystrophy","title":"Median nail dystrophy, also called median canaliform dystrophy of Heller","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Median nail dystrophy, also called median canaliform dystrophy of Heller</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/85707_Median_nail_dystrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85707 Version 3.0</div></div></div>"},"85708":{"type":"graphic_picture","displayName":"Onychorrhexis","title":"Longitudinal nail grooves with distal splits (onychorrhexis)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Longitudinal nail grooves with distal splits (onychorrhexis)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85708_Onychorrhexis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85708 Version 3.0</div></div></div>"},"85709":{"type":"graphic_picture","displayName":"Leukonychia","title":"Leukonychia (white patches or striae of the nail plate)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Leukonychia (white patches or striae of the nail plate)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85709_Leukonychia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85709 Version 4.0</div></div></div>"},"85710":{"type":"graphic_picture","displayName":"Longitudinal erythronychia melanoma in situ","title":"Longitudinal erythronychia secondary to melanoma in situ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal erythronychia secondary to melanoma in situ</div><div class=\"cntnt\"><img style=\"width:392px; height:504px;\" src=\"images/DERM/85710_Long_erythrony_melanoma.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85710 Version 1.0</div></div></div>"},"85711":{"type":"graphic_picture","displayName":"Lupus panniculitis facial lipoatrophy","title":"Lupus panniculitis (lupus profundus)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lupus panniculitis (lupus profundus)</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/DERM/85711_Lupus_pannic_fac_lipoatro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lipoatrophy is present on the face of this patient with lupus panniculitis.</div><div id=\"graphicVersion\">Graphic 85711 Version 1.0</div></div></div>"},"85712":{"type":"graphic_picture","displayName":"Lupus panniculitis on extremities","title":"Lupus panniculitis (lupus profundus)","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Lupus panniculitis (lupus profundus)</div><div class=\"cntnt\"><img style=\"width:550px; height:238px;\" src=\"images/DERM/85712_Lup_pan_extremities.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lipoatrophy, discoid lupus-like changes, and inflammatory nodules are present on the upper extremities in this patient with lupus panniculitis.</div><div id=\"graphicVersion\">Graphic 85712 Version 1.0</div></div></div>"},"85713":{"type":"graphic_picture","displayName":"Lipodermatosclerosis sclerotic changes","title":"Lipodermatosclerosis (sclerosing panniculitis)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lipodermatosclerosis (sclerosing panniculitis)</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/DERM/85713_Lipoderm_sclero_change.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sclerotic changes involving the lower leg in a patient with lipodermatosclerosis.</div><div id=\"graphicVersion\">Graphic 85713 Version 1.0</div></div></div>"},"85714":{"type":"graphic_table","displayName":"Clinical classification of panniculitis","title":"Clinical classification of panniculitis based upon etiology*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical classification of panniculitis based upon etiology*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infection and infestation</td> </tr> <tr> <td class=\"indent1\">Bacterial, mycobacterial, or fungal infections</td> </tr> <tr> <td class=\"indent1\">Parasites</td> </tr> <tr> <td class=\"indent1\">Arthropod bite</td> </tr> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> <tr> <td class=\"indent1\">Cold panniculitis (popsicle panniculitis, equestrian panniculitis, subcutaneous fat necrosis of the newborn, sclerema neonatorum)</td> </tr> <tr> <td class=\"indent1\">Blunt trauma</td> </tr> <tr> <td class=\"indent1\">Factitial panniculitis (iatrogenic, accidental, or intentional injections)</td> </tr> <tr> <td class=\"indent1\">Post-irradiation panniculitis</td> </tr> <tr> <td class=\"subtitle1_single\">Enzymatic destruction</td> </tr> <tr> <td class=\"indent1\">Pancreatic panniculitis</td> </tr> <tr> <td class=\"indent1\">Alpha-1 antitrypsin deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy</td> </tr> <tr> <td class=\"indent1\">Lymphoma</td> </tr> <tr> <td class=\"indent1\">Cytophagic histiocytic panniculitis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Leukemia cutis/metastases</td> </tr> <tr> <td class=\"subtitle1_single\">Deposition</td> </tr> <tr> <td class=\"indent1\">Gouty panniculitis</td> </tr> <tr> <td class=\"indent1\">Calciphylaxis</td> </tr> <tr> <td class=\"indent1\">Hyperoxaluria</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory</td> </tr> <tr> <td class=\"indent1\">Erythema nodosum</td> </tr> <tr> <td class=\"indent1\">Lipodermatosclerosis (sclerosing panniculitis)</td> </tr> <tr> <td class=\"indent1\">Erythema nodosum migrans/subacute nodular migratory panniculitis/chronic erythema nodosum<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Erythema induratum/nodular vasculitis</td> </tr> <tr> <td class=\"indent1\">Vasculitis (especially polyarteritis nodosa)</td> </tr> <tr> <td class=\"indent1\">Superficial migratory thrombophlebitis</td> </tr> <tr> <td class=\"indent1\">Post-steroid panniculitis</td> </tr> <tr> <td class=\"indent1\">Lupus panniculitis</td> </tr> <tr> <td class=\"indent1\">Panniculitis of dermatomyositis</td> </tr> <tr> <td class=\"indent1\">Connective tissue disease panniculitis</td> </tr> <tr> <td class=\"indent1\">Deep morphea</td> </tr> <tr> <td class=\"indent1\">Necrobiosis lipoidica diabeticorum</td> </tr> <tr> <td class=\"indent1\">Rheumatoid nodule</td> </tr> <tr> <td class=\"indent1\">Subcutaneous granuloma annulare</td> </tr> <tr> <td class=\"indent1\">Subcutaneous sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Erythema nodosum leprosum</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The list is not intended to be exhaustive. Some conditions may be multifocal in etiology, (eg, traumatic and inflammatory). In some conditions, the etiology is not definitively established.<br />¶ Cytophagic histiocytic panniculitis may not represent malignancy in all cases.<br />Δ There is not consensus about whether subacute nodular migratory panniculitis is a variant of chronic erythema nodosum or a separate entity.</div><div id=\"graphicVersion\">Graphic 85714 Version 3.0</div></div></div>"},"85715":{"type":"graphic_table","displayName":"Histological classification of panniculitis","title":"Classification of panniculitis based upon histology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of panniculitis based upon histology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Predominantly septal panniculitis, without vasculitis</td> </tr> <tr> <td>Erythema nodosum</td> </tr> <tr> <td>Erythema nodosum migrans/subacute nodular migratory panniculitis/chronic erythema nodosum</td> </tr> <tr> <td>Deep morphea</td> </tr> <tr> <td>Necrobiosis lipoidica diabeticorum</td> </tr> <tr> <td>Rheumatoid nodule</td> </tr> <tr> <td>Subcutaneous granuloma annulare</td> </tr> <tr> <td class=\"subtitle1_single\">Predominantly septal panniculitis, with vasculitis</td> </tr> <tr> <td>Polyarteritis nodosa</td> </tr> <tr> <td>Superficial migratory thrombophlebitis</td> </tr> <tr> <td class=\"subtitle1_single\">Predominantly lobular panniculitis, without vasculitis</td> </tr> <tr> <td>Infectious panniculitis</td> </tr> <tr> <td>Traumatic panniculitis (cold, injections, post-irradiation, blunt trauma)</td> </tr> <tr> <td>Enzymatic destruction (pancreatic panniculitis, alpha-1 antitrypsin deficiency*)</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td>Deposition (gout, calciphylaxis, hyperoxaluria)</td> </tr> <tr> <td>Lipodermatosclerosis/sclerosing panniculitis</td> </tr> <tr> <td>Lupus panniculitis</td> </tr> <tr> <td>Panniculitis of dermatomyositis</td> </tr> <tr> <td>Connective tissue disease panniculitis</td> </tr> <tr> <td>Post-steroid panniculitis</td> </tr> <tr> <td>Subcutaneous sarcoidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Predominantly lobular panniculitis with vasculitis</td> </tr> <tr> <td>Erythema induratum/nodular vasculitis</td> </tr> <tr> <td>Erythema nodosum leprosum</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Alpha-1 antitrypsin deficiency panniculitis has been variably described as predominantly septal and predominantly lobular.</div><div id=\"graphicVersion\">Graphic 85715 Version 1.0</div></div></div>"},"85716":{"type":"graphic_table","displayName":"Therapies for castration-resistant prostate cancer","title":"Therapies for castration-resistant prostate cancer (CRPC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapies for castration-resistant prostate cancer (CRPC)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Approach</td> <td class=\"subtitle1\">Indications</td> <td class=\"subtitle1\">Route, schedule</td> <td class=\"subtitle1\">Steroids</td> <td class=\"subtitle1\">Symptoms, disease burden</td> <td class=\"subtitle1\">Contraindications</td> <td class=\"subtitle1\">PSA response to treatment</td> <td class=\"subtitle1\">Median overall survival benefit for men with metastatic disease*</td> </tr> <tr> <td>Abiraterone</td> <td>Metastatic CRPC</td> <td>Oral, daily</td> <td>Required</td> <td class=\"centered\">&ndash;</td> <td>Severe liver dysfunction; hypokalemia; heart failure</td> <td>Yes</td> <td> <p>Post docetaxel: 4.6 months<sup>[1]</sup></p> Chemotherapy naive:&nbsp;4.4<sup> </sup>months<sup>[2]</sup></td> </tr> <tr> <td>Enzalutamide</td> <td>Metastatic CRPC</td> <td>Oral, daily</td> <td>Not required</td> <td class=\"centered\">&ndash;</td> <td>Seizures</td> <td>Yes</td> <td>4.8 months<sup>[3]</sup></td> </tr> <tr> <td>Apalutamide</td> <td>Non-metastatic CRPC</td> <td>Oral, daily</td> <td>Not required</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td>Yes</td> <td>Pending<sup>[4]</sup></td> </tr> <tr> <td>Sipuleucel-T</td> <td>Pre or post docetaxel</td> <td>IV, every 2 weeks x 3 doses</td> <td>Possibly contraindicated</td> <td>Asymptomatic or minimally symptomatic</td> <td>Steroids; narcotics for cancer-related pain; GM-CSF; liver metastases</td> <td>No</td> <td>4.1 months<sup>[5]</sup></td> </tr> <tr> <td>Docetaxel</td> <td>Metastatic CRPC<sup>&#182;</sup></td> <td>IV, every 3 weeks</td> <td>Required</td> <td class=\"centered\">&ndash;</td> <td>Moderate liver dysfunction; cytopenias</td> <td>Yes</td> <td>2.5 months<sup>[6]</sup></td> </tr> <tr> <td>Cabazitaxel</td> <td>Post docetaxel</td> <td>IV, every 3 weeks</td> <td>Required</td> <td class=\"centered\">&ndash;</td> <td>Moderate liver dysfunction; cytopenias</td> <td>Yes</td> <td>2.4 months<sup>[7]</sup></td> </tr> <tr> <td>Radium-223</td> <td>Symptomatic bone metastases with no known visceral metastases</td> <td>IV, every 4 weeks</td> <td>Not required</td> <td>Symptomatic bone metastases</td> <td>Visceral metastases</td> <td>Not reported</td> <td>3.6 months<sup>[8]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PSA: prostate-specific antigen; IV: intravenously; GM-CSF: granulocyte macrophage colony-stimulating factor.<br />* The therapeutic approaches have not been compared with each other in large randomized trials. Only enzalutamide and apalutamide&nbsp;have been evaluated in men whose only evidence of disseminated disease is an elevated or rising serum PSA.<br />¶&nbsp;Docetaxel is also indicated for castration-sensitive disease&nbsp;in combination with androgen deprivation therapy for metastatic prostate cancer.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983.</LI>&#xD;&#xA;<LI>Ryan CJ, Smith MR, Fizazi K,&nbsp;et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.&nbsp;Lancet Oncol&nbsp;2015; 16:152.</LI>&#xD;&#xA;<LI>Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187.</LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med 2018.</SPAN></LI>&#xD;&#xA;<LI>Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411.</LI>&#xD;&#xA;<LI>Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242.</LI>&#xD;&#xA;<LI>de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147.</LI>&#xD;&#xA;<LI>Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 30, 2012 (suppl; abst LBA4512).</LI></OL></div><div id=\"graphicVersion\">Graphic 85716 Version 22.0</div></div></div>"},"85717":{"type":"graphic_picture","displayName":"Half-and-half nails","title":"Half-and-half nails in chronic renal failure","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Half-and-half nails in chronic renal failure</div><div class=\"cntnt\"><img style=\"width:504px; height:387px;\" src=\"images/DERM/85717_Half_and_half_nails.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85717 Version 1.0</div></div></div>"},"85718":{"type":"graphic_picture","displayName":"Digital clubbing","title":"Digital clubbing","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Digital clubbing</div><div class=\"cntnt\"><img style=\"width:504px; height:322px;\" src=\"images/DERM/85718_Digital_clubbing.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85718 Version 1.0</div></div></div>"},"85722":{"type":"graphic_picture","displayName":"Contact dermatitis vulva","title":"Contact dermatitis of the vulva","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Contact dermatitis of the vulva</div><div class=\"cntnt\"><img style=\"width:504px; height:374px;\" src=\"images/DERM/85722_Contact_dermatitis_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Rodriguez MI, Leclair CM. Benign vulvar dermatoses. Obstet Gynecol Surv 2012; 67:55. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85722 Version 4.0</div></div></div>"},"85723":{"type":"graphic_picture","displayName":"Disciform erythrasma","title":"Disciform erythrasma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Disciform erythrasma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85723_Disciform_erythrasma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85723 Version 3.0</div></div></div>"},"85726":{"type":"graphic_picture","displayName":"Lichen sclerosus vulvar","title":"Vulvar lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Vulvar lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:504px; height:335px;\" src=\"images/DERM/85726_Lichen_sclerosus_vulvar.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Rodriguez MI, Leclair CM. Benign vulvar dermatoses. Obstet Gynecol Surv 2012; 67:55. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85726 Version 6.0</div></div></div>"},"85732":{"type":"graphic_picture","displayName":"Instruments nail surgery","title":"Instruments for nail surgery","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Instruments for nail surgery</div><div class=\"cntnt\"><img style=\"width:504px; height:382px;\" src=\"images/DERM/85732_Instruments_nail_surgery.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85732 Version 1.0</div></div></div>"},"85733":{"type":"graphic_picture","displayName":"Wing block 2","title":"Anesthesia of the nail apparatus by wing block","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Anesthesia of the nail apparatus by wing block</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85733_Wing_block_2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85733 Version 1.0</div></div></div>"},"85734":{"type":"graphic_picture","displayName":"Glove finger tourniquet","title":"Glove finger tourniquet","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Glove finger tourniquet</div><div class=\"cntnt\"><img style=\"width:504px; height:298px;\" src=\"images/DERM/85734_Glove_finger_tourniquet.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85734 Version 1.0</div></div></div>"},"85735":{"type":"graphic_picture","displayName":"Pinching tourniquet","title":"Pinching tourniquet","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pinching tourniquet</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85735_Pinching_tourniquet.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85735 Version 1.0</div></div></div>"},"85736":{"type":"graphic_picture","displayName":"Nail excision en bloc","title":"Margins for en bloc nail excision","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Margins for en bloc nail excision</div><div class=\"cntnt\"><img style=\"width:504px; height:350px;\" src=\"images/ENDO/85736_Nail_excision_en_bloc.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85736 Version 1.0</div></div></div>"},"85737":{"type":"graphic_picture","displayName":"Nail unit en bloc excision","title":"En bloc excision of the nail unit","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">En bloc excision of the nail unit</div><div class=\"cntnt\"><img style=\"width:480px; height:504px;\" src=\"images/DERM/85737_Nail_unit_en_bloc_excision.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85737 Version 1.0</div></div></div>"},"85738":{"type":"graphic_picture","displayName":"Nail unit excision defect","title":"Defect following en bloc excision of the nail unit","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Defect following en bloc excision of the nail unit</div><div class=\"cntnt\"><img style=\"width:470px; height:504px;\" src=\"images/DERM/85738_Nail_unit_excision_defect.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85738 Version 1.0</div></div></div>"},"85739":{"type":"graphic_picture","displayName":"Longitudinal erythronychia excision","title":"Fusiform longitudinal excision for longitudinal erythronychia","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Fusiform longitudinal excision for longitudinal erythronychia</div><div class=\"cntnt\"><img style=\"width:455px; height:515px;\" src=\"images/DERM/85739_Longit_erythr_excision.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Jellinek NJ. Longitudinal erythronychia: Suggestions for evaluation and management. J Am Acad Dermatol 2011; 64:167.e1. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85739 Version 1.0</div></div></div>"},"85740":{"type":"graphic_picture","displayName":"Onychomatricoma surgery","title":"Surgical excision of onychomatricoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Surgical excision of onychomatricoma</div><div class=\"cntnt\"><img style=\"width:504px; height:348px;\" src=\"images/DERM/85740_Onychomatricoma_removal.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85740 Version 1.0</div></div></div>"},"85741":{"type":"graphic_picture","displayName":"Glomus tumor surgery","title":"Surgical excision of glomus tumor","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Surgical excision of glomus tumor</div><div class=\"cntnt\"><img style=\"width:504px; height:434px;\" src=\"images/GAST/85741_Glomus_tumor_surgery.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85741 Version 1.0</div></div></div>"},"85742":{"type":"graphic_picture","displayName":"Pincer nail","title":"Pincer nail","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Pincer nail</div><div class=\"cntnt\"><img style=\"width:479px; height:504px;\" src=\"images/DERM/85742_Pincer_nail.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85742 Version 1.0</div></div></div>"},"85752":{"type":"graphic_algorithm","displayName":"Algorithm for vascular testing in asymptomatic PAD","title":"Algorithm for vascular testing in asymptomatic PAD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for vascular testing in asymptomatic PAD</div><div class=\"cntnt\"><img style=\"width:307px; height:251px;\" src=\"images/SURG/85752_Algo_vasc_test_asymp_PAD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with diabetes or end-stage renal disease may have falsely elevated ABIs as a result of arterial calcification. The toe-brachial index may be more accurate.</div><div class=\"graphic_footnotes\">ABI: ankle brachial index; PAD: peripheral artery disease.</div><div id=\"graphicVersion\">Graphic 85752 Version 2.0</div></div></div>"},"85753":{"type":"graphic_picture","displayName":"Pyogenic granuloma toe","title":"Pyogenic granuloma of the toe","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pyogenic granuloma of the toe</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/85753_Pyogenic_granuloma_toe.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85753 Version 1.0</div></div></div>"},"85754":{"type":"graphic_picture","displayName":"Pentax Airway Scope","title":"Pentax Airway Scope®","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Pentax Airway Scope&#174;</div><div class=\"cntnt\"><img style=\"width:576px; height:473px;\" src=\"images/EM/85754_Airway_scope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Pentax Airway Scope&#174; has a disposable L-shaped plastic blade with a video display integrated into the handle.</div><div class=\"graphic_reference\">Reproduced with permission from: PENTAX Medical Company. Copyright &copy; 2012. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85754 Version 1.0</div></div></div>"},"85755":{"type":"graphic_table","displayName":"Classification of osteochondritis dissecans","title":"Classification of osteochondritis dissecans","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of osteochondritis dissecans</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"5%\"></colgroup><colgroup span=\"3\" width=\"31%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Plain radiograph findings</td> <td class=\"subtitle1\">Magnetic resonance imaging findings</td> <td class=\"subtitle1\">Arthroscopic findings</td> </tr> <tr> <td class=\"centered\">I</td> <td>Depressed osteochondral fragment</td> <td>Articular cartilage thickening and low signal changes</td> <td>Irregular and softened articular cartilage with no fragment</td> </tr> <tr> <td class=\"centered\">II</td> <td>Osteochondral fragment attached by an osseous bridge</td> <td>Articular cartilage breached, low signal rim behind fragment representing fibrous attachment</td> <td>Articular cartilage breached with definable fragment that is not displaceable</td> </tr> <tr> <td class=\"centered\">III</td> <td>Detached, nondisplaced fragment</td> <td>Articular cartilage breached, high signal changes behind fragment indicating synovial fluid between fragment and subchondral bone</td> <td>Articular cartilage breached with definable fragment that is displaceable but attached by overlying articular cartilage</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Displaced fragment</td> <td>Loose foreign body</td> <td>Loose foreign body</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>DeLee JC, Drez Jr D, Miller MD. DeLee &amp; Drez's Orthopaedic Sports Medicine Principles and Practice, 2nd ed, Elsevier Science, Philadelphia 2003.</LI>&#xD;&#xA;<LI>Dipaola JD, Nelson DW, Colville MR. Characterizing osteochondral lesions by magnetic resonance imaging. Arthroscopy 1991; 7:101.</LI>&#xD;&#xA;<LI>Guhl JF. Arthroscopic treatment of osteochondritis dissecans. Clin Orthop Relat Res 1982; :65.</LI></OL></div><div id=\"graphicVersion\">Graphic 85755 Version 2.0</div></div></div>"},"85756":{"type":"graphic_table","displayName":"Stepwise diagnostic evaluation for cardiac sarcoidosis ","title":"Stepwise diagnostic evaluation for cardiac sarcoidosis ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stepwise diagnostic evaluation for cardiac sarcoidosis </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td rowspan=\"2\"> <p><strong>Step 1</strong></p> Initial evaluation for cardiac disease in all patients with sarcoidosis</td> <td>History and physical examination</td> <td>Findings may include dyspnea, dizziness, bradycardia, ventricular or atrial arrhythmia, although some patients are asymptomatic and have no physical findings</td> </tr> <tr> <td>Electrocardiogram</td> <td>Abnormal: heart block</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"> <p><strong>Step 2</strong></p> Initial noninvasive evaluation for patients with suspected cardiac disease</td> <td>Holter monitor</td> <td>Abnormal: &#62;100 extra ventricular beats</td> </tr> <tr> <td>Echocardiogram</td> <td>Abnormal: hypokinesia, aneurysmal dilatation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"> <p><strong>Step 3</strong></p> Additional noninvasive imaging in patients with suspected cardiac disease: CMR plus PET are suggested if available</td> <td>Cardiovascular magnetic resonance (CMR) imaging</td> <td>Useful in detecting granulomatous inflammation (more sensitive than gallium, thallium, or technetium scans)</td> </tr> <tr> <td>FDG PET</td> <td>Useful in assessing granulomas or ischemia (more sensitive than gallium, thallium, or technetium scans)</td> </tr> <tr> <td>Radionuclide (gallium, thallium, technetium sestamibi) scans</td> <td>Useful in assessing granulomas or ischemia</td> </tr> <tr class=\"divider_top\"> <td> <p><strong>Step 4</strong></p> In selected patients</td> <td>Coronary angiography</td> <td>Useful in excluding coronary artery disease when noninvasive testing reveals regional abnormalities which may be caused by either coronary disease or sarcoidosis</td> </tr> <tr class=\"divider_top\"> <td> <p><strong>Step 5</strong></p> In selected patients</td> <td>Endomyocardial biopsy</td> <td>Only if the patient has no histological confirmation from any other source</td> </tr> <tr class=\"divider_top\"> <td> <p><strong>Step 6</strong></p> In selected patients</td> <td>Electrophysiologic study</td> <td>In selected patients with high risk features (eg, abnormalities on CMR or PET imaging) who lack established indications for implantable-cardioverter defibrillator (ICD) placement</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted and expanded from: Schulte W, Kirsten D, Drent M, Costabel U. Cardiac involvement in sarcoidosis. Eur Respir Mon 2005; 32:130.</div><div id=\"graphicVersion\">Graphic 85756 Version 1.0</div></div></div>"},"85757":{"type":"graphic_table","displayName":"Causes of neonatal polycythemia","title":"Causes of neonatal polycythemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of neonatal polycythemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Erythrocyte transfusion (passive)</td> </tr> <tr> <td>Delayed clamping of the umbilical cord (eg, &#62;2 minutes after birth)</td> </tr> <tr> <td>Uncontrolled or precipitous delivery</td> </tr> <tr> <td>Intrapartum hypoxia</td> </tr> <tr> <td>Twin-to-twin transfusion (10 to 15 percent of monochorionic twins)</td> </tr> <tr> <td>Maternal-fetal transfusion (rare)</td> </tr> <tr> <td class=\"subtitle1_single\">Increased intrauterine erythropoiesis (active)</td> </tr> <tr> <td class=\"sublist1_start\">Placental insufficiency</td> </tr> <tr> <td class=\"sublist1\">Preeclampsia</td> </tr> <tr> <td class=\"sublist1\">Other hypertensive disorders</td> </tr> <tr> <td class=\"sublist1\">Other vascular disorders</td> </tr> <tr> <td class=\"sublist1_start\">Maternal hypoxemia due to cardiac or pulmonary disorders</td> </tr> <tr> <td class=\"sublist1\">Cardiac or pulmonary disorders</td> </tr> <tr> <td class=\"sublist1\">Drugs (eg, propranolol)</td> </tr> <tr> <td class=\"sublist1\">Smoking</td> </tr> <tr> <td class=\"sublist1\">High altitude</td> </tr> <tr> <td class=\"sublist1\">Post term delivery</td> </tr> <tr> <td class=\"sublist1_start\">Infant risk factors</td> </tr> <tr> <td class=\"sublist1\">Large for gestational age</td> </tr> <tr> <td class=\"sublist1\">Maternal diabetes mellitus</td> </tr> <tr> <td class=\"sublist1\">Beckwith-Wiedemann syndrome</td> </tr> <tr> <td class=\"sublist1\">Endocrine abnormalities (congenital adrenal hyperplasia, hypothyroidism, hyperthyroidism)</td> </tr> <tr> <td class=\"sublist1\">Chromosomal anomalies (trisomy 21, 18, and 13)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Joseph Garcia-Prats.</div><div id=\"graphicVersion\">Graphic 85757 Version 1.0</div></div></div>"},"85758":{"type":"graphic_algorithm","displayName":"Algorithm for management of neonatal polycythemia","title":"Algorithm for management of neonatal polycythemia","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of neonatal polycythemia</div><div class=\"cntnt\"><img style=\"width:592px; height:661px;\" src=\"images/PEDS/85758_Algo_mang_neonatal_polycyth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The management approaches outlined in this algorithm are based primarily upon expert opinion. There is insufficient evidence to fully assess the efficacy or safety of partial exchange transfusion (PET), or the clinical indications for this procedure.</div><div class=\"graphic_footnotes\">* Refer to table on Causes of neonatal polycythemia.<br />Δ Observation consists of: monitor intake, urine output, weight, blood glucose, and bilirubin; follow up blood glucose as indicated based on initial results; monitor for symptoms.<br /><FONT color=#0000ff><FONT class=lozenge>◊</FONT> Preferred pathways in the authors' institution.</FONT></div><div id=\"graphicVersion\">Graphic 85758 Version 4.0</div></div></div>"},"85759":{"type":"graphic_figure","displayName":"Osgood-Schlatter PI","title":"Painful and swollen area in Osgood-Schlatter disease","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Painful and swollen area in Osgood-Schlatter disease</div><div class=\"cntnt\"><img style=\"width:469px; height:645px;\" src=\"images/PI/85759_Osgood_Schlatter_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Osgood-Schlatter disease causes pain and sometimes swelling on the front of the knee, right below the knee cap. The medical term for this spot is the tibial tuberosity.</div><div id=\"graphicVersion\">Graphic 85759 Version 1.0</div></div></div>"},"85761":{"type":"graphic_figure","displayName":"Potassium label PI","title":"Potassium on food labels","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Potassium on food labels</div><div class=\"cntnt\"><img style=\"width:541px; height:550px;\" src=\"images/PI/85761_Potassium-label-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To figure out how much potassium you are eating, check the label to find out how much potassium is in 1 serving. If you are having more than 1 serving, multiply the amount of potassium by the number of servings you plan to eat. For instance, this whole can of soup has 2 servings. If you are going to eat the whole can, you should multiply 450 by 2. That means you will be having 900 milligrams (mg) of potassium.</div><div class=\"graphic_footnotes\">%: percent.</div><div id=\"graphicVersion\">Graphic 85761 Version 4.0</div></div></div>"},"85762":{"type":"graphic_picture","displayName":"Yellow nail syndrome","title":"Yellow nail syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Yellow nail syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:399px;\" src=\"images/DERM/85762_Yellow_nail_syndrome.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85762 Version 2.0</div></div></div>"},"85763":{"type":"graphic_table","displayName":"Monitoring the HL survivor for long-term complications","title":"Monitoring the Hodgkin lymphoma (HL) survivor for long-term complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring the Hodgkin lymphoma (HL) survivor for long-term complications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Cancer screening</td> </tr> <tr> <td colspan=\"2\">HL survivors should be advised of their increased risk of developing a malignancy following treatment, encouraged to participate in routine age-appropriate cancer surveillance, and to report any concerning symptoms to their physician.</td> </tr> <tr> <td class=\"indent1\">Breast cancer</td> <td>Starting at age 40 years (or if chest irradiated, eight years after radiation or age 25, whichever is later): <ul> <li>Annual screening mammogram </li> <li>Consider annual breast MRI in addition to mammogram for women who received radiation to the chest between the age of 10 and 35 years </li> <li>Consider referral to high-risk breast clinic for discussion of chemoprevention </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lung cancer</td> <td> <ul> <li>Consider annual low-dose spiral computed tomography scan starting five years after diagnosis for those with a significant smoking history </li> <li>Smoking cessation </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Skin cancer</td> <td> <ul> <li>Annual complete skin examination </li> <li>Sun safety practice </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Colon cancer</td> <td> <ul> <li>Begin colorectal cancer screening 10 years earlier than for the general population </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Cardiovascular health</td> </tr> <tr> <td colspan=\"2\">Screening and counseling techniques are similar to those used for other high risk populations. At a minimum, patients should be instructed not to ignore persistent troubling symptoms and to bring such symptoms to the attention of their physician without delay.</td> </tr> <tr> <td class=\"indent1\">Cardiac disease</td> <td> <ul> <li>Referral to cardiologist for baseline evaluation after treatment </li> <li>Resting and stress echocardiogram (frequency depending on baseline findings and existence of other cardiac risk factors) </li> <li>Traditional risk factors should be minimized (eg, smoking, obesity, hyperlipidemia, hypertension) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Non-coronary vascular disease</td> <td> <ul> <li>Annual examination for carotid bruits; obtain carotid ultrasound if suspicious clinical findings </li> <li>Traditional risk factors should be minimized (eg, smoking, obesity, hyperlipidemia, hypertension) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Endocrine assessment</td> </tr> <tr> <td class=\"indent1\">Infertility</td> <td> <ul> <li>Referral to reproductive endocrinologist as needed </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> <td> <ul> <li>Annual thyroid examination and thyroid function tests (ie, TSH) for HL survivors whose treatment included radiation to the neck or mediastinum </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Fasting glucose or hemoglobin A1c every two years in HL survivors whose treatment included radiation to the chest or abdomen</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Neurologic and psychiatric evaluation</td> </tr> <tr> <td colspan=\"2\">Annual evaluation should include a discussion of psychiatric health including an assessment of symptoms of depression.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 85763 Version 2.0</div></div></div>"},"85768":{"type":"graphic_diagnosticimage","displayName":"Osteochondritis dissecans of the knee","title":"Plain radiograph showing osteochondritis dissecans of the knee","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Plain radiograph showing osteochondritis dissecans of the knee</div><div class=\"cntnt\"><img style=\"width:513px; height:483px;\" src=\"images/EM/85768_Osteochon_diss_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteror-posterior radiograph of the right knee of a patient with an OCD lesion on the medial femoral condyle (A). The abnormality of the articular surface is difficult to visualize on this view. The tunnel view (B and C) clearly shows the lesion on the medial femoral condyle.</div><div class=\"graphic_footnotes\">OCD: osteochondritis dissecans.</div><div class=\"graphic_reference\">Reproduced with permission from: Robertson W, Kelly BT, Green DW. Osteochondritis dissecans of the knee in children. Curr Opin Pediatr 2003; 15:38. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85768 Version 5.0</div></div></div>"},"85769":{"type":"graphic_diagnosticimage","displayName":"Osteochondritis dissecans of the elbow","title":"Osteochondritis dissecans of the elbow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteochondritis dissecans of the elbow</div><div class=\"cntnt\"><img style=\"width:227px; height:427px;\" src=\"images/EM/85769_Osteoch_dissecans_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal radiograph demonstrates lucency with surrounding sclerosis (arrow) in the capitellum in keeping with grade 4 osteochondritis dissecans (OCD).</div><div class=\"graphic_reference\">Reproduced from: Kotnis NA, Chiavaras MM, Harish S. Lateral epicondylitis and beyond: imaging of lateral elbow pain with clinical-radiologic correlation. Skeletal Radiol 2012; 41:369; with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 85769 Version 4.0</div></div></div>"},"85770":{"type":"graphic_diagnosticimage","displayName":"Osteochondritis dissecans of the ankle - medial talus","title":"Osteochondritis dissecans of the ankle (medial talus)","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Osteochondritis dissecans of the ankle (medial talus)</div><div class=\"cntnt\"><img style=\"width:511px; height:494px;\" src=\"images/EM/85770_Osteo_diss_ankle_mt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Irregularity of the medial aspect of the talar dome with surrounding sclerosis in an 11-year-old girl indicating juvenile osteochondritis dissecans.</div><div class=\"graphic_reference\">Reproduced with permission from: Perumal V, Wall E, Babekir N. Juvenile osteochondritis dissecans of the talus. J Pediatr Orthop 2007; 27:821. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85770 Version 4.0</div></div></div>"},"85771":{"type":"graphic_table","displayName":"Amyloid mutations","title":"Mutations/polymorphisms that have been associated with heritable and acquired forms of amyloidosis, 2016","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mutations/polymorphisms that have been associated with heritable and acquired forms of amyloidosis, 2016</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Subunit proteins</td> </tr> <tr> <td class=\"subtitle2\">Subunit proteins</td> <td class=\"subtitle2\">Number of mutations shown</td> </tr> <tr> <td>Transthyretin (TTR)</td> <td class=\"centered\">&#62;130</td> </tr> <tr> <td>Prion protein (PrP)</td> <td class=\"centered\">&#62;30</td> </tr> <tr> <td>Alzheimer precursor protein (APP)</td> <td class=\"centered\">52</td> </tr> <tr> <td>Bri2</td> <td class=\"centered\">2</td> </tr> <tr> <td>Lysozyme (Lys)</td> <td class=\"centered\">8</td> </tr> <tr> <td>Apolipoprotein AI (ApoAI)</td> <td class=\"centered\">20</td> </tr> <tr> <td>Apolipoprotein AII (ApoAII)</td> <td class=\"centered\">5</td> </tr> <tr> <td>Apolipoprotein CII (ApoCII)</td> <td class=\"centered\">1</td> </tr> <tr> <td>Apolipoprotein CIII (ApoCIII)</td> <td class=\"centered\">1</td> </tr> <tr> <td>Fibrinogen A-alpha</td> <td class=\"centered\">13</td> </tr> <tr> <td>Gelsolin</td> <td class=\"centered\">4</td> </tr> <tr> <td>Cystatin C</td> <td class=\"centered\">1</td> </tr> <tr> <td>Keratoepithelin/TGF1B1</td> <td class=\"centered\">&#62;40</td> </tr> <tr> <td>Beta-2 microglobulin</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td>Tumor-associated Ca signal transducer 2</td> <td class=\"centered\">21</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Polymorphisms</td> </tr> <tr> <td class=\"subtitle2\">Polymorphisms</td> <td class=\"subtitle2\">Number of mutations shown</td> </tr> <tr> <td>SAA1/SAA2</td> <td class=\"centered\">5/2</td> </tr> <tr class=\"divider_bottom\"> <td>Apo E4/E2</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"subtitle2\">Other</td> <td class=\"subtitle2\">Number of mutations shown</td> </tr> <tr> <td>Pyrin (MEFV)</td> <td class=\"centered\">174</td> </tr> <tr> <td>Cryopyrin (CIAS1)</td> <td class=\"centered\">145</td> </tr> <tr> <td>TRAPS (TNFR1)</td> <td class=\"centered\">99</td> </tr> <tr> <td>Mevalonate kinase (MVK)</td> <td class=\"centered\">&#62;75</td> </tr> <tr> <td>Presenilin-1 (PS-1)/presenilin-2 (PS-2)</td> <td class=\"centered\">215/15</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data obtained from&nbsp;resources&nbsp;listing&nbsp;mutations associated with systemic amyloidosis (<A style=\"FONT-STYLE: italic\" href=\"http://www.amyloidosismutations.com/\" target=_blank>www.amyloidosismutations.com</A>), autoinflammatory diseases (<A style=\"FONT-STYLE: italic\" href=\"http://fmf.igh.cnrs.fr/ISSAID/infevers\" target=_blank>http://fmf.igh.cnrs.fr/ISSAID/infevers</A>), and Alzheimers and related neurodegenerative disorders (<A style=\"FONT-STYLE: italic\" href=\"http://www.molgen.ua.ac.be/ADMutations\" target=_blank>www.molgen.ua.ac.be/ADMutations</A>).</div><div class=\"graphic_reference\">Courtesy of Peter D Gorevic, MD.</div><div id=\"graphicVersion\">Graphic 85771 Version 2.0</div></div></div>"},"85773":{"type":"graphic_picture","displayName":"Pityriasis lichenoides et varioliformis acuta on thigh","title":"Pityriasis lichenoides et varioliformis acuta","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pityriasis lichenoides et varioliformis acuta</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/85773_Pity_lichen_et_vario_thigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and papulovesicles are present on the thigh. Postinflammatory hyperpigmentation is evident at sites of previous lesions.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85773 Version 4.0</div></div></div>"},"85775":{"type":"graphic_table","displayName":"Risk-adapted treatment of newly diagnosed HL in children","title":"Risk-adapted treatment of newly diagnosed Hodgkin lymphoma in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk-adapted treatment of newly diagnosed Hodgkin lymphoma in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Low risk disease*</td> </tr> <tr> <td class=\"indent1\">Four cycles of VAMP (vinblastine, doxorubicin, methotrexate, prednisone) plus LD-IFRT administered after the second cycle of chemotherapy<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">Four cycles of COPP (cyclophosphamide, vincristine, procarbazine, prednisone)/ABV (doxorubicin, bleomycin, vinblastine) plus LD-IFRT<sup>[2]</sup></td> </tr> <tr> <td class=\"indent1\">ABVE (doxorubicin, bleomycin, vinblastine, etoposide), administered for two to four courses depending on response, followed by LD-IFRT<sup>[3]</sup></td> </tr> <tr> <td class=\"indent1\">OEPA (vincristine, etoposide, prednisone, doxorubicin; for males) or OPPA (vincristine, procarbazine, prednisone, doxorubicin; for females) followed by LD-IFRT, depending upon the initial response to chemotherapy<sup>[4,5]</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Intermediate risk disease*</td> </tr> <tr> <td class=\"indent1\">Six cycles of COPP/ABV plus LD-IFRT<sup>[2]</sup></td> </tr> <tr> <td class=\"indent1\">ABVE-PC (doxorubicin, bleomycin, vinblastine, etoposide, prednisone, cyclophosphamide), administered for three to five courses depending upon response, followed by LD-IFRT<sup>[4]</sup></td> </tr> <tr> <td class=\"indent1\">Two cycles of OPPA (for males) or OEPA (for females), followed by two cycles of COPP (for females) or COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine, for males) plus LD-IFRT<sup>[4-6]</sup></td> </tr> <tr> <td class=\"subtitle1_single\">High risk disease*</td> </tr> <tr> <td class=\"indent1\">ABVE-PC, administered for three to five courses depending upon response, followed by LD-IFRT<sup>[4]</sup></td> </tr> <tr> <td class=\"indent1\">Two cycles of OPPA (for males) or OEPA (for females), followed by two cycles of COPP (for females) or COPDAC (for males) plus LD-IFRT<sup>[4-6]</sup></td> </tr> <tr> <td class=\"indent1\">Two cycles of cytarabine/etoposide, COPP/ABV, and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) plus LD-IFRT<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">Four cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) with subsequent therapy dependent upon response; rapid responders: four cycles of COPP/ABV without IFRT (for females) or two cycles ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) with IFRT (for males); slow responders: four additional cycles of BEACOPP plus IFRT<sup>[7]</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table provides examples of treatment regimens that have been successfully employed in children and adolescents with newly diagnosed Hodgkin lymphoma. A choice among these treatment options is largely based upon physician experience, cancer center preference, and expected toxicities. The determination of preferred therapy for an individual patient should involve a multidisciplinary approach from the time of diagnosis.</div><div class=\"graphic_footnotes\">LD: low dose; IFRT: involved field radiation therapy.<br />* For definition refer to UpToDate topics on Hodgkin lymphoma in children and adolescents.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007; 25:332.</li>&#xD;&#xA;    <li>Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20:3765.</li>&#xD;&#xA;    <li>Tebbi CK, Mendenhall N, London WB, et al. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 2006; 46:198.</li>&#xD;&#xA;    <li>Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009; 114:2051.</li>&#xD;&#xA;    <li>D&ouml;rffel W, R&uuml;hl U, L&uuml;ders H, et al. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: Final results of the multinational trial GPOH-HD 95. J Clin Oncol 2013; 31:1562.</li>&#xD;&#xA;    <li>Mauz-K&ouml;rholz C, Hasenclever D, D&ouml;rffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010; 28:3680.</li>&#xD;&#xA;    <li>Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 2011; 117:2596.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 85775 Version 4.0</div></div></div>"},"85776":{"type":"graphic_table","displayName":"Enzymatic debriding agents","title":"Enzymatic debriding agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Enzymatic debriding agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"3\" width=\"23%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Enzyme source</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> <td class=\"subtitle1\">Precautions</td> </tr> <tr class=\"divider_bottom\"> <td>Collagenase</td> <td>Strain of <em>Clostridium histolyticum</em></td> <td> <ul> <li>Approved by the United States FDA for the debridement of chronic wounds and burns </li> <li>Selective for collagen </li> <li>Generally pain-free delivery </li> <li>May be combined with a variety of other topical dressings </li> </ul> </td> <td> <ul> <li>Effectiveness compared with other forms of debridement may be questionable </li> <li>Prescription based upon wound area </li> <li>High cost </li> <li>Relatively slow-acting </li> </ul> </td> <td> <ul> <li>Moist wound environment required for activation </li> <li>Topical silver dressings significantly inhibit collagenase activity </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Papain</td> <td>Papaya</td> <td> <ul> <li>Provides relatively \"aggressive\" enzymatic debridement </li> <li>Generally pain-free delivery </li> <li>May be combined with a variety of other topical dressings </li> </ul> </td> <td> <ul> <li>Not readily available in the United States </li> <li>Nonselective (ie, will cleave any protein containing cysteine) </li> <li>Relatively slow-acting </li> </ul> </td> <td> <ul> <li>Agent is often combined with a chlorophyll-complex that causes green wound discoloration following application </li> <li>Need to avoid adjacent healthy tissues </li> </ul> </td> </tr> <tr> <td>Bromolain</td> <td>Pineapple</td> <td> <ul> <li>Relatively rapid-acting </li> <li>Selective for non-viable tissue </li> </ul> </td> <td> <ul> <li>Removal from base of wound required after several hours </li> <li>Inhibits platelet function but is reversible </li> </ul> </td> <td> <ul> <li>Evidence of efficacy is based on acute wounds or burns, not chronic wounds </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FDA: Food and Drug Administration.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ramundo J, Gray M. Collagenase for enzymatic debridement: a systematic review. J Wound Ostomy Continence Nurs 2009; 36:S4.</li>&#xD;&#xA;    <li>Kravitz SR, McGuire J, Zinszer K. Management of skin ulcers: understanding the mechanism and selection of enzymatic debriding agents. Adv Skin Wound Care 2008; 21:72.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 85776 Version 3.0</div></div></div>"},"85777":{"type":"graphic_figure","displayName":"Heart attack symptoms women PI","title":"Heart attack symptoms ","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Heart attack symptoms </div><div class=\"cntnt\"><img style=\"width:522px; height:703px;\" src=\"images/PI/85777_Heart_attack_symptoms_women-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the main symptoms of a heart attack. People who are having a heart attack often have only some of these symptoms. The pain, pressure, and discomfort caused by a heart attack mostly affect the left side of the body (shown in darker red) but can also affect the right.<br />If you think you are having a heart attack, <STRONG>call for an ambulance</STRONG> (in the US and Canada, dial 9-1-1). Do not try to get yourself to the hospital.</div><div id=\"graphicVersion\">Graphic 85777 Version 2.0</div></div></div>"},"85778":{"type":"graphic_figure","displayName":"Anatomy occult SUI","title":"Anatomy of occult stress urinary incontinence","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Anatomy of occult stress urinary incontinence</div><div class=\"cntnt\"><img style=\"width:584px; height:319px;\" src=\"images/OBGYN/85778_Anatomy_occult_SUI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Advanced anterior or apical pelvic organ prolapse (usually prolapse past the vaginal introitus) displaces the bladder neck posteriorly and the urethra is kinked, resulting in urethral obstruction. The obstruction then becomes the mechanism of continence.<br />(B) When the prolapsed structures are elevated (approximating normal anatomy) during prolapse reduction testing in women with urethral obstruction due to advanced prolapse, the urethra is unblocked and stress urinary incontinence often becomes evident when a urinary stress test is performed.</div><div class=\"graphic_reference\">Courtesy of Jasmine Tan-Kim, MD.</div><div id=\"graphicVersion\">Graphic 85778 Version 1.0</div></div></div>"},"85779":{"type":"graphic_table","displayName":"Acute and late oral complications associated with cancer therapy","title":"Acute and late oral complications associated with cancer therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute and late oral complications associated with cancer therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Complication</td> <td class=\"subtitle1\">Patients at risk</td> <td class=\"subtitle1\">Considerations</td> </tr> <tr> <td rowspan=\"4\"><strong>Acute</strong></td> <td>Oral infection (viral, bacterial and fungal)</td> <td> <ul> <li>Intensive high-dose chemotherapy regimens</li> <li>Head and neck radiation</li> </ul> </td> <td> <ul> <li>Odontogenic infections may present with pain/fever but without cardinal signs of erythema and purulence</li> <li>Intraoral HSV recrudescence may affect keratinized and non-keratinized mucosal sites</li> </ul> </td> </tr> <tr> <td>Oral mucositis</td> <td> <ul> <li>Intensive high-dose chemotherapy regimens</li> <li>Head and neck radiation</li> <li>mTOR inhibitor therapy</li> </ul> </td> <td> <ul> <li>Starts 7 to 10 days after chemotherapy, resolves within three weeks</li> <li>Peaks after third week of radiation, resolves weeks after completion of therapy</li> <li>mTOR inhibitor stomatitis appears aphthous-like, develops within first week of therapy</li> </ul> </td> </tr> <tr> <td>Salivary dysfunction</td> <td> <ul> <li>Head and neck radiation</li> </ul> </td> <td> <ul> <li>Oral burning common</li> <li>Increased risk of candidiasis</li> </ul> </td> </tr> <tr> <td>Oral hemorrhage</td> <td> <ul> <li>Thrombocytopenia secondary to chemotherapy</li> </ul> </td> <td> <ul> <li>Appears in the oral cavity as areas of active bleeding, petechiae, or ecchymosis</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"7\"><strong>Late</strong></td> <td>Chronic GVHD</td> <td> <ul> <li>Patients who received allogeneic hematopoietic cell transplantation</li> </ul> </td> <td> <ul> <li>Typically appears after day +100</li> <li>Reticulation, erythema and/or ulcerations, primarily affecting the tongue and buccal mucosa</li> <li>Superficial mucoceles of the palate</li> </ul> </td> </tr> <tr> <td>Jaw osteonecrosis</td> <td> <ul> <li>Anti-resorptive therapy</li> <li>Head and neck radiation</li> </ul> </td> <td> <ul> <li>Characterized by exposed necrotic bone in the oral cavity</li> <li>Symptoms usually due to secondary soft tissue infection</li> </ul> </td> </tr> <tr> <td>Taste dysfunction</td> <td> <ul> <li>Head and neck radiation</li> <li>Chemotherapy</li> <li>Chronic GVHD</li> </ul> </td> <td> <ul> <li>Typically recovers after several months</li> </ul> </td> </tr> <tr> <td>Trismus</td> <td> <ul> <li>Head and neck surgery</li> <li>Head and neck radiation</li> <li>Chronic GVHD</li> </ul> </td> <td> <ul> <li>Develops gradually over time</li> <li>Maintaining oral hygiene and providing dental care can be challenging</li> <li>Requires long-term physical therapy</li> </ul> </td> </tr> <tr> <td>Impairment of craniofacial development in children</td> <td> <ul> <li>Chemotherapy or head and neck radiation at a young age</li> </ul> </td> <td> <ul> <li>Dental abnormalities include delayed eruption of teeth, microdontia, and tooth agenesis</li> <li>Bone abnormalities include deficient head and neck skeletal growth</li> </ul> </td> </tr> <tr> <td>Salivary dysfunction</td> <td> <ul> <li>Head and neck radiation</li> <li>Chronic GVHD</li> </ul> </td> <td> <ul> <li>Oral burning common</li> <li>Increased risk of candidiasis and dental caries</li> <li>Prescription and non-prescription management</li> </ul> </td> </tr> <tr> <td>Oral squamous cell carcinoma</td> <td> <ul> <li>History of head and neck cancer</li> <li>Recipients of allogeneic hematopoietic cell transplantation</li> </ul> </td> <td> <ul> <li>Field cancerization changes increase risk of new primary lesions</li> <li>Well-defined, abnormal mucosal lesions, require biopsy for diagnosis</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HSV: herpes simplex virus; mTOR: mammalian target of rapamycin; GVHD: graft versus host disease.</div><div id=\"graphicVersion\">Graphic 85779 Version 1.0</div></div></div>"},"85780":{"type":"graphic_figure","displayName":"Metastatic breast cancer involving the mandible","title":"Metastatic breast cancer involving the mandible","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Metastatic breast cancer involving the mandible</div><div class=\"cntnt\"><img style=\"width:584px; height:220px;\" src=\"images/ONC/85780_Metast_breast_canc_mandible.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Notable facial swelling due to tumor growth, with associated neural deficiency.<br />(B) Coronal CT image demonstrating extensive bone destruction and a large soft tissue mass.</div><div class=\"graphic_reference\">Courtesy of Nathaniel Treister, DMD, DMSc.</div><div id=\"graphicVersion\">Graphic 85780 Version 3.0</div></div></div>"},"85781":{"type":"graphic_algorithm","displayName":"Initial evaluation of hyperandrogenemia","title":"Initial evaluation of hyperandrogenemia","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Initial evaluation of hyperandrogenemia</div><div class=\"cntnt\"><img style=\"width:582px; height:472px;\" src=\"images/PEDS/85781_Initevhyperandrogenism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm outlines the author's initial work-up for causes of hyperandrogenism. The most common cause of hyperandrogenism in women is polycystic ovary syndrome (PCOS). The algorithm outlines an approach to exclude most other causes of hyperandrogenism, using the combination of ultrasonography and an endocrine screening work-up. Other experts select among these tests based on clinical symptoms and signs or laboratory data such as very high androgen levels that raise concerns for one of the disorders listed above (see topic text).</div><div class=\"graphic_footnotes\"><FONT color=black>* Ultrasonography is the initial study that excludes ovarian pathology other than polycystic ovaries. The abdominal ultrasound that is indicated for pelvic ultrasonographic imaging in virginal adolescents can be used to screen for adrenal enlargement or mass.&nbsp;The current consensus criteria for polycystic ovary morphology in adults is an ovary with a volume &gt;10 cc and/or containing ≥12 follicles 2-9 mm in diameter, in the absence of a dominant follicle (≥10 mm diameter) or corpus luteum. One-third to one-half of normal adolescents meet these adult criteria. Until further research establishes definitive criteria, current evidence suggests that a mean ovarian volume &gt;12cc (or single ovary &gt;15 cc) be considered enlarged in adolescents. The normal range for follicle number in adolescents remains to be defined. Unless the ultrasound reveals an abnormality other than polycystic ovary morphology, further work-up for hyperandrogenism is indicated</FONT><FONT color=black>.</FONT><br />Δ Ovotesticular disorder of sex development (DSD) was formerly termed true hermaphroditism.<br /><FONT class=lozenge>◊</FONT> Virilization during pregnancy may be due to androgen hypersecretion by a luteoma or hyper-reactio luteinalis.<br />§ The presence of a polycystic ovary supports the diagnosis of PCOS in hyperandrogenic adolescents. However, the presence of a polycystic ovary is not necessary - nor does it suffice - for the diagnosis of PCOS in a patient with hyperandrogenic anovulation.<br />¥ In a eumenorrheic symptomatically hyperandrogenic adolescent with normal menses, the presence of a polycystic ovary (which meets Rotterdam-AES diagnostic criteria in adults) is a risk factor for a subsequent diagnosis of PCOS.<br />‡ A polycystic ovary is not specific for PCOS; it has been reported in several specific endocrinopathies (eg, hypothyroidism and Cushing's disease) and is also common in asymptomatic individuals.<br />† Further evaluation should include levels of serum prolactin, thyroid stimulating hormone (TSH), insulin-like growth factor I (IGF-I), cortisol, 17-hydroxyprogesterone and dehydroepiandrosterone sulfate (DHEAS). An abnormality of any of these endocrine tests is suggestive of one of the disorders that most commonly mimic PCOS.<br />** 8AM 17-hydroxyprogesterone &gt;170 to 200 ng/dL is approximately 95 percent sensitive and 90 percent specific for detecting common type (21-hydroxylase deficient) nonclassic congenital adrenal hyperplasia (CAH) in anovulatory or follicular phase women; it is often found in virilizing neoplasms. DHEAS &gt;700 mcg/dL suggests adrenal virilizing tumor or a rare type of CAH (3β-hydroxysteroid dehydrogenase deficiency).<br />ΔΔ Computed tomographic scanning of the adrenal gland is a more definitive study for identifying adrenal tumor than is ultrasound.<br /><FONT class=double_lozenge>◊◊</FONT> Plasma cortisol &lt;10 mcg/dL essentially rules out endogenous Cushing's syndrome, unless the clinical index of suspicion is high.<br />§§ Exclusion of the preceding disorders in a hyperandrogenic patient with menstrual dysfunction meets standard diagnostic criteria for PCOS with approximately 95 percent reliability. However, this work-up does not identify rare adrenal disorders (eg, some types of CAH and related types of congenital adrenal steroid metabolic disorders), the rare testosterone-secreting adrenal tumor, or, most commonly, idiopathic hyperandrogenism (hyperandrogenism of unknown origin, which can arise from obesity or possibly metabolic abnormalities).</div><div class=\"graphic_reference\">Original figure modified for this publication. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005; 34:677. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85781 Version 10.0</div></div></div>"},"85783":{"type":"graphic_figure","displayName":"Etonogestrel levels in etonogestrel implant users","title":"Etonogestrel levels in etonogestrel implant users","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Etonogestrel levels in etonogestrel implant users</div><div class=\"cntnt\"><img style=\"width:632px; height:476px;\" src=\"images/OBGYN/85783_Etonogestrel_levels_implant.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum concentration over time profile of etonogestrel during three years of use of Nexplanon.</div><div class=\"graphic_reference\">Data from: NEXPLANON: Highlights of prescribing information. MSD Oss B.V., a subsidiary of Merck &amp; Co., Inc., Whitehouse Station, New Jersey, USA.</div><div id=\"graphicVersion\">Graphic 85783 Version 1.0</div></div></div>"},"85784":{"type":"graphic_table","displayName":"Choosing treatment prostate cancer PI","title":"Choosing treatment for low-risk localized prostate cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Choosing treatment for low-risk localized prostate cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Active surveillance</td> <td class=\"subtitle1\">Prostatectomy (surgery to remove the prostate gland)</td> <td class=\"subtitle1\">External-beam radiation therapy</td> <td class=\"subtitle1\">Brachytherapy</td> </tr> <tr> <td>What are the benefits?</td> <td>You can avoid the side effects that can come with the different treatments.</td> <td>The cancer is treated right away.</td> <td>The cancer is treated right away.</td> <td>The cancer is treated right away.</td> </tr> <tr> <td>What are the downsides or side effects?</td> <td> <p>You will need regular monitoring and testing.</p> <p>You know that you have cancer in your body, which might worry you.</p> Your cancer might start growing more quickly and be harder to treat.</td> <td> <p>This is major surgery. All surgeries can cause pain, infection, or bleeding.</p> Side effects can include trouble with sex and leaking urine.</td> <td> <p>Short-term side effects include having frequent bowel movements or urinating often.</p> Long-term side effects can include trouble with sex or having frequent bowel movements.</td> <td> <p>You need to avoid being near children or pregnant women during treatment.</p> <p>Short-term side effects can include having frequent bowel movements, urinating a lot, or having pain with urination.</p> Long-term side effects can include trouble with sex and leaking urine.</td> </tr> <tr> <td>Will I need further treatment?</td> <td>Yes, if your cancer starts to grow.</td> <td>Probably not</td> <td>Probably not</td> <td>Probably not</td> </tr> <tr> <td>What is the chance that my cancer will come back after treatment?</td> <td>The cancer stays in your body until it is treated. Many men will have treatment for their cancer at some point.</td> <td>Very low</td> <td>Very low</td> <td>Very low</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 85784 Version 4.0</div></div></div>"},"85785":{"type":"graphic_picture","displayName":"Contraceptive vaginal ring","title":"Contraceptive vaginal ring","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Contraceptive vaginal ring</div><div class=\"cntnt\"><img style=\"width:712px; height:467px;\" src=\"images/OBGYN/85785_Contraceptive_vaginal_ring.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">NUVARING® image reproduced with permission of Merck Sharp &amp; Dohme B.V., a subsidiary of Merck &amp; Co., Inc., Kenilworth, New Jersey, U.S.A. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85785 Version 3.0</div></div></div>"},"85791":{"type":"graphic_table","displayName":"Classification and characterization of proteinuria types","title":"Classification and characterization of proteinuria types","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification and characterization of proteinuria types</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Classification of proteinuria</td> <td class=\"subtitle1\">Clinical setting</td> <td class=\"subtitle1\">Typical level of proteinuria</td> </tr> <tr> <td>Transient proteinuria</td> <td>Fever, heavy exercise, vasopressor infusion, albumin infusion</td> <td>&#60;1 g/day</td> </tr> <tr> <td>Persistent proteinuria&nbsp;<a name=\"_GoBack\"></a><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">&ndash;</span> orthostatic proteinuria</td> <td>Uncommon over age 30 years, may occur in 2 to 5 percent of adolescents</td> <td>&#60;1 to 2&nbsp;g/day</td> </tr> <tr> <td>Persistent proteinuria&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">&ndash;</span> overflow proteinuria</td> <td>Myeloma (monoclonal light chains), Hemolysis (hemoglobinuria), Rhabdomyolysis (myoglobinuria)</td> <td>Variable, could be nephrotic range</td> </tr> <tr> <td>Persistent proteinuria&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">&ndash;</span> glomerular proteinuria</td> <td>Primary glomerular diseases, secondary glomerular diseases, diabetic nephropathy, hypertensive nephrosclerosis</td> <td>Variable, often nephrotic range</td> </tr> <tr> <td>Persistent proteinuria&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">&ndash;</span> tubulointerstitial proteinuria</td> <td>Heavy metal intoxications, autoimmune or allergic interstitial inflammation, medication-induced interstitial injury</td> <td>&#60;3 g/day</td> </tr> <tr> <td>Post-renal proteinuria</td> <td>Urinary tract infections, nephrolithiasis, genitourinary tumor</td> <td>&#60;1 g/day</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 85791 Version 3.0</div></div></div>"},"85792":{"type":"graphic_algorithm","displayName":"Algorithm for the evaluation of proteinuria","title":"Algorithm for the evaluation of proteinuria","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Algorithm for the evaluation of proteinuria</div><div class=\"cntnt\"><img style=\"width:458px; height:733px;\" src=\"images/NEPH/85792_Algo_eval_proteinuria.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85792 Version 2.0</div></div></div>"},"85793":{"type":"graphic_picture","displayName":"CNS lymphoma subretinal pigment epithelium infiltrates","title":"Characteristic fundus findings of intraocular-central nervous system lymphomalymphomatous subretinal pigment epithelial (subRPE) infiltrates, retinochoroiditis, and vasculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Characteristic fundus findings of intraocular-central nervous system lymphomalymphomatous subretinal pigment epithelial (subRPE) infiltrates, retinochoroiditis, and vasculitis</div><div class=\"cntnt\"><img style=\"width:442px; height:329px;\" src=\"images/HEME/85793_CNS_lymp_sbrtnl_pgmnt_epthl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fundus photograph of the right eye shows characteristic subretinal pigment epithelium yellow infiltrates.</div><div class=\"graphic_reference\">Reproduced from: Akpek EK, Ahmed I, Hochberg FH, et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 1999; 106:1805. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85793 Version 2.0</div></div></div>"},"85794":{"type":"graphic_picture","displayName":"Vitreous cells in intraocular-CNS lymphoma","title":"Vitreous cells in intraocular-central nervous system lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vitreous cells in intraocular-central nervous system lymphoma</div><div class=\"cntnt\"><img style=\"width:426px; height:333px;\" src=\"images/HEME/85794_Vtrs_cll_intrclr_CNS_lymp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fundus photograph of the right eye shows large clumps of vitreous cells.</div><div class=\"graphic_reference\">Reproduced from: Akpek EK, Ahmed I, Hochberg FH, et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 1999; 106:1805. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85794 Version 2.0</div></div></div>"},"85802":{"type":"graphic_figure","displayName":"Oocyte fertilization and zygote migration","title":"Oocyte fertilization and zygote migration","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Oocyte fertilization and zygote migration</div><div class=\"cntnt\"><img style=\"width:539px; height:483px;\" src=\"images/OBGYN/85802_Oocyte-fertilization-and-zygote-migration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fertilization normally occurs in the ampulla of the Fallopian tube, typically within 24 hours after ovulation. Fertilization initiates cleavage of the zygote into smaller, equipotential cells called blastomeres. The first cleavage into two cells is completed in about 30 hours, with subsequent divisions occurring at 10- to 12-hour intervals. By the end of the third day after fertilization, the structure contains 16 blastomeres, which are called the morula.<br />The morula enters the uterus about four days after fertilization and \"floats\" in the uterine cavity. During this time, it continues to divide and absorbs fluid from the uterine cavity. The resulting fluid-filled spaces coalesce to form a blastocyst cavity, at which time the morula becomes a blastocyst. A single spherical layer of trophoblast cells (trophectoderm) form the outer wall of the blastocyst while its inner cell mass becomes the embryo. The blastocyst remains free within the uterine cavity for two to four days before attaching to the uterine wall. Implantation begins seven to eight days after fertilization.</div><div id=\"graphicVersion\">Graphic 85802 Version 2.0</div></div></div>"},"85804":{"type":"graphic_figure","displayName":"Actuarial success rates with HVAD and predicted survival rates","title":"Actuarial success rates with HVAD and predicted survival rates based on the SHFM","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Actuarial success rates with HVAD and predicted survival rates based on the SHFM</div><div class=\"cntnt\"><img style=\"width:579px; height:413px;\" src=\"images/CARD/85804_ActuarsuccessratesHVAD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Actuarial success rates with HeartWare implantation in the bridge to transplant European trial versus prediction of survival with continued medical therapy on the basis of the Seattle Heart Failure Model.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced from: Strueber M, O'Driscoll G, Jansz P, et al. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol 2011; 57:1375. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85804 Version 2.0</div></div></div>"},"85807":{"type":"graphic_table","displayName":"Neurobehavioral Rx effect body weight","title":"Categorization of anti-depressants, anti-convulsants, and anti-psychotic drugs by their effects on body weight","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categorization of anti-depressants, anti-convulsants, and anti-psychotic drugs by their effects on body weight</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Produce weight loss</td> </tr> <tr> <td>Bupropion</td> </tr> <tr> <td>Venlafaxine</td> </tr> <tr> <td>Desvenlafaxine</td> </tr> <tr> <td>Topiramate</td> </tr> <tr> <td>Zonisamide</td> </tr> <tr> <td>Lamotrigine</td> </tr> <tr> <td>Ziprasidone</td> </tr> <tr> <td class=\"subtitle1_single\">Are weight neutral</td> </tr> <tr> <td>Haloperidol </td> </tr> <tr> <td>Aripiprazole</td> </tr> <tr> <td class=\"subtitle1_left\">Produce weight gain</td> </tr> <tr> <td>Tricyclic antidepressants*</td> </tr> <tr> <td>Monoamine oxidase inhibitors</td> </tr> <tr> <td>Paroxetine</td> </tr> <tr> <td>Escitalopram</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>Olanzapine</td> </tr> <tr> <td>Clozapine</td> </tr> <tr> <td>Risperidone</td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td>Valproate</td> </tr> <tr> <td>Divalproex</td> </tr> <tr> <td>Mirtazapine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Nortriptyline, amitriptyline, doxepin.</div><div class=\"graphic_reference\">Reproduced with permission from: Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation 2012; 125:1695. Copyright © 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85807 Version 5.0</div></div></div>"},"85808":{"type":"graphic_figure","displayName":"Survival with HMII versus medical management","title":"Inference of survival benefit of current destination therapy with current continuous-flow left ventricular assist device (LVAD) compared with medical management from the REMATCH trial","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Inference of survival benefit of current destination therapy with current continuous-flow left ventricular assist device (LVAD) compared with medical management from the REMATCH trial</div><div class=\"cntnt\"><img style=\"width:578px; height:404px;\" src=\"images/CARD/85808_Surv_HMII_vs_med_man.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival of destination therapy with the current HeartMate II continuous-flow left ventricular assist device (LVAD) from the latest DT trial compared with medical management from the REMATCH trial.</div><div class=\"graphic_reference\">Reproduced with permission from: Park SJ, Milano CA, Tatooles AJ,&nbsp;et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012; 5:241. Copyright © 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85808 Version 4.0</div></div></div>"},"85810":{"type":"graphic_table","displayName":"Spitz nevus variants","title":"Spitz nevus/tumor and variants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spitz nevus/tumor and variants</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Spitz nevus: junctional, compound, dermal</td> </tr> <tr> <td>Desmoplastic Spitz tumor</td> </tr> <tr> <td>Pigmented spindle cell tumor</td> </tr> <tr> <td>Plexiform pigmented spindle (and epithelioid) cell tumor</td> </tr> <tr> <td>Spitz tumor, halo variant</td> </tr> <tr> <td>Recurrent Spitz tumor</td> </tr> <tr> <td class=\"sublist1_start\">Spitz tumor with atypical features (atypical Spitz tumor)</td> </tr> <tr> <td class=\"sublist1\">Pagetoid Spitz tumor</td> </tr> <tr> <td class=\"sublist1\">Spitz&nbsp;tumor with architectural disorder and cytologic atypia (dysplastic Spitz tumor)</td> </tr> <tr> <td>Spitz&nbsp;tumor with atypical features and indeterminate biologic potential</td> </tr> <tr> <td>\"Spitzoid\", Spitz-like melanoma, malignant Spitz tumor</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Barnhill RL, Cerroni L, Cook M, et al. State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: Outcome of an international workshop. Adv Anat Pathol 2010; 17:73. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85810 Version 5.0</div></div></div>"},"85814":{"type":"graphic_table","displayName":"Spitz nevi conventional","title":"Clinical features of conventional Spitz nevi","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of conventional Spitz nevi</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Architecture</td> </tr> <tr> <td>Diameter &#60;5 to 6 mm*</td> </tr> <tr> <td>Symmetric outline*</td> </tr> <tr> <td>Sharp lateral circumscription*</td> </tr> <tr> <td>Regular pattern of epidermal hyperplasia</td> </tr> <tr> <td>Maturation with depth in dermis</td> </tr> <tr> <td>Zonation across the horizontal axis</td> </tr> <tr> <td>Wedge-shaped configuration within dermis</td> </tr> <tr> <td>Orderly nondisruptive infiltration of collagen by melanocytes</td> </tr> <tr> <td class=\"subtitle1_single\">Cytology</td> </tr> <tr> <td>Spindle or epithelioid cell type*</td> </tr> <tr> <td>Uniform population of cells*</td> </tr> <tr> <td>Low nuclear-to-cytoplasmic ratio</td> </tr> <tr> <td>Opaque or ground glass cytoplasm</td> </tr> <tr> <td>Nuclei with open, delicate chromatin pattern</td> </tr> <tr> <td>Uniform nucleoli</td> </tr> <tr> <td>Rare pleomorphism</td> </tr> <tr> <td class=\"subtitle1_single\">Other helpful diagnostic features</td> </tr> <tr> <td>Mitotic rate &#60;2/mm<sup>2</sup>*</td> </tr> <tr> <td>Absent or rare mitoses in deep dermis*</td> </tr> <tr> <td>Lack of atypical mitoses*</td> </tr> <tr> <td>Irregular contours of growth at deep margin*</td> </tr> <tr> <td>Kamino bodies*</td> </tr> <tr> <td>Mononuclear or multinucleate giant cells</td> </tr> <tr> <td>Minimal central pagetoid upward scatter</td> </tr> <tr> <td>Junctional clefts</td> </tr> <tr> <td>Loss of cohesion between cells (retraction spaces)</td> </tr> <tr> <td>Perivascular or diffuse inflammation</td> </tr> <tr> <td>Superficial distribution of pigmentation</td> </tr> <tr> <td>Telangiectasia and edema</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Most helpful features.</div><div class=\"graphic_reference\">Adapted by permission from: Macmillan Publishers Ltd: Modern Pathology. Barnhill RL. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment. Mod Pathol 2006; 19 Suppl 2:S21. Copyright © 2006. <A style=\"FONT-STYLE: italic\" href=\"http://www.nature.com/modpathol/index.html\" target=_blank>http://www.nature.com/modpathol/index.html</A>.</div><div id=\"graphicVersion\">Graphic 85814 Version 2.0</div></div></div>"},"85815":{"type":"graphic_table","displayName":"Atypical Spitz histo","title":"Histologic features of atypical Spitz tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic features of atypical Spitz tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Architecture</td> </tr> <tr> <td class=\"indent1\">&#8226; Diameter usually &#62;5 and often &#62;10 mm</td> </tr> <tr> <td class=\"indent1\">&#8226; Involvement of the subcutaneous tissue</td> </tr> <tr> <td class=\"indent1\">&#8226; Ulceration</td> </tr> <tr> <td class=\"indent1\">&#8226; Poor circumscription</td> </tr> <tr> <td class=\"indent1\">&#8226; Extensive pagetoid scatter</td> </tr> <tr> <td class=\"indent1\">&#8226; Effacement of the epidermis</td> </tr> <tr> <td class=\"indent1\">&#8226; Prominent confluence of melanocytes</td> </tr> <tr> <td class=\"indent1\">&#8226; High cellular density</td> </tr> <tr> <td class=\"indent1\">&#8226; Lack of zonation and maturation</td> </tr> <tr> <td class=\"indent1\">&#8226; Asymmetry</td> </tr> <tr> <td class=\"indent1\">&#8226; Absent or few eosinophilic hyaline globules (Kamino bodies)</td> </tr> <tr> <td class=\"subtitle1_single\">Proliferation</td> </tr> <tr> <td class=\"indent1\">&#8226; Significant mitotic rate (2 to 6/mm<sup>2</sup>) (particularly &#62;6/mm<sup>2</sup>)</td> </tr> <tr> <td class=\"indent1\">&#8226; Deep or marginal dermal mitoses</td> </tr> <tr> <td class=\"indent1\">&#8226; Proliferative index (Ki-67 expression)</td> </tr> <tr> <td class=\"indent2\">- Between 2 to 10 percent<sup>[1]</sup></td> </tr> <tr> <td class=\"indent2\">- &#8805;10 to 15 percent<sup>[2]</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Cytology</td> </tr> <tr> <td class=\"indent1\">&#8226; Granular versus ground glass cytoplasm</td> </tr> <tr> <td class=\"indent1\">&#8226; High nuclear to cytoplasmic ratio</td> </tr> <tr> <td class=\"indent1\">&#8226; Loss of delicate or dispersed chromatin pattern</td> </tr> <tr> <td class=\"indent1\">&#8226; Thickening of nuclear membranes</td> </tr> <tr> <td class=\"indent1\">&#8226; Hyperchromatism</td> </tr> <tr> <td class=\"indent1\">&#8226; Large nucleoli</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Vollmer RT. Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma. Am J Clin Pathol 2004; 122:499.</LI>&#xD;&#xA;<LI>Kapur P, Selim MA, Roy LC, et al. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Mod Pathol 2005; 18:197.</LI></OL>Reprinted by permission from Macmillan Publishers Ltd: Modern Pathology. Barnhill RL. The Spitzoid lesion: Rethinking spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment. Mod Pathol 2006; 19 Suppl 2:S21. Copyright © 2006.</div><div id=\"graphicVersion\">Graphic 85815 Version 2.0</div></div></div>"},"85817":{"type":"graphic_picture","displayName":"Spitz nevus face","title":"Spitz nevus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Spitz nevus</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/85817_Spitz_nevus_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spitz nevus presenting as a&nbsp;pink, symmetric, dome-shaped papule on the face of a&nbsp;child.<br /><br /></div><div id=\"graphicVersion\">Graphic 85817 Version 5.0</div></div></div>"},"85818":{"type":"graphic_picture","displayName":"Spitz nevi in nevus spilus","title":"Multiple Spitz nevi arising in a nevus spilus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple Spitz nevi arising in a nevus spilus</div><div class=\"cntnt\"><img style=\"width:335px; height:504px;\" src=\"images/DERM/85818_Spitz_nevi_nevus_spilus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85818 Version 1.0</div></div></div>"},"85819":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image incarcerated gravid uterus","title":"Ultrasound image incarcerated gravid uterus","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Ultrasound image incarcerated gravid uterus</div><div class=\"cntnt\"><img style=\"width:597px; height:265px;\" src=\"images/RADIOL/85819_US_incarcerat_gravid_uterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transabdominal ultrasound of the gravid uterus at 22 weeks (A) in the longitudinal projection reveals an elongated cervix (Cx +----+) which is positioned superiorly. The fundus of the uterus (arrowheads) is situated posteriorly and pointing inferiorly. Image B is a transvaginal study in the longitudinal projection, again showing the elongated and superiorly positioned cervix with an inferiorly directed fundus. These findings suggest uterine incarceration.</div><div class=\"graphic_reference\">Reproduced with permisison from Carol Benson, MD.</div><div id=\"graphicVersion\">Graphic 85819 Version 1.0</div></div></div>"},"85820":{"type":"graphic_diagnosticimage","displayName":"Radiograph left foot normal","title":"Plain radiograph of normal left foot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of normal left foot</div><div class=\"cntnt\"><img style=\"width:379px; height:597px;\" src=\"images/RADIOL/85820_Xray_left_foot_normal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal radiograph&nbsp;of the left foot is from a 53-year-old female. The foot is shown in the AP (A), oblique (B), and lateral projections (C).</div><div class=\"graphic_footnotes\">AP: anterior-posterior.</div><div id=\"graphicVersion\">Graphic 85820 Version 2.0</div></div></div>"},"85821":{"type":"graphic_diagnosticimage","displayName":"Radiograph right foot normal","title":"Radiograph right foot normal","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Radiograph right foot normal</div><div class=\"cntnt\"><img style=\"width:508px; height:554px;\" src=\"images/RADIOL/85821_Xray_right_foot_normal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph of the right foot is from a 48-year-old female. The normal foot is shown in the AP (A), oblique (B), and lateral projections (C).</div><div class=\"graphic_footnotes\">AP: anterior-posterior.</div><div id=\"graphicVersion\">Graphic 85821 Version 2.0</div></div></div>"},"85823":{"type":"graphic_diagnosticimage","displayName":"MRI amebic encephalitis due to Balamuthia mandrillaris","title":"MRI amebic encephalitis due to <EM>Balamuthia mandrillaris</EM>","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">MRI amebic encephalitis due to <EM>Balamuthia mandrillaris</EM></div><div class=\"cntnt\"><img style=\"width:553px; height:462px;\" src=\"images/RADIOL/85823_MRI_amebic_enceph_Bala_Mand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MRI is from a two-year-old boy who presented with fevers, obtundation, and seizures. The T2-weighted images (A and B) show bilateral hemispheric lesions (arrows) in the right posterior parietal lobe (A) and in the left caudate nucleus (B). The pre-gadolinium T1-weighted sequence in the sagittal plane (C) shows subtle findings that become more apparent as enhancing lesions (arrows) in the post-gadolinium sequence (D). The ependymal enhancement (arrowhead) confirms the presence of ependymitis. The diagnosis of amebic meningoencephalitis due to <EM>Balamuthia mandrillaris </EM>was confirmed by surgical biopsy.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Images courtesy of Steven Goldstein, MD, University of Kentucky. Reproduced with permission from: James Smirniotopoulos, MD (Editor, MedPix, USUHS).</div><div id=\"graphicVersion\">Graphic 85823 Version 4.0</div></div></div>"},"85824":{"type":"graphic_diagnosticimage","displayName":"RA PIP erosions","title":"Plain radiograph of rheumatoid arthritis proximal interphalangeal joint erosions","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of rheumatoid arthritis proximal interphalangeal joint erosions</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/RADIOL/85824_RA_PIP_erosions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain x-ray of the right hand magnified at the proximal interphalangeal joints shows soft tissue swelling (arrows) and mild erosive changes (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 85824 Version 2.0</div></div></div>"},"85825":{"type":"graphic_diagnosticimage","displayName":"RA MCP osteopenia","title":"Plain radiograph of osteopenia of metacarpophalangeal joints in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of osteopenia of metacarpophalangeal joints in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:598px; height:228px;\" src=\"images/RADIOL/85825_RA_MCP_osteopenia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiograph of the left hand in the AP projection shows a normal patient (A) and a patient with radiologically mild rheumatoid arthritis (B). The patient with rheumatoid arthritis demonstrates osteopenia around the metacarpophalangeal joints (arrows) and mild soft tissue swelling (arrowheads).</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Image B courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 85825 Version 2.0</div></div></div>"},"85826":{"type":"graphic_diagnosticimage","displayName":"RA MCP mild erosion","title":"Plain radiograph of mild metacarpophalangeal joint erosion rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of mild metacarpophalangeal joint erosion rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:597px; height:398px;\" src=\"images/RADIOL/85826_RA_MCP_mild_erosion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain x-ray of the left hand is from a patient with radiologically mild rheumatoid arthritis. The magnified view of the second metacarpophalangeal joint in (A) is shown with arrows in (B). Subtle erosive changes are noted at the second metacarpophalangeal joint (arrow), while soft tissue changes are more obvious (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 85826 Version 2.0</div></div></div>"},"85827":{"type":"graphic_diagnosticimage","displayName":"Normal left hand x-ray","title":"Plain radiograph of normal left hand (AP, lateral, and oblique)","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of normal left hand (AP, lateral, and oblique)</div><div class=\"cntnt\"><img style=\"width:486px; height:598px;\" src=\"images/RADIOL/85827_Normal_left_hand_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiographs of the left hand in the AP (A), lateral (B), and oblique (C) projections are normal.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div id=\"graphicVersion\">Graphic 85827 Version 2.0</div></div></div>"},"85828":{"type":"graphic_diagnosticimage","displayName":"RA ulnar styloid erosion x-ray","title":"Plain radiograph of ulnar styloid erosion in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of ulnar styloid erosion in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/RADIOL/85828_RA_ulnar_styl_erosion_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph of the right wrist in the AP projection reveals a deformed and eroded ulnar styloid process (arrow) in this patient who has rheumatoid arthritis. No other remarkable changes are present.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 85828 Version 2.0</div></div></div>"},"85829":{"type":"graphic_diagnosticimage","displayName":"RA wrist osteopenia x-ray","title":"Plain radiograph of osteopenia of the wrist in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of osteopenia of the wrist in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:598px; height:235px;\" src=\"images/RADIOL/85829_RA_wrist_osteopenia_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal radiograph of the left wrist in the AP projection (A) is compared with the left wrist of a patient with rheumatoid arthritis (B). The subtle diffuse osteopenia of the carpal bones is typified by an overall decrease in the density of the bones and by a relative paucity of trabecular markings. Less subtle is the prominent soft tissue nodule overlying the styloid process (arrow).</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Image B courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 85829 Version 2.0</div></div></div>"},"85830":{"type":"graphic_diagnosticimage","displayName":"Plain radiograph of a normal wrist","title":"Plain radiograph of a normal wrist","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of a normal wrist</div><div class=\"cntnt\"><img style=\"width:473px; height:532px;\" src=\"images/RADIOL/85830_Normal_wrist_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph of the normal right wrist is displayed in the AP (A), oblique (B), and lateral (C) projections.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div id=\"graphicVersion\">Graphic 85830 Version 3.0</div></div></div>"},"85831":{"type":"graphic_diagnosticimage","displayName":"RA MTP erosions x-ray","title":"Plain radiograph of metatarsophalangeal joint space narrowing and erosions in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of metatarsophalangeal joint space narrowing and erosions in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/RADIOL/85831_RA_MTP_erosions_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph of the left foot in the AP projection demonstrates an erosion in the periarticular, marginal \"bare\" area of the joint of the 5th MTP joint and more subtle erosions at the 1st, 2nd, 3rd, and 4th MTPs (arrows), characteristic of rheumatoid arthritis. Also present is joint space narrowing of the 1st and 2nd MTP joints (arrowheads).</div><div class=\"graphic_footnotes\">AP: anteroposterior; MTP: metatarsophalangeal.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 85831 Version 2.0</div></div></div>"},"85832":{"type":"graphic_table","displayName":"IPSS-R in MDS","title":"Revised international prognostic scoring system (IPSS-R) in myelodysplastic syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised international prognostic scoring system (IPSS-R) in myelodysplastic syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Prognostic variable</td> <td class=\"subtitle1\" colspan=\"7\">Score</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">0.5</td> <td class=\"subtitle2\">1.0</td> <td class=\"subtitle2\">1.5</td> <td class=\"subtitle2\">2.0</td> <td class=\"subtitle2\">3.0</td> <td class=\"subtitle2\">4.0</td> </tr> <tr> <td>Cytogenetics*</td> <td>Very good</td> <td>&nbsp;</td> <td>Good</td> <td>&nbsp;</td> <td>Intermediate</td> <td>Poor</td> <td>Very poor</td> </tr> <tr> <td>Bone marrow blast (percent)</td> <td>&#8804;2 </td> <td>&nbsp;</td> <td>&#62;2 to &#60;5 </td> <td>&nbsp;</td> <td>5 to 10 </td> <td>&#62;10 </td> <td>&nbsp;</td> </tr> <tr> <td>Hemoglobin (g/dL)</td> <td>&#8805;10</td> <td>&nbsp;</td> <td>8 to &#60;10</td> <td>&#60;8</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Platelets (cells/microL)</td> <td>&#8805;100</td> <td>50 to 100</td> <td>&#60;50</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Absolute neutrophil count (cells/microL)</td> <td>&#8805;0.8</td> <td>&#60;0.8</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"8\">This scoring system was applied to an initial group of 7012 patients with primary MDS by the French-American-British classification who had at least two months of stable blood counts, &#8804;30 percent bone marrow blasts and &#8804;19 percent peripheral blood blasts, and who were observed until progression to AML transformation or death (did not receive disease-modifying agents for MDS). Patients could be stratified into five groups with the following estimated overall survival and progression to AML.</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Risk group</td> <td class=\"subtitle2\" colspan=\"2\">IPSS-R score</td> <td class=\"subtitle2\" colspan=\"2\">Median overall survival (years)</td> <td class=\"subtitle2\" colspan=\"2\">Median time to 25 percent AML evolution (years)</td> </tr> <tr> <td colspan=\"2\">Very low</td> <td colspan=\"2\">&#8804;1.5</td> <td colspan=\"2\">8.8</td> <td colspan=\"2\">&#62;14.5</td> </tr> <tr> <td colspan=\"2\">Low</td> <td colspan=\"2\">&#62;1.5 to 3.0</td> <td colspan=\"2\">5.3</td> <td colspan=\"2\">10.8</td> </tr> <tr> <td colspan=\"2\">Intermediate</td> <td colspan=\"2\">&#62;3 to 4.5</td> <td colspan=\"2\">3.0</td> <td colspan=\"2\">3.2</td> </tr> <tr> <td colspan=\"2\">High</td> <td colspan=\"2\">&#62;4.5 to 6</td> <td colspan=\"2\">1.6</td> <td colspan=\"2\">1.4</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Very high</td> <td colspan=\"2\">&#62;6</td> <td colspan=\"2\">0.8</td> <td colspan=\"2\">0.7</td> </tr> <tr> <td colspan=\"8\">The prognostic value of the IPSS-R was validated in an external cohort of 200 patients with MDS</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AML: acute myeloid leukemia; MDS: myelodysplastic syndrome.<br />* Cytogenetic definitions:<br />Very good: -Y, del(11q).<br />Good: Normal, del(5q), del(12p), del(20q), double including del(5q).<br />Intermediate: del(7q), +8, +19, i(17q), any other single,&nbsp;double not including del(5q) or -7/del(7q), or independent clones.<br />Poor: -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), complex: 3 abnormalities.<br />Very poor: Complex: &gt;3 abnormalities.</div><div class=\"graphic_reference\">This research was originally published in Blood. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012. Copyright &copy; 2012 the American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 85832 Version 2.0</div></div></div>"},"85833":{"type":"graphic_table","displayName":"Differential diagnosis of metabolic alkalosis","title":"Differential diagnosis of metabolic alkalosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of metabolic alkalosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Low urinary [Cl] (&#60;20 meq/L) chloride responsive</td> <td class=\"subtitle1\">High urinary [Cl] (&#62;20 meq/L) chloride unresponsive</td> </tr> <tr> <td><strong>Diuretics (remote)</strong></td> <td><strong>Diuretics (recent)</strong></td> </tr> <tr> <td><strong>Vomiting/nasogastric tube suction</strong></td> <td><strong>High blood pressure</strong></td> </tr> <tr> <td><strong>Status post chronic hypercarbia</strong></td> <td class=\"indent1\">Primary hyperaldosteronism</td> </tr> <tr> <td><strong>Chloridorrhea</strong></td> <td class=\"indent1\">Cushing's disease</td> </tr> <tr> <td><strong>Cystic fibrosis</strong></td> <td class=\"indent1\">Ectopic ACTH production</td> </tr> <tr> <td rowspan=\"7\">&nbsp;</td> <td class=\"indent1\">Exogenous mineralocorticoid production</td> </tr> <tr> <td class=\"indent1\">Mineralocorticoid-like substances</td> </tr> <tr> <td class=\"indent1\">Liddle's syndrome</td> </tr> <tr> <td><strong>Low blood pressure</strong></td> </tr> <tr> <td class=\"indent1\">Bartter syndrome</td> </tr> <tr> <td class=\"indent1\">Gitelman syndrome</td> </tr> <tr> <td class=\"sublist_other_start\"><strong>Severe potassium depletion</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Cl: chloride;&nbsp;ACTH: adrenocorticotropic hormone.</div><div class=\"graphic_reference\">Reproduced from: Emmett M. Diagnosis of Simple and Mixed Disorders. In: Acid-Base and Electrolyte Disorders: A Companion to Brenner &amp; Rector's The Kidney, DuBose TD Jr, Hamm LL (Eds), Saunders, Philadelphia 2002. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85833 Version 5.0</div></div></div>"},"85835":{"type":"graphic_diagnosticimage","displayName":"RA AC joint erosion x-ray","title":"Plain radiograph of acromioclavicular joint erosion in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of acromioclavicular joint erosion in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:576px; height:437px;\" src=\"images/RADIOL/85835_RA_AC_joint_erosion_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The AP projection of the left clavicle shows erosion of the undersurface of the distal clavicle (arrow) at the acromioclavicular joint characteristic of rheumatoid arthritis.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 85835 Version 2.0</div></div></div>"},"85836":{"type":"graphic_diagnosticimage","displayName":"Normal right hand x-ray","title":"Plain radiograph of a normal right hand (AP, lateral, and oblique)","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of a normal right hand (AP, lateral, and oblique)</div><div class=\"cntnt\"><img style=\"width:506px; height:584px;\" src=\"images/RADIOL/85836_Normal_right_hand_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph of the right hand in the AP (A), lateral (B), and oblique (C) projections are normal.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div id=\"graphicVersion\">Graphic 85836 Version 2.0</div></div></div>"},"85839":{"type":"graphic_table","displayName":"Nail surgery history","title":"Relevant history aspects for patients undergoing nail surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relevant history aspects for patients undergoing nail surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Raynaud phenomenon</td> </tr> <tr> <td>Autoimmune connective tissue disease</td> </tr> <tr> <td>Cardiac disease, including heart block</td> </tr> <tr> <td>Peripheral vascular disease</td> </tr> <tr> <td>Tobacco use</td> </tr> <tr> <td>Diabetes mellitus</td> </tr> <tr> <td>Neuropathy</td> </tr> <tr> <td>Prosthetic heart valves</td> </tr> <tr> <td>Prosthetic joints</td> </tr> <tr> <td>History of coagulopathy</td> </tr> <tr> <td>Medications known to interfere with anesthetic drugs or coagulation (eg, beta blockers, phenothiazines, anticoagulants, aspirin, NSAIDs)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 85839 Version 1.0</div></div></div>"},"85843":{"type":"graphic_table","displayName":"Spitz conventional histo","title":"Histopathologic features of conventional Spitz nevi","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histopathologic features of conventional Spitz nevi</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Architecture</td> </tr> <tr> <td>Diameter &#60;5 to 6 mm*</td> </tr> <tr> <td>Symmetric outline*</td> </tr> <tr> <td>Sharp lateral circumscription*</td> </tr> <tr> <td>Regular pattern of epidermal hyperplasia</td> </tr> <tr> <td>Maturation with dermal depth</td> </tr> <tr> <td>Zonation across the horizontal axis</td> </tr> <tr> <td>Wedge-shaped configuration within dermis</td> </tr> <tr> <td>Orderly nondisruptive infiltration of collagen by melanocytes</td> </tr> <tr> <td class=\"subtitle1_single\">Cytology</td> </tr> <tr> <td>Spindle or epithelioid cell type*</td> </tr> <tr> <td>Uniform population of cells*</td> </tr> <tr> <td>Low nuclear to cytoplasmic ratio</td> </tr> <tr> <td>Opaque or ground glass cytoplasm</td> </tr> <tr> <td>Nuclei with open, delicate chromatin pattern</td> </tr> <tr> <td>Uniform nucleoli</td> </tr> <tr> <td>Rare pleomorphism</td> </tr> <tr> <td class=\"subtitle1_single\">Other helpful diagnostic features</td> </tr> <tr> <td>Mitotic rate &#60;2/mm<sup>2</sup>*</td> </tr> <tr> <td>Absent or rare mitoses in deep dermis*</td> </tr> <tr> <td>Lack of atypical mitoses*</td> </tr> <tr> <td>Irregular contours of growth at deep margin*</td> </tr> <tr> <td>Kamino bodies*</td> </tr> <tr> <td>Mononuclear or multinucleate giant cells</td> </tr> <tr> <td>Minimal central pagetoid upward scatter</td> </tr> <tr> <td>Junctional clefts</td> </tr> <tr> <td>Loss of cohesion between cells (retraction spaces)</td> </tr> <tr> <td>Perivascular or diffuse inflammation</td> </tr> <tr> <td>Superficial distribution of pigmentation</td> </tr> <tr> <td>Telangiectasia and edema</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Most helpful features.</div><div class=\"graphic_reference\">Adapted by permission from: Macmillan Publishers Ltd: Modern Pathology. Barnhill RL. The Spitzoid lesion: Rethinking spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment. Mod Pathol 2006; 19 Suppl 2:S21. Copyright &copy; 2006.</div><div id=\"graphicVersion\">Graphic 85843 Version 1.0</div></div></div>"},"85844":{"type":"graphic_figure","displayName":"Lifecycle African trypanosomiasis","title":"Lifecycle of African trypanosomiasis","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Lifecycle of African trypanosomiasis</div><div class=\"cntnt\"><img style=\"width:611px; height:445px;\" src=\"images/ID/85844_Life_cycle_African_trypano.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a blood meal on the mammalian host, an infected tsetse fly (genus <EM>Glossina</EM>) injects metacyclic trypomastigotes into skin tissue. The parasites enter the lymphatic system and pass into the bloodstream <STRONG>(1)</STRONG>. Inside the host, they transform into bloodstream trypomastigotes <STRONG>(2)</STRONG>, are carried to other sites throughout the body, reach other blood fluids (eg, lymph, spinal fluid), and continue the replication by binary fission <STRONG>(3)</STRONG>. The entire lifecycle of African trypanosomes is represented by extracellular stages. The tsetse fly becomes infected with bloodstream trypomastigotes when taking a blood meal on an infected mammalian host <STRONG>(4,5)</STRONG>. In the fly's midgut, the parasites transform into procyclic trypomastigotes, multiply by binary fission <STRONG>(6)</STRONG>, leave the midgut, and transform into epimastigotes <STRONG>(7)</STRONG>. The epimastigotes reach the fly's salivary glands and continue multiplication by binary fission <STRONG>(8)</STRONG>. The cycle in the fly takes approximately three weeks. Humans are the main reservoir for <EM>Trypanosoma brucei gambiense</EM>, but this species can also be found in animals. Wild game animals are the main reservoir of&nbsp;<EM>Trypanosoma brucei rhodesiense</EM>.</div><div class=\"graphic_reference\">Reproduced from: Centers of Disease Control and Prevention. DPDx: Trypanosomiasis, African. Available at: <A href=\"http://www.cdc.gov/dpdx/trypanosomiasisAfrican/index.html\">http://www.cdc.gov/dpdx/trypanosomiasisAfrican/index.html</A>.</div><div id=\"graphicVersion\">Graphic 85844 Version 3.0</div></div></div>"},"85845":{"type":"graphic_picture","displayName":"Blood smear African trypanosomiasis","title":"Blood smear of African trypanosomiasis","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Blood smear of African trypanosomiasis</div><div class=\"cntnt\"><img style=\"width:547px; height:546px;\" src=\"images/ID/85845_Blood_smear_African_trypan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The two <EM>Trypanosoma brucei</EM> subspecies that cause African trypanosomiasis, <EM>T. b. gambiense</EM> and <EM>T. b. rhodesiense</EM>, are indistinguishable morphologically. A typical trypomastigote has a small kinetoplast located at the posterior end, a centrally located nucleus, an undulating membrane, and a flagellum running along the undulating membrane, leaving the body at the anterior end. Trypomastigotes are the only stage found in patients. Trypanosomes range in length from 14 to 33 micrometers.<br />(A) <EM>Trypansoma brucei</EM> ssp in thick blood smears stained with Giemsa.<br />(B) Trypomastigotes of <EM>T. brucei</EM> ssp in a blood smear stained with Giemsa.<br />(C) <EM>Trypanosoma brucei</EM> ssp in a thin blood smear stained with Giemsa. The trypomastigote is beginning to divide; dividing forms are seen in African trypanosomes but not in American trypanosomes.</div><div class=\"graphic_reference\">Reproduced from: Centers of Disease Control and Prevention. DPDx: Trypanosomiasis, African. Available at: <A href=\"http://www.cdc.gov/dpdx/trypanosomiasisAfrican/index.html\">http://www.cdc.gov/dpdx/trypanosomiasisAfrican/index.html</A>.</div><div id=\"graphicVersion\">Graphic 85845 Version 3.0</div></div></div>"},"85846":{"type":"graphic_table","displayName":"HAT species characteristics","title":"Characteristics of African trypanosomiasis species","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of African trypanosomiasis species</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\"><em>Trypanosoma brucei gambiense</em></td> <td class=\"subtitle1\"><em>Trypanosoma brucei rhodesiense</em></td> </tr> <tr> <td><strong>Geographic distribution</strong></td> <td>West, Central Africa</td> <td>East Africa</td> </tr> <tr> <td><strong>Fly species</strong></td> <td><em>Glossina palpalis</em></td> <td><em>Glossina morsitans</em></td> </tr> <tr> <td><strong>Fly habitat</strong></td> <td>Humid; river habitat</td> <td>Dry; savannah and woodland habitat</td> </tr> <tr> <td><strong>Primary host</strong></td> <td>Humans</td> <td>Animals</td> </tr> <tr> <td><strong>Nature of clinical infection</strong></td> <td>Chronic</td> <td>Acute</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 85846 Version 2.0</div></div></div>"},"85847":{"type":"graphic_table","displayName":"Spitz tumors histo differential","title":"Histopathologic criteria for conventional Spitz nevi, atypical Spitz tumors, and melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histopathologic criteria for conventional Spitz nevi, atypical Spitz tumors, and melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Conventional Spitz tumors</td> <td class=\"subtitle1\">Atypical Spitz tumors</td> <td class=\"subtitle1\">Melanoma</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Architecture</td> </tr> <tr> <td class=\"indent1\">Diameter</td> <td>&#60;5 to 6 mm</td> <td>&#8805;5 to 6 mm</td> <td>&#8805;10 mm</td> </tr> <tr> <td class=\"indent1\">Outline</td> <td>Symmetric (wedge-shaped)</td> <td>Asymmetric</td> <td>Asymmetric</td> </tr> <tr> <td class=\"indent1\">Circumscription</td> <td>Sharp lateral circumscription</td> <td>Often poor circumscription</td> <td>Poor circumscription</td> </tr> <tr> <td class=\"indent1\">Epidermal hyperplasia</td> <td>Present</td> <td>Effacement of the epidermis may be present</td> <td>Absent, or effacement of the epidermis may be present</td> </tr> <tr> <td class=\"indent1\">Maturation with dermal depth</td> <td>Present</td> <td>Possibly diminished or lack of zonation and maturation</td> <td>Lack of zonation and maturation often present</td> </tr> <tr> <td class=\"indent1\">Eosinophilic hyaline globules (Kamino bodies)</td> <td>Present</td> <td>Absent or few </td> <td>Typically absent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cellular density</td> <td>Orderly nondisruptive infiltration of collagen by melanocytes</td> <td>High cellular density</td> <td>High cellular density</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Cytology</td> </tr> <tr> <td class=\"indent1\">Cellular population</td> <td>Uniform spindle and/or epithelioid</td> <td>Spindle and/or epithelioid cells showing increasing cytologic atypia</td> <td>Spindle and/or epithelioid cells showing increasing cytologic atypia and pleomorphism</td> </tr> <tr> <td class=\"indent1\">Cytoplasm</td> <td>Opaque or ground glass cytoplasm</td> <td>Granular versus ground glass cytoplasm</td> <td>Granular or mixed cytoplasm</td> </tr> <tr> <td class=\"indent1\">Nuclear to cytoplasmic ratio</td> <td>Low nuclear to cytoplasmic ratio</td> <td>Increasingly high nuclear to cytoplasmic ratio</td> <td>High nuclear to cytoplasmic ratio</td> </tr> <tr> <td class=\"indent1\">Chromatin pattern</td> <td>Nuclei with open, delicate chromatin pattern</td> <td>Loss of delicate or dispersed chromatin pattern</td> <td>Loss of delicate or dispersed chromatin pattern</td> </tr> <tr> <td class=\"indent1\">Nucleoli</td> <td>Uniform nucleoli</td> <td>Increasingly prominent nucleoli</td> <td>Large nucleoli</td> </tr> <tr> <td class=\"indent1\">Pleomorphism</td> <td>Rare</td> <td>May be present</td> <td>Usually present</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hyperchromatism</td> <td>Absent</td> <td>May be present</td> <td>Present</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Proliferation</td> </tr> <tr> <td>Mitotic rate </td> <td>&#60;2/mm<sup>2</sup><br /> Absent or rare mitoses in deep dermis<br /> Lack of atypical mitoses</td> <td> <p>2 to 6/mm<sup>2</sup> (particularly &#62;6/mm<sup>2</sup>)<br /> Deep or marginal dermal mitoses may be present</p> <br /> </td> <td> <p>2 to 6/mm<sup>2</sup> (particularly &#62;6/mm<sup>2</sup>)<br /> Deep or marginal dermal mitoses frequently present</p> <br /> </td> </tr> <tr> <td>Proliferative index (Ki-67 expression)</td> <td>&nbsp;&#60;2% </td> <td> <p>2 to &#62;10% </p> </td> <td>Often &#62;15 to 30%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Barnhill RL. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment. Mod Pathol 2006; 19 Suppl 2:S21.</div><div id=\"graphicVersion\">Graphic 85847 Version 3.0</div></div></div>"},"85848":{"type":"graphic_figure","displayName":"Systolic pressure variation and pulse pressure variation","title":"Systolic pressure variation and pulse pressure variation","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Systolic pressure variation and pulse pressure variation</div><div class=\"cntnt\"><img style=\"width:503px; height:409px;\" src=\"images/ANEST/85848_Systolic_pressure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Respiratory variations in arterial pressure.</div><div class=\"graphic_footnotes\">SPV: systolic pressure variation; PP<sub>MAX</sub>: pulse pressure maximal; PP<sub>MIN</sub>: pulse pressure minimal.</div><div id=\"graphicVersion\">Graphic 85848 Version 4.0</div></div></div>"},"85849":{"type":"graphic_table","displayName":"Classification of allergic rhinitis","title":"Classification of allergic rhinitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of allergic rhinitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>\"Intermittent\" means that the symptoms are present: <ul> <li>Less than&nbsp;four days a week </li> <li>Or for less than&nbsp;four weeks </li> </ul> </td> </tr> <tr> <td>\"Persistent\" means that the symptoms are present: <ul> <li>More than&nbsp;four days a week </li> <li>And for more than&nbsp;four weeks </li> </ul> </td> </tr> <tr> <td>\"Mild\" means that none of the following items are present: <ul> <li>Sleep disturbance </li> <li>Impairment of daily activities, leisure, and/or sport </li> <li>Impairment of school or work </li> <li>Troublesome symptoms </li> </ul> </td> </tr> <tr> <td>\"Moderate-severe\" means that one or more of the following items are present: <ul> <li>Sleep disturbance </li> <li>Impairment of daily activities, leisure, and/or sport </li> <li>Impairment of school or work </li> <li>Troublesome symptoms </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108:S147. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85849 Version 2.0</div></div></div>"},"85850":{"type":"graphic_table","displayName":"Dynamic parameters for intraoperative fluid therapy","title":"Dynamic parameters for intraoperative fluid therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dynamic parameters for intraoperative fluid therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Advantage</td> <td class=\"subtitle1\">Disadvantage</td> </tr> <tr> <td><strong>Systolic pressure variations</strong></td> <td> <p>Easy to manually calculate</p> </td> <td> <p>Depends on diastolic pressure and on changes in pleural pressure</p> <p><span style=\"color: #ff0000;\"><span style=\"color: black;\">(Has not&nbsp;been studied in the prone position</span><span style=\"color: black;\">)</span></span></p> </td> </tr> <tr> <td rowspan=\"2\"><strong>Pulse pressure variations</strong></td> <td rowspan=\"2\">Directly related to stroke volume variations</td> <td>Not easy to manually calculate</td> </tr> <tr> <td>Need specific device for continuous display</td> </tr> <tr> <td><strong>Stroke volume variations</strong></td> <td>Accurate analysis despite multiple extrasystoles</td> <td>Need specific device</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Biais M, Ouattara A, Janvier G, Sztark F. Case scenario: Respiratory variations in arterial pressure for guiding fluid management in mechanically ventilated patients. Anesthesiology 2012; 116:1354. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85850 Version 9.0</div></div></div>"},"85851":{"type":"graphic_picture","displayName":"Periocular syringomas","title":"Syringomas","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Syringomas</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/85851_Periocular_syringomas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple skin-colored papules are present on the periocular skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85851 Version 3.0</div></div></div>"},"85852":{"type":"graphic_waveform","displayName":"ECG in a patient with L-TGA","title":"ECG in a patient with L-transposition of the great arteries","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">ECG in a patient with L-transposition of the great arteries</div><div class=\"cntnt\"><img style=\"width:582px; height:438px;\" src=\"images/PEDS/85852_ECG_in_patient_L_GTA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram (ECG) performed in pediatric patient with isolated L-transposition of the great arteries. Note the absence of initial Q waves that are typically seen in leads V5 and V6 (lateral precordial leads), as well as the abnormal presence of initial Q waves in leads V3R and V1 (anterior precordial leads). These findings represent the abnormal depolarization sequence of the interventricular septum present in ventricular inversion.</div><div id=\"graphicVersion\">Graphic 85852 Version 2.0</div></div></div>"},"85855":{"type":"graphic_diagnosticimage","displayName":"Mycobacterium marinum osteomyelitis","title":"Osteomyelitis and septic arthritis due to Mycobacterium marinum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis and septic arthritis due to Mycobacterium marinum</div><div class=\"cntnt\"><img style=\"width:194px; height:504px;\" src=\"images/ID/85855_Myobact_marin_osteomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">65-year-old woman with history of puncture wound of distal phalanx from contact with fish spines who presented with swelling and pain at site of minor injury. Mycobacterium marinum was recovered from synovial biopsy. Frontal radiograph of digit shows soft-tissue swelling (arrowheads), marginal osseous erosion at corner of distal interphalangeal joint (curved arrow), and remarkable joint-space narrowing (straight arrows), consistent with septic arthritis and osteomyelitis.</div><div class=\"graphic_reference\">From: Theodorou DJ, Theodorou SJ, Kakitsubata Y, et al. Imaging Characteristics and Epidemiologic Features of Atypical Mycobacterial Infections Involving the Musculoskeletal System. AJR Am J Roentgenol 2001; 176:341. Reprinted with permission from the American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 85855 Version 4.0</div></div></div>"},"85856":{"type":"graphic_diagnosticimage","displayName":"Vertebral NTM osteomyelitis on MRI","title":"MRI of vertebral osteomyelitis caused by nontuberculous mycobacteria","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">MRI of vertebral osteomyelitis caused by nontuberculous mycobacteria</div><div class=\"cntnt\"><img style=\"width:460px; height:460px;\" src=\"images/ID/85856_Vertebral_NTM_osteomyle_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spine MRI of a 39-year-old immunocompromised man who developed M. fortuitum spinal infection thought to be a result of paraspinal steroid injections for low back pain. The T2-weighted MRI image demonstrates enhancement within the L4 and L5 vertebral bodies consistent with osteomyelitis. Culture of a biopsy specimen of the vertebral bone grew M. fortuitum.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Dr. Shannon Kasperbauer and Dr. Charles Daley.</div><div id=\"graphicVersion\">Graphic 85856 Version 3.0</div></div></div>"},"85857":{"type":"graphic_diagnosticimage","displayName":"NTM clavicle osteomyelitis on CT scan","title":"CT scan of the chest showing osteomyelitis of the right clavicle due to M. abscessus","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">CT scan of the chest showing osteomyelitis of the right clavicle due to M. abscessus</div><div class=\"cntnt\"><img style=\"width:576px; height:435px;\" src=\"images/ID/85857_Vertebral_NTM_osteo_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of a 55-year-old man with disseminated M. abscessus. The infection began in the left ankle and seeded multiple other bones including the right clavicle. The CT scan demonstrates advanced destruction of the right distal clavicle with bony fragmentation and an associated soft tissue mass. The histopathology at the time of debridement showed granulomas. This case supports the theory of locus minoris resistentiae, since this patient had received local radiation therapy to his right chest wall thirty years earlier for Hodgkin lymphoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Dr. Shannon Kasperbauer and Dr. Charles Daley.</div><div id=\"graphicVersion\">Graphic 85857 Version 2.0</div></div></div>"},"85858":{"type":"graphic_diagnosticimage","displayName":"Brain MRI of CLIPPERS","title":"Brain MRI of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain MRI of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)</div><div class=\"cntnt\"><img style=\"width:366px; height:590px;\" src=\"images/NEURO/85858_Brain_MRI_CLIPPERS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Initial T1-weighted postgadolinium brain MRI of a 48-year-old man with progressive vertigo, ataxia, and dysarthria.<br />(A) Symmetric enhancement of the pons and both cerebellar peduncles, with pattern highly suggestive of a perivascular distribution.<br />(B) Near complete resolution with corticosteroids.<br />(C) Recurrence of the same lesions without corticosteroids.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Lefaucheur R, Bouwyn JP, Ahtoy P, G&eacute;rardin E, Derrey S, Malt&ecirc;te D. Teaching neuroimages: punctuate and curvilinear enhancement peppering the pons responsive to steroids. Neurology 2011; 77:e57. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85858 Version 5.0</div></div></div>"},"85859":{"type":"graphic_figure","displayName":"Extensor tendons traversing wrist","title":"Extensor tendons traversing the wrist","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Extensor tendons traversing the wrist</div><div class=\"cntnt\"><img style=\"width:585px; height:439px;\" src=\"images/EM/85859_Extentendonstraverswrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: The Upper Limb. In: Clinically Oriented Anatomy, 6th ed, Moore KM, Dalley AF, Agur A (ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85859 Version 7.0</div></div></div>"},"85861":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of first extensor compartment wrist","title":"Ultrasound of the first extensor compartment of the wrist","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Ultrasound of the first extensor compartment of the wrist</div><div class=\"cntnt\"><img style=\"width:590px; height:260px;\" src=\"images/SM/85861_US_first_exten_comp_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the first extensor compartment. The image was obtained with an ultrasound probe placed at the site of the red mark in the photograph.</div><div class=\"graphic_footnotes\">A: artery; APL: abductor pollicis longus; EPB: extensor pollicis brevis; V: vein.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 85861 Version 4.0</div></div></div>"},"85862":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of second extensor compartment wrist","title":"Ultrasound of the second extensor compartment of the wrist","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Ultrasound of the second extensor compartment of the wrist</div><div class=\"cntnt\"><img style=\"width:612px; height:347px;\" src=\"images/SM/85862_US_second_exten_comp_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These ultrasound images show the second extensor compartment of the wrist. The superior image, marked by the red box, was obtained with the ultrasound probed positioned at the site of the red mark in the photograph. The image below was obtained with the probe at the yellow mark.</div><div class=\"graphic_footnotes\">APL: abductor pollicis longus; ECRL: extensor carpi radialis longus; ECRB: extensor carpi radialis brevis; EPB: extensor pollicis brevis.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 85862 Version 4.0</div></div></div>"},"85863":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of third extensor compartment wrist","title":"Ultrasound of the third extensor compartment of the wrist","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Ultrasound of the third extensor compartment of the wrist</div><div class=\"cntnt\"><img style=\"width:590px; height:271px;\" src=\"images/SM/85863_US_third_exten_comp_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the third extensor compartment of the wrist. The image was obtained with the ultrasound probe placed at the site of the red mark in the photograph.</div><div class=\"graphic_footnotes\">ECRB: extensor carpi radialis brevis tendon; LT: Listers tubercle; EPL: extensor pollicis longus tendon; IV: fourth extensor compartment.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 85863 Version 3.0</div></div></div>"},"85864":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of fourth extensor compartment wrist","title":"Ultrasound of the fourth extensor compartment of the wrist","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Ultrasound of the fourth extensor compartment of the wrist</div><div class=\"cntnt\"><img style=\"width:590px; height:235px;\" src=\"images/SM/85864_US_fourth_exten_comp_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The extensor digitorum and the extensor indicis of the fourth extensor compartment (IV) are shown in this ultrasound image, along with the ECRL, ECRB, and EPL. The image was obtained with an ultrasound probe placed at the site of the red mark in the photograph.</div><div class=\"graphic_footnotes\">ECRL: extensor carpi radialis longus tendon; ECRB: extensor carpi radialis brevis; EPL: extensor pollicis longus; LT: Listers tubercle; IV:&nbsp;fourth extensor compartment (extensor digitorum; extensor indicis).</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 85864 Version 3.0</div></div></div>"},"85865":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of fifth extensor compartment wrist","title":"Ultrasound of the fifth extensor compartment of the wrist","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Ultrasound of the fifth extensor compartment of the wrist</div><div class=\"cntnt\"><img style=\"width:590px; height:236px;\" src=\"images/SM/85865_US_fifth_exten_comp_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound shows the fifth extensor compartment, in addition to the other structures pictured. The image was obtained with an ultrasound probe placed at the site of the red mark in the photograph.&nbsp;</div><div class=\"graphic_footnotes\">ECRL: extensor carpi radialis longus tendon; ECRB: extensor carpi radialis brevis tendon; EPL: extensor pollicis longus; LT: Listers tubercle; V:&nbsp;fifth extensor&nbsp;compartment, containing extensor digiti minimi.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 85865 Version 4.0</div></div></div>"},"85866":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of sixth extensor compartment wrist","title":"Ultrasound of the sixth extensor compartment of the wrist","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Ultrasound of the sixth extensor compartment of the wrist</div><div class=\"cntnt\"><img style=\"width:612px; height:355px;\" src=\"images/SM/85866_US_sixth_exten_comp_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These ultrasound images show the sixth extensor compartment of the wrist. The superior image, marked by the red box, was obtained with the ultrasound probe positioned where the red mark appears on the wrist in the photograph. The image below was obtained where the yellow mark appears on the wrist.</div><div class=\"graphic_footnotes\">ECU: extensor carpi ulnaris tendon.</div><div class=\"graphic_reference\">Courtesy of Blake Boggess, DO.</div><div id=\"graphicVersion\">Graphic 85866 Version 4.0</div></div></div>"},"85868":{"type":"graphic_figure","displayName":"Urethral sling PI","title":"Sling to treat incontinence in women","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Sling to treat incontinence in women</div><div class=\"cntnt\"><img style=\"width:529px; height:484px;\" src=\"images/PI/85868_UrethralslingPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The urethra is the tube that carries urine from the bladder out of the body. A sling is a small piece of material that goes&nbsp;under the urethra. The material stays in your body and helps keep the urethra from leaking urine. In this picture, the ends of the sling are placed just below the skin in the belly. The ends of&nbsp;a sling can also be placed lower down, closer to the hips.</div><div id=\"graphicVersion\">Graphic 85868 Version 2.0</div></div></div>"},"85871":{"type":"graphic_picture","displayName":"Fissured tongue 1","title":"Fissured tongue","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fissured tongue</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/85871_Fissured_tongue_adult_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 85871 Version 4.0</div></div></div>"},"85872":{"type":"graphic_picture","displayName":"Atrophic glossitis 2","title":"Atrophic glossitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrophic glossitis</div><div class=\"cntnt\"><img style=\"width:194px; height:299px;\" src=\"images/DERM/85872_Atrophic_glossitis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: British Dental Journal. Scully C, Felix DH. Oral medicine-update for the dental practitioner: red and pigmented lesions. Br Dent J 2005; 199:639. Copyright &copy; 2005.</div><div id=\"graphicVersion\">Graphic 85872 Version 1.0</div></div></div>"},"85874":{"type":"graphic_figure","displayName":"Pancreatic panniculitis in patient w acinar cell panc cancer","title":"Pancreatic panniculitis in a patient with acinar cell pancreatic cancer","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Pancreatic panniculitis in a patient with acinar cell pancreatic cancer</div><div class=\"cntnt\"><img style=\"width:468px; height:619px;\" src=\"images/ONC/85874_Pancr_pannic_acinar_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Painful subcutaneous nodules (pancreatic panniculitis) [A] in a patient with a mass within the pancreas (on CT, arrows) [B], which on endoscopically-guided ultrasound (EUS)-guided biopsy [C] proved to be an acinar cell cancer (histology) [D].</div><div id=\"graphicVersion\">Graphic 85874 Version 2.0</div></div></div>"},"85875":{"type":"graphic_figure","displayName":"Endovascular surgery PI","title":"Endovascular surgery","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Endovascular surgery</div><div class=\"cntnt\"><img style=\"width:488px; height:630px;\" src=\"images/PI/85875_Endovascular_surgery_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For endovascular surgery, the surgeon inserts a tube called a catheter into a large blood vessel, usually in the arm or leg. Then the surgeon pushes the tube further and further into the blood vessel until it reaches the part of the body that needs surgery. In this case, the catheter has been placed in the heart. Within the tube are special tools that the surgeon can use to treat different medical problems.</div><div id=\"graphicVersion\">Graphic 85875 Version 1.0</div></div></div>"},"85880":{"type":"graphic_picture","displayName":"CMML peripheral smear","title":"Chronic myelomonocytic leukemia peripheral smear","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chronic myelomonocytic leukemia peripheral smear</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/85880_CMMLperipheralsmear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic myelomonocytic leukemia, peripheral blood. Monocytes are increased and show a higher nucleus:cytoplasm ratio compared with normal cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Farhi DC. Myelodysplastic syndromes. In: Pathology of Bone Marrow and Blood Cells, 2nd ed, Farhi DC (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85880 Version 6.0</div></div></div>"},"85881":{"type":"graphic_picture","displayName":"Dysplastic neutrophils MDS","title":"Dysplastic neutrophils in myelodysplastic syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dysplastic neutrophils in myelodysplastic syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/HEME/85881_DysplasticneutroMDS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dysplastic neutrophils, peripheral blood. The cells are nearly agranular. The nuclear segmentation is also abnormal.</div><div class=\"graphic_reference\">Reproduced with permission from: Farhi DC. Myelodysplastic syndromes. In: Pathology of Bone Marrow and Blood Cells, 2nd ed, Farhi DC (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85881 Version 7.0</div></div></div>"},"85882":{"type":"graphic_picture","displayName":"Dysplastic RBC in MDS","title":"Dysplastic red blood cell in myelodysplastic syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dysplastic red blood cell in myelodysplastic syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:380px;\" src=\"images/HEME/85882_DysplasticRBCMDS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dysplastic nucleated red blood cell, peripheral blood. The nucleus shows an abnormal shape and size.</div><div class=\"graphic_reference\">Reproduced with permission from: Farhi DC. Myelodysplastic syndromes. In: Pathology of Bone Marrow and Blood Cells, 2nd ed, Farhi DC (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85882 Version 6.0</div></div></div>"},"85883":{"type":"graphic_picture","displayName":"RBC dysplasia in MDS","title":"Red blood cell dysplasia in myelodysplastic syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Red blood cell dysplasia in myelodysplastic syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/HEME/85883_RBCdysplasiaMDS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dysplastic nucleated red blood cells, peripheral blood. Abnormal nuclear shape (black arrow) and basophilic stippling (red arrow) are present.</div><div class=\"graphic_reference\">Reproduced with permission from: Farhi DC. Myelodysplastic syndromes. In: Pathology of Bone Marrow and Blood Cells, 2nd ed, Farhi DC (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85883 Version 6.0</div></div></div>"},"85884":{"type":"graphic_figure","displayName":"Flow cytometry FL","title":"Flow cytometry follicular lymphoma","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Flow cytometry follicular lymphoma</div><div class=\"cntnt\"><img style=\"width:594px; height:388px;\" src=\"images/HEME/85884_FlowcytometryFL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow cytometric histograms show dual staining of CD10 and CD19, as well as CD20 and bcl-2. A monoclonal &kappa; pattern, positive FMC-7, and partial positive CD23 are also demonstrated. A small percentage of T cells are also present in the gated population, as represented by the CD5-positive and bcl-2-positive/CD20-negative clusters.</div><div class=\"graphic_footnotes\">SS: side scatter; PC5: phycoerythrin-cyanin 5; PE: phycoerythrin; ECD: phycoerythrin-Texas Red; FITC: fluorescein isothiocyanate.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85884 Version 6.0</div></div></div>"},"85885":{"type":"graphic_picture","displayName":"FL immunohistochemistry","title":"Follicular lymphoma immunohistochemistry","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Follicular lymphoma immunohistochemistry</div><div class=\"cntnt\"><img style=\"width:515px; height:380px;\" src=\"images/HEME/85885_FLimmunohistchem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lymph node biopsy shows positive CD10 staining in malignant follicles. Immunoperoxidase, 10x magnification. <br />(B) Lymph node biopsy shows positive bcl-2 staining in malignant follicles. Immunoperoxidase, 10x magnification. <br />(C) Lymph node biopsy shows positive bcl-6 staining in malignant follicles. Immunoperoxidase, 10x magnification. <br />(D) Lymph node biopsy shows moderate Ki-67 staining in malignant follicle. Immunoperoxidase, 10x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85885 Version 6.0</div></div></div>"},"85886":{"type":"graphic_picture","displayName":"FL paratrabecular lymphoid infiltration","title":"Follicular lymphoma: paratrabecular lymphoid infiltration","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Follicular lymphoma: paratrabecular lymphoid infiltration</div><div class=\"cntnt\"><img style=\"width:504px; height:369px;\" src=\"images/HEME/85886_FLparatrablymph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow biopsy shows a paratrabecular lymphoid infiltration pattern, characteristic of follicular lymphoma. Hematoxylin and eosin, 20x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_parent>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85886 Version 6.0</div></div></div>"},"85887":{"type":"graphic_picture","displayName":"FL grade 3","title":"Follicular lymphoma, grade 3","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Follicular lymphoma, grade 3</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/85887_FLgrade3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The nodule in the upper half of the picture is made largely of large cells with highly pleomorphic nuclei, prominent nucleoli, and mitoses. Hematoxylin, phloxine, and saffron stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85887 Version 6.0</div></div></div>"},"85888":{"type":"graphic_picture","displayName":"Packed nodules FL","title":"Follicular lymphoma showing characteristic pattern of closely packed nodules with some variation in size and shape","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Follicular lymphoma showing characteristic pattern of closely packed nodules with some variation in size and shape</div><div class=\"cntnt\"><img style=\"width:504px; height:403px;\" src=\"images/HEME/85888_PackednodulesFL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin, phloxine, and saffron stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85888 Version 6.0</div></div></div>"},"85889":{"type":"graphic_picture","displayName":"FL grade 1","title":"Follicular lymphoma, grade 1","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Follicular lymphoma, grade 1</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/85889_FLgrade1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lower half of the picture shows nodule composed of fairly homogenous population of cells slightly larger than lymphocytes (upper half) with cleaved nuclei, inconspicuous nucleoli, and lack of mitoses. Hematoxylin, phloxine, and saffron stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85889 Version 6.0</div></div></div>"},"85890":{"type":"graphic_picture","displayName":"FL grade 2","title":"Follicular lymphoma, grade 2","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Follicular lymphoma, grade 2</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/85890_FLgrade2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scattered throughout the centrocyte-like cells are five to 15 large, centroblast-like cells. Hematoxylin, phloxine, and saffron stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85890 Version 7.0</div></div></div>"},"85891":{"type":"graphic_table","displayName":"SCOPER categorization system","title":"SCOPER categorization system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">SCOPER categorization system</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sleep</td> <td class=\"subtitle1\">Cardiovascular</td> <td class=\"subtitle1\">Oximetry</td> <td class=\"subtitle1\">Position</td> <td class=\"subtitle1\">Effort</td> <td class=\"subtitle1\">Respiratory</td> </tr> <tr> <td>S<sub>1 </sub>- Sleep by 3 EEG channels* with EOG and chin EMG</td> <td>C<sub>1</sub> - More than 1 ECG lead - can derive events</td> <td>O<sub>1</sub> - Oximetry (finger or ear) with recommended sampling</td> <td>P<sub>1</sub> - Video or visual position measurement</td> <td>E<sub>1</sub> - 2 RIP belts</td> <td>R<sub>1</sub> - Nasal pressure and thermal device</td> </tr> <tr> <td>S<sub>2</sub>&nbsp;- Sleep by less than 3 EEG channels* with or without EOG or chin EMG</td> <td>C<sub>2</sub> - Peripheral arterial tonometry</td> <td>O<sub>1x</sub> - Oximetry (finger or ear) without recommended sampling (per Scoring Manual) or not described</td> <td>P<sub>2</sub> - Non-visual position measurement</td> <td>E<sub>2</sub> - 1 RIP belt</td> <td>R<sub>2</sub> - Nasal pressure</td> </tr> <tr> <td>S<sub>3</sub> - Sleep surrogate: eg, actigraphy</td> <td>C<sub>3</sub> - Standard ECG measure (1 lead)</td> <td>O<sub>2</sub> - Oximetry with alternative site (eg, forehead)</td> <td>&nbsp;</td> <td>E<sub>3</sub> - Derived effort (eg, forehead versus pressure)</td> <td>R<sub>3</sub> - Thermal device</td> </tr> <tr> <td>S<sub>4</sub> - Other sleep measure</td> <td>C<sub>4</sub> - Derived pulse (typically from oximetry)</td> <td>O<sub>3</sub> - Other oximetry</td> <td>&nbsp;</td> <td>E<sub>4</sub> - Other effort measure (including piezo belts)</td> <td>R<sub>4</sub> - End-Tidal CO<sub>2</sub></td> </tr> <tr> <td>&nbsp;</td> <td>C<sub>5</sub> - Other cardiac measure</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>R<sub>5</sub> - Other respiratory measure</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Proper oximetry sampling is defined as 3 s averaging and a minimum of 10 Hz sampling rate (25 Hz desirable)<sup>[1]</sup>.</div><div class=\"graphic_footnotes\">EEG: electroencephalography; EOG: electrooculography; EMG: electromyography; ECG: electrocardiography; RIP: respiratory inductance plethysmography.<br />* 3 EEG channels defined as frontal, central, and occipital.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Iber C, Ancoli-Israel S, Chesson A, Quan SF. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, 1st ed. American Academy of Sleep Medicine, Westchester, IL 2007.</LI></OL>&#xD;&#xA;Reproduced with permission from: Collop NA, Tracy SL, Kapur V, et al. Obstructive sleep apnea devices for out-of-center (OOC) testing: technology evaluation. J Clin Sleep Med 2011; 7:531. Copyright © 2011 American Academy of Sleep Medicine.</div><div id=\"graphicVersion\">Graphic 85891 Version 1.0</div></div></div>"},"85896":{"type":"graphic_picture","displayName":"Blepharitis eye","title":"Blepharitis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Blepharitis</div><div class=\"cntnt\"><img style=\"width:540px; height:371px;\" src=\"images/PC/85896_Blepharitis_eye.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blepharitis is associated with crusting of the eyelashes, thickening of the eyelids, telangiectatic vessels along the lid margins, and plugging of the meibomian glands.</div><div class=\"graphic_reference\">Reproduced with permission from: The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed, Tasman W, Jaeger E (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85896 Version 1.0</div></div></div>"},"85898":{"type":"graphic_picture","displayName":"Episcleritis nodular","title":"Nodular episcleritis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Nodular episcleritis</div><div class=\"cntnt\"><img style=\"width:540px; height:369px;\" src=\"images/PC/85898_Episcleritis_nodular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Episcleritis is a localized ocular redness from inflammation of the episcleral vessels. In natural light, vessels appear salmon pink and are movable over the scleral surface. Usually benign and self-limited, episcleritis may be nodular, as shown here, or may show only redness and dilated vessels.</div><div class=\"graphic_reference\">Reproduced with permission from: The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed, Tasman W, Jaeger E (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85898 Version 1.0</div></div></div>"},"85900":{"type":"graphic_picture","displayName":"Blepharitis II","title":"Blepharitis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Blepharitis</div><div class=\"cntnt\"><img style=\"width:540px; height:355px;\" src=\"images/PC/85900_BlepharitisII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lid margins diffusely and irregularly swollen and red.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe JD, Hackel RE. Field Guide to the Eyes. Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85900 Version 6.0</div></div></div>"},"85904":{"type":"graphic_picture","displayName":"Anterior uveitis II","title":"Anterior uveitis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Anterior uveitis</div><div class=\"cntnt\"><img style=\"width:540px; height:372px;\" src=\"images/PC/85904_Anterior_uveitis_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The irregular pupil shape is caused by inflammatory adhesion of the iris margin to the anterior lens surface superiorly.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe JD. The Physician's Guide to Eye Care, American Academy of Ophthalmology 1993. Copyright &copy; 1993.</div><div id=\"graphicVersion\">Graphic 85904 Version 1.0</div></div></div>"},"85905":{"type":"graphic_picture","displayName":"Bacterial keratitis","title":"Bacterial keratitis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Bacterial keratitis</div><div class=\"cntnt\"><img style=\"width:540px; height:415px;\" src=\"images/PC/85905_Bacterial_keratitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The white corneal opacity suggests purulence necrosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe JD. The Physician's Guide to Eye Care, American Academy of Ophthalmology 1993. Copyright &copy; 1993.</div><div id=\"graphicVersion\">Graphic 85905 Version 1.0</div></div></div>"},"85906":{"type":"graphic_picture","displayName":"Weeverfish","title":"Weeverfish","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Weeverfish</div><div class=\"cntnt\"><img style=\"width:586px; height:328px;\" src=\"images/EM/85906_Weeverfish.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Weeverfish (also called weevers or weaver fish) can cause painful stings when stepped on by waders in shallow water. Most stings are from the lesser weeverfish&nbsp;(&lt;14 cm, shown above), which buries itself in sand in shallow areas near the shore. It is commonly found around the southern coasts of the United Kingdom and Ireland, Atlantic coasts of France and Spain, and the Northern Mediterranean sea.</div><div class=\"graphic_reference\">Photo by Tom Oates, 2009.</div><div id=\"graphicVersion\">Graphic 85906 Version 1.0</div></div></div>"},"85907":{"type":"graphic_figure","displayName":"Progression of hiatus hernia","title":"Progressive anatomic disruption of the gastroesophageal junction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Progressive anatomic disruption of the gastroesophageal junction</div><div class=\"cntnt\"><img style=\"width:269px; height:623px;\" src=\"images/GAST/85907_Progression_hiatus_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance and corresponding three-dimensional representation of the progressive anatomic disruption of the gastroesophageal junction as occurs with development of a type I hiatus hernia. In the grade I configuration, a ridge of muscular tissue is closely approximated to the shaft of the retroflexed endoscope. With a grade II configuration the ridge of tissue is slightly less well defined and there has been slight orad displacement of the squamocolumnar junction along with widening of the angle of His. In the grade III appearance the ridge of tissue at the gastric entryway is barely present and there is often incomplete luminal closure around the endoscope. Note, however, that this is not a hiatal hernia because the squamocolumnar junction is not displaced axially in the endoscopic photograph. With grade IV deformity, no muscular ridge is present at the gastric entry. The gastroesophageal area stays open all the time, and squamous epithelium of the distal oesophagus can be seen from the retroflexed endoscopic view. A hiatus hernia is always present with grade IV deformity.</div><div class=\"graphic_reference\">Reproduced from: Bredenoord AJ, Pandolfino JE, Smout AJ. Gastro-oesophageal reflux disease. Lancet 2013; 381:1933. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85907 Version 1.0</div></div></div>"},"85909":{"type":"graphic_figure","displayName":"Closed reduction for posterior sternoclavicular dislocation","title":"Closed reduction for posterior sternoclavicular dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Closed reduction for posterior sternoclavicular dislocation</div><div class=\"cntnt\"><img style=\"width:431px; height:455px;\" src=\"images/EM/85909_Closredpossterdis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Technique for closed reduction of the SC joint.<br />(A) The patient is positioned supine with a sandbag placed between the two shoulders. Traction is then applied to the arm against countertraction in an abducted and slightly extended position. In anterior dislocations, direct pressure over the medial end of the clavicle may reduce the joint.<br />(B) In addition to the traction, it may be necessary to manipulate the medial end of the clavicle with the fingers to dislodge the clavicle from behind the manubrium.<br />(C) In stubborn posterior dislocations, it may be necessary to sterilely prepare the medial end of the clavicle and use a towel clip to grasp around the medial clavicle to lift it back into position.</div><div class=\"graphic_reference\">Reproduced with permission from: Dutta AK, Wirth MA, Rockwood CA. Sternoclavicular joint injuries. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Torneta III P (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85909 Version 6.0</div></div></div>"},"85910":{"type":"graphic_table","displayName":"Therapeutic uses of antimalarial drugs","title":"Therapeutic uses of antimalarial drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic uses of antimalarial drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Well-documented benefit</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Malaria</td> </tr> <tr> <td>Cutaneous sarcoidosis</td> </tr> <tr> <td>Cutaneous dermatomyositis</td> </tr> <tr> <td>Polymorphous light eruption</td> </tr> <tr> <td>Primary Sj&#246;gren's syndrome</td> </tr> <tr> <td>Palindromic rheumatism</td> </tr> <tr> <td class=\"subtitle1_single\">Probable benefit</td> </tr> <tr> <td>Thromboprophylaxis relating to orthopedic procedures and in patients with antiphospholipid syndrome</td> </tr> <tr> <td>Osteoporosis</td> </tr> <tr> <td>Hyperlipidemia</td> </tr> <tr> <td class=\"subtitle1_single\">Possible benefit</td> </tr> <tr> <td>Porphyria cutanea tarda</td> </tr> <tr> <td>Hypercalcemia</td> </tr> <tr> <td>Chronic fatigue syndrome, also known as systemic exertion intolerance disease</td> </tr> <tr> <td>Asthma</td> </tr> <tr> <td>Polymyalgia rheumatica</td> </tr> <tr> <td>Atopic dermatitis</td> </tr> <tr> <td>Morphea</td> </tr> <tr> <td>Urticarial vasculitis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Daniel J Wallace, MD.</div><div id=\"graphicVersion\">Graphic 85910 Version 3.0</div></div></div>"},"85912":{"type":"graphic_figure","displayName":"Death rates for coronary heart disease in selected countries","title":"Death rates* for coronary heart disease in selected countries, 1970 to 2009","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Death rates* for coronary heart disease in selected countries, 1970 to 2009</div><div class=\"cntnt\"><img style=\"width:458px; height:604px;\" src=\"images/CARD/85912_Dth_rt_coronary_hrt_cnt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Age-adjusted to the European Standard Population.<br /><span class=\"bullet\">&#8226;</span> United Kingdom for 2008 and 2009; England and Wales for 1970 to 2007.</div><div class=\"graphic_reference\">Reproduced from: NHLBI Fact Book, 2011. National Heart Lung and Blood Institute. Available at: http://www.nhlbi.nih.gov/about/factbook/toc.htm.</div><div id=\"graphicVersion\">Graphic 85912 Version 1.0</div></div></div>"},"85913":{"type":"graphic_table","displayName":"Spitz tumor grading","title":"Grading system for atypical Spitz tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading system for atypical Spitz tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"90%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Age (years)</td> </tr> <tr> <td class=\"indent1\">0 to 10</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">11 to 17</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Diameter, mm</td> </tr> <tr> <td class=\"indent1\">0 to 10</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">&#62;10</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Subcutaneous involvement</td> </tr> <tr> <td class=\"indent1\">Absent</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Present</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Ulceration</td> </tr> <tr> <td class=\"indent1\">Absent</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">Present</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mitotic activity/mm<sup>2</sup></td> </tr> <tr> <td class=\"indent1\">0 to 5</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1\">6 to 8</td> <td class=\"centered\">2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;8</td> <td class=\"centered\">5</td> </tr> <tr> <td><strong>Total</strong>*</td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*0 to 2 indicates low risk; 3 to 4, intermediate risk; 5 to 11, high risk.</div><div class=\"graphic_reference\">Reproduced with permission from: Spatz A, Calonje E, Handfield-Jones S, Barnhill RL. Spitz tumors in children: a grading system for risk stratification. Arch Dermatol 1999; 135:282. Copyright &copy; 1999 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85913 Version 10.0</div></div></div>"},"85916":{"type":"graphic_table","displayName":"Concentration of uremic solutes","title":"The concentration of uremic solutes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The concentration of uremic solutes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Molecule</td> <td class=\"subtitle1\">M/N</td> </tr> <tr> <td>alpha1-Acid glycoprotein</td> <td class=\"centered\">1.96</td> </tr> <tr> <td>Nonanal</td> <td class=\"centered\">1.84</td> </tr> <tr> <td>Dihydroxyphenylalanine</td> <td class=\"centered\">1.72</td> </tr> <tr> <td>Hypoxanthine</td> <td class=\"centered\">1.72</td> </tr> <tr> <td>3-Carboxy-4-methyl-5-propyl-2-furan-propanoic acid</td> <td class=\"centered\">1.70</td> </tr> <tr> <td>Soluble intracellular adhesion molecule-1</td> <td class=\"centered\">1.67</td> </tr> <tr> <td>Uric acid</td> <td class=\"centered\">1.59</td> </tr> <tr> <td>Cysteine</td> <td class=\"centered\">1.56</td> </tr> <tr> <td>IGF-1</td> <td class=\"centered\">1.52</td> </tr> <tr> <td>Adiponectin</td> <td class=\"centered\">1.50</td> </tr> <tr> <td>IL-10</td> <td class=\"centered\">1.49</td> </tr> <tr> <td>IL-6</td> <td class=\"centered\">1.48</td> </tr> <tr> <td>Decanal</td> <td class=\"centered\">1.36</td> </tr> <tr> <td>Prolactin</td> <td class=\"centered\">1.33</td> </tr> <tr> <td>8-Hydroxy-2'-deoxyguanosine</td> <td class=\"centered\">1.28</td> </tr> <tr> <td>2-Octenal</td> <td class=\"centered\">1.25</td> </tr> <tr> <td>Heptanal</td> <td class=\"centered\">1.20</td> </tr> <tr> <td>Calcitonin</td> <td class=\"centered\">1.09</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IGF-1: insulin-like growth factor 1; IL: interleukin.</div><div class=\"graphic_reference\">Reproduced with permission from: Duranton F, Cohen G, Smet RD, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23:1258. Copyright &copy; 2012 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 85916 Version 2.0</div></div></div>"},"85917":{"type":"graphic_figure","displayName":"Perirenal fascia sagittal view","title":"Perirenal fascia sagittal view","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Perirenal fascia sagittal view</div><div class=\"cntnt\"><img style=\"width:511px; height:534px;\" src=\"images/SURG/85917_Perirenal_fascia_sagittal_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal view depicting the perirenal fascia. The anterior fascia was called Gerota's fascia while the posterior fascia was called Zuckerkandl's fascia. The perirenal fascia envelops each kidney and adrenal gland together with a surrounding layer of adipose tissue.</div><div id=\"graphicVersion\">Graphic 85917 Version 2.0</div></div></div>"},"85918":{"type":"graphic_figure","displayName":"Thyroid hormone changes cardiac output","title":"Thyroid hormone-mediated changes in cardiac output","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Thyroid hormone-mediated changes in cardiac output</div><div class=\"cntnt\"><img style=\"width:632px; height:546px;\" src=\"images/ENDO/85918_Thyr_horm_chang_card.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effects of thyroid hormone on cardiovascular hemodynamics. T3 affects tissue thermogenesis, systemic vascular resistance, blood volume, cardiac contractility, heart rate, and cardiac output as indicated by the arrows.</div><div class=\"graphic_footnotes\">Hyper: hyperthyroidism; hypo: hypothyroidism; T3: triiodothyronine; T4: thyroxine.</div><div class=\"graphic_reference\">Reproduced with permission from: Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007; 116:1725. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85918 Version 6.0</div></div></div>"},"85919":{"type":"graphic_figure","displayName":"Patient positioning for laparoscopic adrenalectomy","title":"Patient positioning for laparoscopic adrenalectomy","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Patient positioning for laparoscopic adrenalectomy</div><div class=\"cntnt\"><img style=\"width:524px; height:393px;\" src=\"images/SURG/85919_Position-lap-adrenalect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a patient placed in the latral decubitus position in preparation for a laparoscopic adrenalectomy. The position is secured by an inflatable beanbag.</div><div id=\"graphicVersion\">Graphic 85919 Version 2.0</div></div></div>"},"85920":{"type":"graphic_diagnosticimage","displayName":"PET-CT HSTL ","title":"PET/CT imaging of hepatosplenic T cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">PET/CT imaging of hepatosplenic T cell lymphoma</div><div class=\"cntnt\"><img style=\"width:294px; height:504px;\" src=\"images/HEME/85920_PET_CT_HSTL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Combined positron emission tomography/computed tomography (PET/CT) imaging of a 66-year-old female with hepatosplenic T cell lymphoma demonstrates dramatically increased uptake in the liver and spleen. There was also increased uptake in the pituitary and some lymph nodes.</div><div class=\"graphic_reference\">Kindly provided by German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 85920 Version 1.0</div></div></div>"},"85921":{"type":"graphic_picture","displayName":"Liver biopsy HSTL ","title":"Liver biopsy from a patient with hepatosplenic lymphoma","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Liver biopsy from a patient with hepatosplenic lymphoma</div><div class=\"cntnt\"><img style=\"width:513px; height:196px;\" src=\"images/HEME/85921_Liver_biopsy_HSTL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy from a patient with hepatosplenic lymphoma demonstrates infiltration of monotonous, medium-sized lymphoid cells with round or slightly irregular nuclei, loosely condensed chromatin, and a moderate amount of pale cytoplasm. H&E 1000X.</div><div class=\"graphic_reference\">Kindly provided by German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 85921 Version 1.0</div></div></div>"},"85922":{"type":"graphic_picture","displayName":"HSTL tumor cells immunophenotype","title":"Hepatosplenic T cell lymphoma tumor cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatosplenic T cell lymphoma tumor cells</div><div class=\"cntnt\"><img style=\"width:411px; height:617px;\" src=\"images/HEME/85922_HSTL_tumor_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hepatosplenic T cell lymphoma tumor cells express CD2 (panel A) and surface CD3 (panel B). In most cases, CD5 (panel C) and CD 8 (panel D) are not expressed. The cytotoxic granule protein TIA-1 (panel E) is expressed, but perforin (panel F) and granzyme B (panel G) are absent, features consistent with a non-activated cytotoxic T cell phenotype. Mitotic activity (panel H) is generally low.</div><div class=\"graphic_reference\">Kindly provided by German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 85922 Version 1.0</div></div></div>"},"85923":{"type":"graphic_diagnosticimage","displayName":"Leg CT in ECD","title":"Computed tomography imaging of the leg in Erdheim-Chester disease","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Computed tomography imaging of the leg in Erdheim-Chester disease</div><div class=\"cntnt\"><img style=\"width:513px; height:223px;\" src=\"images/HEME/85923_Leg_CT_ECD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography imaging of the left leg in a 48-year-old male with Erdheim-Chester disease shows an expansile lytic lesion in the distal tibia with lobulated endosteal scalloping, and multiple foci of calcified matrix. There is mild subcutaneous soft tissue stranding anteriorly and medially. Within the fibula, the marrow also appears abnormal, but there is no endosteal scalloping.</div><div class=\"graphic_reference\">Kindly provided by German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 85923 Version 1.0</div></div></div>"},"85924":{"type":"graphic_diagnosticimage","displayName":"Leg MRI in ECD","title":"Magnetic resonance imaging of the leg in Erdheim-Chester disease","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of the leg in Erdheim-Chester disease</div><div class=\"cntnt\"><img style=\"width:509px; height:492px;\" src=\"images/HEME/85924_Leg_MRI_ECD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) T1.<br />(B) T2.<br />Magnetic resonance imaging of the left leg in a 48-year-old male with Erdheim-Chester disease shows abnormal signaling in the distal tibia with surrounding soft tissue edema. There is a heterogeneous signal in the bone marrow on T1 and T2 with areas of patchy enhancement post-gadolinium. The bone marrow signal abnormality extends more proximally than the lesion itself. There is a mild periosteal reaction, but no overt abnormality of true tumor extending out from the bone.</div><div class=\"graphic_reference\">Kindly provided by German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 85924 Version 1.0</div></div></div>"},"85925":{"type":"graphic_picture","displayName":"Bone curettage samples ECD","title":"Bone curettage samples in Erdheim-Chester disease","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Bone curettage samples in Erdheim-Chester disease</div><div class=\"cntnt\"><img style=\"width:516px; height:304px;\" src=\"images/HEME/85925_Bone_curettage_samp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone curettage samples (panels A and B) from a patient with Erdheim-Chester disease demonstrate tissue infiltration by sheets of foamy (xanthomatous) histiocytes with interspersed inflammatory cells and multinucleate giant cells (Touton cells). The histiocytes express the histiocyte markers CD68 (panel C) and CD163 (panel D), but do not express CD1a (panel E) or Langerin (panel F).</div><div class=\"graphic_reference\">Kindly provided by German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 85925 Version 1.0</div></div></div>"},"85927":{"type":"graphic_picture","displayName":"Gravity stress mortise radiograph of the ankle","title":"Gravity stress mortise radiograph of the ankle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gravity stress mortise&nbsp;radiograph of the&nbsp;ankle</div><div class=\"cntnt\"><img style=\"width:447px; height:598px;\" src=\"images/EM/85927_Grav_stres_mortise_xray_ank.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photographs show the position for obtaining a gravity stress mortise view of the ankle. This view can demonstrate injury of the medial ankle ligaments and can be obtained without inflicting unnecessary pain on the patient, as&nbsp;occurs with a manual stress view.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 85927 Version 3.0</div></div></div>"},"85928":{"type":"graphic_table","displayName":"Angina meds PI","title":"Medicines to treat angina","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicines to treat angina</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of medicine</td> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Sample US brand names</td> </tr> <tr> <td rowspan=\"6\">Nitrates</td> <td>Nitroglycerin pill for under the tongue</td> <td>Nitrostat&#174;</td> </tr> <tr> <td>Nitroglycerin spray for on or under the tongue</td> <td>Nitrolingual&#174;, NitroMist&#8482;</td> </tr> <tr> <td>Nitroglycerin patch</td> <td>Minitran&#8482;, Nitro-Dur&#174;</td> </tr> <tr> <td>Nitroglycerin ointment</td> <td>Nitro-Bid&#174;</td> </tr> <tr> <td>Isosorbide dinitrate</td> <td>Isordil&#174;</td> </tr> <tr> <td>Isosorbide mononitrate</td> <td>Imdur&#174;, Ismo&#174;, Monoket&#174;</td> </tr> <tr> <td rowspan=\"6\">Beta blockers</td> <td>Atenolol</td> <td>Tenormin&#174;</td> </tr> <tr> <td>Metoprolol</td> <td>Lopressor&#174;, Toprol-XL&#174;</td> </tr> <tr> <td>Acebutolol</td> <td>Sectral&#174;</td> </tr> <tr> <td>Propranolol</td> <td>Inderal&#174;</td> </tr> <tr> <td>Labetalol</td> <td>Trandate&#174;</td> </tr> <tr> <td>Carvedilol</td> <td>Coreg&#174;</td> </tr> <tr> <td rowspan=\"5\">Calcium channel blockers</td> <td>Amlodipine</td> <td>Norvasc&#174;</td> </tr> <tr> <td>Felodipine</td> <td>Plendil&#174;</td> </tr> <tr> <td>Nifedipine</td> <td>Adalat&#174; CC,</td> </tr> <tr> <td>Verapamil</td> <td>Calan&#174;, Verelan&#174;</td> </tr> <tr> <td>Diltiazem</td> <td>Cardizem&#174;, Cartia&#174;, many others</td> </tr> <tr> <td>Other</td> <td>Ranolazine</td> <td>Ranexa&#174;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Most common medicines to treat angina (except ranolazine and nitroglycerin spray) are usually sold as generic drugs in the US. In many countries outside the US, nitroglycerin is also called glyceryl trinitrate.</div><div id=\"graphicVersion\">Graphic 85928 Version 2.0</div></div></div>"},"85929":{"type":"graphic_figure","displayName":"Female self-catheterization PI","title":"Putting in a catheter (Women)","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Putting in a catheter (Women)</div><div class=\"cntnt\"><img style=\"width:496px; height:650px;\" src=\"images/PI/85929_Female-self-catheterization-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most women find it easier to put one foot up on the toilet when putting in a catheter. But you might find a different position more comfortable. Put the other end of the catheter over the toilet or another container.</div><div id=\"graphicVersion\">Graphic 85929 Version 1.0</div></div></div>"},"85930":{"type":"graphic_figure","displayName":"Male self-catheterization PI","title":"Putting in a catheter (Men)","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Putting in a catheter (Men)</div><div class=\"cntnt\"><img style=\"width:496px; height:608px;\" src=\"images/PI/85930_Male-self-catheterization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">You can sit on the toilet to put the catheter in your penis. Put the other end of the catheter over the toilet or another container.</div><div id=\"graphicVersion\">Graphic 85930 Version 1.0</div></div></div>"},"85932":{"type":"graphic_picture","displayName":"Body stuffer wrapping method large bag step 1","title":"Body stuffer wrapping method: Large bag step one","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Body stuffer wrapping method: Large bag step one</div><div class=\"cntnt\"><img style=\"width:576px; height:428px;\" src=\"images/EM/85932_Body_stuffer_wrap_method_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a corner of a sandwich bag. The drug is placed in the lower corner.</div><div class=\"graphic_reference\">Courtesy of Steven E Aks, DO.</div><div id=\"graphicVersion\">Graphic 85932 Version 2.0</div></div></div>"},"85933":{"type":"graphic_picture","displayName":"Body stuffer wrapping method large bag step 2","title":"Body stuffer wrapping method: Large bag step two","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Body stuffer wrapping method: Large bag step two</div><div class=\"cntnt\"><img style=\"width:590px; height:321px;\" src=\"images/EM/85933_Body_stuffer_wrap_method_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After drug is in the corner, it is folded up once or twice. Next, the upper corners are tied into a knot.</div><div class=\"graphic_reference\">Courtesy of Steven E Aks, DO.</div><div id=\"graphicVersion\">Graphic 85933 Version 1.0</div></div></div>"},"85934":{"type":"graphic_picture","displayName":"Body stuffer wrapping method small bag","title":"Body stuffer wrapping method with small Ziploc-style bag","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Body stuffer wrapping method with small Ziploc-style bag</div><div class=\"cntnt\"><img style=\"width:576px; height:410px;\" src=\"images/EM/85934_Body_stuffer_Ziploc_bag.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ziploc-style bags are commonly used in the United States&nbsp;for packing drugs.</div><div class=\"graphic_reference\">Courtesy of Steven E Aks, DO.</div><div id=\"graphicVersion\">Graphic 85934 Version 2.0</div></div></div>"},"85935":{"type":"graphic_picture","displayName":"22 Ziploc packets used for body stuffing","title":"22 Ziploc packets used for body stuffing","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">22 Ziploc packets used for body stuffing</div><div class=\"cntnt\"><img style=\"width:564px; height:576px;\" src=\"images/EM/85935_22_Ziploc_packets.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a large bag seen by endoscopy. This contains the 22 small Ziploc packets containing crack.</div><div class=\"graphic_reference\">Courtesy of Steven E Aks, DO, Mercy Hospital, Chicago.</div><div id=\"graphicVersion\">Graphic 85935 Version 2.0</div></div></div>"},"85936":{"type":"graphic_table","displayName":"Grading scale for aging skin","title":"Comprehensive grading scale of rhytides, laxity, and photodamage in skin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comprehensive grading scale of rhytides, laxity, and photodamage in skin</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Grading scale</td> <td class=\"subtitle1\" rowspan=\"2\">Descriptive parameter</td> <td class=\"subtitle1\" colspan=\"7\">Categories of skin aging and photodamage</td> </tr> <tr> <td class=\"subtitle2\">Rhytides</td> <td class=\"subtitle2\">Laxity</td> <td class=\"subtitle2\">Elastosis</td> <td class=\"subtitle2\">Dyschromia</td> <td class=\"subtitle2\">Erythema telangiectasia</td> <td class=\"subtitle2\">Keratoses</td> <td class=\"subtitle2\">Texture</td> </tr> <tr> <td>0</td> <td>None</td> <td>None</td> <td>None</td> <td>None</td> <td>None</td> <td>None</td> <td>None</td> <td>None</td> </tr> <tr> <td>1</td> <td>Mild</td> <td>Wrinkles in motion, few, superficial</td> <td>Localized to NL folds</td> <td>Early, minimal yellow hue</td> <td>Few (1-3) discrete small (&#60;5 mm) lentigines</td> <td>Pink E or few T, localized to single site</td> <td>Few</td> <td>Subtle irregularity</td> </tr> <tr> <td>1.5</td> <td>Mild</td> <td>Wrinkles in motion, multiple, superficial</td> <td>Localized, NL and early ML folds</td> <td>Yellow hue or early, localized PO EB</td> <td>Several (3-6), discrete small lentigines</td> <td>Pink E or several T localized to 2 sites</td> <td>Several</td> <td>Mild irregularity in few areas</td> </tr> <tr> <td>2</td> <td>Moderate</td> <td>Wrinkles at rest, few, localized, superficial</td> <td>Localized, NL/ML folds, early jowels, early submental/SM</td> <td>Yellow hue, localized PO EB</td> <td>Multiple (7-10), small lentigines</td> <td>Red E or multiple T localized to 2 sites</td> <td>Multiple, small</td> <td>Rough in few, localized sites</td> </tr> <tr> <td>2.5</td> <td>Moderate</td> <td>Wrinkles at rest, multiple, localized, superficial</td> <td>Localized, prominent NL/ML folds, jowels and SM</td> <td>Yellow hue, PO and malar EB</td> <td>Multiple, small and few large lentigines</td> <td>Red E or multiple T, localized to 3 sites</td> <td>Multiple, large</td> <td>Rough in several localized areas</td> </tr> <tr> <td>3</td> <td>Advanced</td> <td>Wrinkles at rest, multiple, forehead, PO and perioral sites, superficial</td> <td>Prominent NL/ML folds, jowels and SM, early neck strands</td> <td>Yellow hue, EB involving PO, malar, and other sites</td> <td>Many (10-20) small and large lentigines</td> <td>Violaceous E or many T, multiple sites</td> <td>Many</td> <td>Rough in multiple, localized sites</td> </tr> <tr> <td>3.5</td> <td>Advanced</td> <td>Wrinkles at rest, multiple, generalized, superficial; few, deep</td> <td>Deep NL/ML folds, prominent jowels and SM, prominent neck strands</td> <td>Deep yellow hue, extensive EB with little uninvolved skin</td> <td>Numerous (&#62;20) or multiple large with little uninvolved skin</td> <td>Violaceous E, numerous T, little uninvolved skin</td> <td>Little uninvolved skin</td> <td>Mostly rough, little uninvolved skin</td> </tr> <tr> <td>4</td> <td>Severe</td> <td>Wrinkles throughout, numerous, extensively distributed, deep</td> <td>Marked NL/ML folds, jowels and SM, neck redundancy and strands</td> <td>Deep yellow hue, EB throughout, comedones</td> <td>Numerous, extensive, no uninvolved skin</td> <td>Deep, violaceous E, numerous T throughout</td> <td>No uninvolved skin</td> <td>Rough throughout</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">E: Erythema; EB: elastotic beads; ML: melolabial; NL: nasolabial; PO: periorbital; SM: submental/submandibular; T: telangiectasia.</div><div class=\"graphic_reference\">Reproduced from: Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: Nonablative fractional, and ablative laser resurfacing. J Am Acad Dermatol 2008; 58:719. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85936 Version 2.0</div></div></div>"},"85937":{"type":"graphic_diagnosticimage","displayName":"Magnetic resonance imaging of acute hamstring tear","title":"Magnetic resonance imaging of acute hamstring tear","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of acute hamstring tear</div><div class=\"cntnt\"><img style=\"width:598px; height:508px;\" src=\"images/RADIOL/85937_MRI_acute_hamstring_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The T2 weighted images are from a 22-year-old professional baseball player who complained of acute pain in the posteromedial aspect of his knee. Image A is an axial section just above the knee joint and shows a fluid collection (arrow) with an absent semitendinosus tendon. The region of interest is magnified in image B. Image C is taken slightly more cephalad and reveals the low intensity retracted and torn semitendinosus tendon (arrowhead), detached from the tibial insertion. Image D is a magnified view.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 85937 Version 2.0</div></div></div>"},"85938":{"type":"graphic_table","displayName":"Mod NIH risk strat for GIST incl rupture","title":"Modified NIH risk stratification criteria for GIST with rupture included","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified NIH risk stratification criteria for GIST with rupture included</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk category</td> <td class=\"subtitle1\">Tumor size (cm)</td> <td class=\"subtitle1\">Mitotic index (per 50 HPFs)</td> <td class=\"subtitle1\">Primary tumor site</td> </tr> <tr> <td>Very low risk</td> <td>&#60;2.0</td> <td>&#8804;5</td> <td>Any</td> </tr> <tr> <td>Low risk</td> <td>2.1 to 5.0</td> <td>&#8804;5</td> <td>Any</td> </tr> <tr> <td rowspan=\"3\">Intermediate risk</td> <td>2.1 to 5.0</td> <td>&#62;5</td> <td>Gastric</td> </tr> <tr> <td>&#60;5.0</td> <td>6 to 10</td> <td>Any</td> </tr> <tr> <td>5.1 to 10.0</td> <td>&#8804;5</td> <td>Gastric</td> </tr> <tr> <td rowspan=\"6\">High risk</td> <td>Any</td> <td>Any</td> <td>Tumor rupture</td> </tr> <tr> <td>&#62;10 cm</td> <td>Any</td> <td>Any</td> </tr> <tr> <td>Any</td> <td>&#62;10</td> <td>Any</td> </tr> <tr> <td>&#62;5.0</td> <td>&#62;5</td> <td>Any</td> </tr> <tr> <td>2.1 to 5.0</td> <td>&#62;5</td> <td>Nongastric</td> </tr> <tr> <td>5.1 to 10.0</td> <td>&#8804;5</td> <td>Nongastric</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPF: high power fields.</div><div class=\"graphic_reference\">Reproduced from: Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39:1411. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85938 Version 1.0</div></div></div>"},"85939":{"type":"graphic_algorithm","displayName":"Screening renal transplant recipients for PR","title":"An algorithm for screening renal transplant recipients for polyoma virus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">An algorithm for screening renal transplant recipients for polyoma virus</div><div class=\"cntnt\"><img style=\"width:423px; height:658px;\" src=\"images/NEPH/85939_Scr_renal_transpl_recip_PR.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PVAN: polyomavirus-associated nephropathy.</div><div class=\"graphic_reference\">Reproduced with permission from: Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79:1277. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 85939 Version 6.0</div></div></div>"},"85940":{"type":"graphic_table","displayName":"Diagnostic criteria for Sweet syndrome","title":"Diagnostic criteria for Sweet syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for Sweet syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Classical*</td> </tr> <tr> <td class=\"indent1\">1. Abrupt onset of painful erythematous plaques or nodules</td> </tr> <tr> <td class=\"indent1\">2. Histopathologic evidence of a dense neutrophilic infiltrate without evidence of leukocytoclastic vasculitis</td> </tr> <tr> <td class=\"indent1\">3. Pyrexia &#62;38&#176;C</td> </tr> <tr> <td class=\"indent1\">4. Association with an underlying hematologic or visceral malignancy, inflammatory disease, or pregnancy, or preceded by an upper respiratory or gastrointestinal infection or vaccination</td> </tr> <tr> <td class=\"indent1\">5. Excellent response to treatment with systemic corticosteroids or potassium iodide</td> </tr> <tr> <td class=\"indent1\">6. Abnormal laboratory values at presentation (three of four): erythrocyte sedimentation rate &#62;20 mm/hr; positive C-reactive protein; &#62;8,000 leukocytes; &#62;70 percent neutrophils</td> </tr> <tr> <td class=\"subtitle1_single\">Drug-induced<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">A. Abrupt onset of painful erythematous plaques or nodules</td> </tr> <tr> <td class=\"indent1\">B. Histopathologic evidence of a dense neutrophilic infiltrate without evidence of leukocytoclastic vasculitis</td> </tr> <tr> <td class=\"indent1\">C. Pyrexia &#62;38&#176;C</td> </tr> <tr> <td class=\"indent1\">D. Temporal relationship between drug ingestion and clinical presentation, or temporally-related recurrence after oral challenge</td> </tr> <tr> <td class=\"indent1\">E. Temporally-related resolution of lesions after drug withdrawal or treatment with systemic corticosteroids</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The patients with malignancy-associated Sweet syndrome are included with the patients with classical Sweet syndrome in this list of diagnostic criteria.</div><div class=\"graphic_footnotes\">* The presence of both major criteria (1 and 2), and two of the four minor classical Sweet syndrome.<br />¶ All five criteria (A, B, C, D, and E) are required for the diagnosis of drug-induced Sweet syndrome.</div><div class=\"graphic_reference\">Original figure modified for this publication. Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol 1996; 34:918. Table used with the permission for Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85940 Version 3.0</div></div></div>"},"85941":{"type":"graphic_table","displayName":"Clinical features of Sweet syndrome","title":"Clinical features of Sweet syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of Sweet syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Characteristic</td> <td class=\"subtitle1\" colspan=\"4\">Clinical form</td> </tr> <tr> <td class=\"subtitle2\">Classical*</td> <td class=\"subtitle2\">Hematologic malignancy*</td> <td class=\"subtitle2\">Solid tumor*</td> <td class=\"subtitle2\">Drug-induced<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Epidemiology</td> </tr> <tr> <td class=\"indent1\">Women</td> <td class=\"centered\">80</td> <td class=\"centered\">50</td> <td class=\"centered\">59</td> <td class=\"centered\">71</td> </tr> <tr> <td class=\"indent1\">Prior upper respiratory tract infection</td> <td class=\"centered\">75-90</td> <td class=\"centered\">16</td> <td class=\"centered\">20</td> <td class=\"centered\">21</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Recurrence<sup>&#916;</sup></td> <td class=\"centered\">30</td> <td class=\"centered\">69</td> <td class=\"centered\">41</td> <td class=\"centered\">67</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Clinical symptoms</td> </tr> <tr> <td class=\"indent1\">Fever<sup>&#9674;</sup></td> <td class=\"centered\">80-90</td> <td class=\"centered\">88</td> <td class=\"centered\">79</td> <td class=\"centered\">100</td> </tr> <tr> <td class=\"indent1\">Musculoskeletal involvement</td> <td class=\"centered\">12-56</td> <td class=\"centered\">26</td> <td class=\"centered\">34</td> <td class=\"centered\">21</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ocular involvement</td> <td class=\"centered\">17-72</td> <td class=\"centered\">7</td> <td class=\"centered\">15</td> <td class=\"centered\">21</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Lesion location</td> </tr> <tr> <td class=\"indent1\">Upper extremities</td> <td class=\"centered\">80</td> <td class=\"centered\">89</td> <td class=\"centered\">97</td> <td class=\"centered\">71</td> </tr> <tr> <td class=\"indent1\">Head and neck</td> <td class=\"centered\">50</td> <td class=\"centered\">63</td> <td class=\"centered\">52</td> <td class=\"centered\">43</td> </tr> <tr> <td class=\"indent1\">Trunk and back</td> <td class=\"centered\">30</td> <td class=\"centered\">42</td> <td class=\"centered\">33</td> <td class=\"centered\">50</td> </tr> <tr> <td class=\"indent1\">Lower extremities</td> <td class=\"centered\">Infrequent</td> <td class=\"centered\">49</td> <td class=\"centered\">48</td> <td class=\"centered\">36</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oral mucous membranes</td> <td class=\"centered\">2</td> <td class=\"centered\">12</td> <td class=\"centered\">3</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Laboratory findings</td> </tr> <tr> <td class=\"indent1\">Neutrophilia<sup>&#167;</sup></td> <td class=\"centered\">80</td> <td class=\"centered\">47</td> <td class=\"centered\">60</td> <td class=\"centered\">38</td> </tr> <tr> <td class=\"indent1\">Elevated erythrocyte sedimentation rate<sup>&#165;</sup></td> <td class=\"centered\">90</td> <td class=\"centered\">100</td> <td class=\"centered\">95</td> <td class=\"centered\">100</td> </tr> <tr> <td class=\"indent1\">Anemia<sup>&#135;</sup></td> <td class=\"centered\">Infrequent</td> <td class=\"centered\">82</td> <td class=\"centered\">83</td> <td class=\"centered\">100</td> </tr> <tr> <td class=\"indent1\">Abnormal platelet count<sup>&#134;</sup></td> <td class=\"centered\">Infrequent</td> <td class=\"centered\">68</td> <td class=\"centered\">50</td> <td class=\"centered\">50</td> </tr> <tr> <td class=\"indent1\">Abnormal renal function**</td> <td class=\"centered\">11-50</td> <td class=\"centered\">15</td> <td class=\"centered\">7</td> <td class=\"centered\">0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Percentages for classical, hematologic malignancy, and solid tumor associated Sweet syndrome adapted with permission from Cohen PR, Kurzrock R: Sweet's syndrome and cancer. Clin Dermatol 1993; 11:149-157. Copyright 1993, Reprinted with permission from Elsevier Ltd, Oxford, United Kingdom.<br />¶ Percentages for drug-induced Sweet syndrome adapted with permission from Walker DC, Cohen PR: Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug induced Sweet's syndrome. J Am Acad Dermatol 1996; 34:918–923. Copyright 1996, Reprinted with permission from the American Academy of Dermatology, Inc., Elsevier Ltd, Oxford, United Kingdom.<br />Δ Recurrence following oral rechallenge testing in the patients with drug-induced Sweet syndrome.<br /><FONT class=lozenge>◊</FONT> Temperature greater than 38°C.<br />§ Neutrophil count greater than 6,000 cells/ul.<br />¥ Erythrocyte sedimentation rate greater than 20 mm/hr.<br />‡ Hemoglobin less than 13 g/dl in men and less than 12 g/dl in women.<br />† Platelet count less than 150,000/ul or greater than 500,000/ul.<br />** This includes hematuria, proteinuria, and renal insufficiency.<br /></div><div class=\"graphic_reference\">Original figure modified for this publication. Cohen PR, Kurzrock R. Sweet's syndrome and cancer. Clin Dermatol 1993; 11:149. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85941 Version 3.0</div></div></div>"},"85942":{"type":"graphic_table","displayName":"Medications associated with drug-induced Sweet syndrome","title":"Medications associated with drug-induced Sweet syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications associated with drug-induced Sweet syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Antibiotics</strong></td> <td> <p>Minocycline</p> <p>Nitrofurantoin</p> <p>Norfloxacin</p> <p>Ofloxacin</p> <p>Quinupristin/dalfopristin</p> Trimethoprim-sulfamethoxazole</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Antiepileptics</strong></td> <td> <p>Carbemazepine</p> Diazepam</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Antihuman immunodeficiency virus drugs</strong></td> <td>Abacavir (synthetic carbocyclic nucleoside analogue)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Antihypertensives</strong></td> <td>Hydralazine</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Antineoplastics</strong></td> <td> <p>Bortezomib</p> <p>Imatinib mesylate</p> <p>Ipilimumab</p> <p>Lenalidomide</p> <p>Topotecan</p> Vemurafenib</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Antipsychotics</strong></td> <td>Clozapine</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Antithyroid hormone synthesis drugs</strong></td> <td>Propylthiouracil</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Colony stimulating factors</strong></td> <td> <p>Granulocyte-colony stimulating factor</p> <p>Granulocyte-macrophage-colony stimulating factor</p> Pegfilgrastim</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Contraceptives</strong></td> <td> <p>Levonorgestrel/ethinyl estradiol (Triphasil)</p> Levonorgestrel-releasing intrauterine system (Mirena)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Diuretics</strong></td> <td>Furosemide</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Immunosuppressants</strong></td> <td>Azathioprine</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Nonsteroidal antiinflammatory agents</strong></td> <td> <p>Celecoxib</p> Diclofenac</td> </tr> <tr> <td><strong>Retinoids</strong></td> <td> <p>All-trans retinoic acid</p> 13-cis-retinoic acid</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The possibility of acyclovir-induced Sweet syndrome cannot be completely ruled out in a 13-year-old girl with systemic lupus erythematosus (that had been diagnosed three months earlier and was being treated with oral prednisolone and azathioprine) whose Sweet syndrome lesions appeared five days after beginning intravenous acyclovir treatment for a herpes zoster infection.<br />Photodistributed neutrophilic dermatosis with overlapping features of Sweet syndrome, acute generalized exanthematous pustulosis and sterile neutrophilic folliculitis with perifollicular vasculopathy developed in a patient who had received antidepressant (amoxapine and citalopram) and anxiolytic (perphenazine) therapy.</div><div class=\"graphic_reference\">Adapted from: Cohen PR. Sweet's syndrome - a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007; 2:34. Copyright &copy; 2007 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 85942 Version 6.0</div></div></div>"},"85944":{"type":"graphic_table","displayName":"WAO subcutaneous immunotherapy systemic reaction grading system","title":"World Allergy Organization subcutaneous immunotherapy systemic reaction grading system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Allergy Organization subcutaneous immunotherapy systemic reaction grading system</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong><em>Symptom(s)/sign(s) of one organ system present*</em></strong></p> <p><strong>Cutaneous</strong></p> <p>Generalized pruritus, urticaria, flushing, or sensation of heat or warmth<sup>&#182;</sup></p> <p><strong>or</strong></p> <p>Angioedema (not laryngeal, tongue or uvular)</p> <p><strong>or</strong></p> <p><strong>Upper respiratory</strong></p> <p>Rhinitis: (eg, sneezing, rhinorrhea, nasal pruritus and/or nasal congestion)</p> <p><strong>or</strong></p> <p>Throat-clearing (itchy throat)</p> <p><strong>or</strong></p> <p>Cough perceived to originate in the upper airway, not the lung, larynx, or trachea</p> <p><strong>or</strong></p> <p><strong>Conjunctival</strong></p> <p>Erythema, pruritus, or tearing </p> <p><strong>Other</strong></p> Nausea, metallic taste, or headache</td> <td> <p><strong><em>Symptom(s)/sign(s) of more than one organ system present</em></strong></p> <p><strong>or</strong></p> <p><strong>Lower respiratory</strong></p> <p>Asthma: cough, wheezing, shortness of breath (eg, less than 40 percent PEF or FEV<sub>1</sub> drop, responding to an inhaled bronchodilator)</p> <p><strong>or</strong></p> <p><strong>Gastrointestinal</strong></p> <p>Abdominal cramps, vomiting, or diarrhea</p> <p><strong>or</strong></p> <p><strong>Other</strong></p> Uterine cramps</td> <td> <p><strong>Lower respiratory</strong></p> <p>Asthma (eg, 40 percent PEF or FEV<sub>1</sub> drop NOT responding to an inhaled bronchodilator)</p> <p><strong>or</strong></p> <p><strong>Upper respiratory</strong></p> Laryngeal, uvula, or tongue edema with or without stridor</td> <td> <p><strong>Lower or upper respiratory</strong></p> <p>Respiratory failure with or without loss of consciousness</p> <p><strong>or</strong></p> <p><strong>Cardiovascular</strong></p> Hypotension with or without loss of consciousness</td> <td>Death</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\">Patients may also have a feeling of impending doom, especially in grades 2, 3, or 4.<br /> <strong>NOTE:</strong> Children with anaphylaxis seldom convey a sense of impending doom and their behavior changes may be a sign of anaphylaxis; eg, becoming very quiet or irritable and cranky.<br /> <strong>Scoring includes a suffix that denotes if and when epinephrine is or is not administered in relationship to onset of symptom(s)/sign(s) of the systemic reaction (SR): a: &#8804;5 minutes; b: &#62;5 minutes to &#8804;10 minutes; c: &#62;10 to &#8804;20 minutes; d: &#62;20 minutes; z: epinephrine not administered.</strong><br /> The final grade of the reaction will not be determined until the event is over, regardless of the medication administered. The final report should include the first symptom(s)/sign(s) and the time of onset after the subcutaneous allergen immunotherapy injection<sup>&#916;</sup> and a suffix reflecting if and when epinephrine was or was not administered, eg, Grade 2a; rhinitis: 10 minutes.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"> <p><strong>Final report:</strong></p> <p>Grade a to d, or z___________</p> <p>First symptom(s)/sign(s)___________</p> Time of onset of first symptom___________</td> </tr> <tr> <td colspan=\"5\"><strong>Comments:</strong><sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PEF: peak expiratory flow; FEV<SUB>1</SUB>: forced expiratory volume in one second.<br />* Each grade is based on organ system involved and severity. Organ systems are defined as cutaneous, conjunctival, upper respiratory, lower respiratory, gastrointestinal, cardiovascular, and other. A reaction from a single organ system, such as cutaneous, conjunctival, or upper respiratory, but not asthma, gastrointestinal, or cardiovascular is classified as a grade 1. Symptom(s)/sign(s) from more than one organ system or asthma, gastrointestinal, or cardiovascular are classified as grades 2 or 3. Respiratory failure or hypotension with or without loss of consciousness define grade 4 and death grade 5. The grade is determined by the clinician's clinical judgment.<br />¶ This constellation of symptoms may rapidly progress to a more severe reaction.<br />Δ Symptoms occurring within the first minutes after the injection may be a sign of severe anaphylaxis. Mild symptoms may progress rapidly to severe anaphylaxis and death.<br /><FONT class=lozenge>◊</FONT> If signs or symptoms are not included in the table or the differentiation between a SR and vasovagal (vasodepressor) reaction, which may occur with any medical intervention, is difficult, please include comment, as appropriate.</div><div class=\"graphic_reference\">Reproduced from: Cox L, Larenas-Linnemann D, Lockey RF, et al. Speaking the same language: The World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010; 125:569. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85944 Version 6.0</div></div></div>"},"85945":{"type":"graphic_table","displayName":"Immunohistochemical staining of cutaneous tumors","title":"Immunohistochemical staining of select cutaneous tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunohistochemical staining of select cutaneous tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">&#62;25 percent p53<sup>[1]</sup></td> <td class=\"subtitle1\">Ki 67<sup>[1]</sup></td> <td class=\"subtitle1\">Ber EP4</td> <td class=\"subtitle1\">p63<sup>[2]</sup></td> <td class=\"subtitle1\">CEA</td> <td class=\"subtitle1\">AE14<sup>[3]</sup></td> <td class=\"subtitle1\">CK 20</td> <td class=\"subtitle1\">CK 15<sup>[4]</sup></td> <td class=\"subtitle1\">CK 7<sup>[4]</sup></td> <td class=\"subtitle1\">AR<sup>[7]</sup>&nbsp;</td> </tr> <tr> <td><strong>MAC</strong></td> <td>20 percent</td> <td>&#60;5 percent</td> <td> <p>0 percent<sup>[5]</sup></p> 38 percent<sup>[4]</sup></td> <td>Peripheral staining 100 percent</td> <td>50 percent<sup>[3]</sup><br /> 54 percent<sup>[4]</sup></td> <td>100 percent</td> <td>0 percent<sup>[4,6]</sup></td> <td>92 percent</td> <td>15 percent</td> <td> <p>&nbsp;</p> <p>Negative</p> </td> </tr> <tr> <td><strong>BCC</strong></td> <td>80 percent</td> <td>20 to 40 percent</td> <td> <p>100 percent<sup>[5]</sup></p> 100 percent<sup>[4]</sup></td> <td>Diffuse 100 percent</td> <td>0 percent<sup>[3,4]</sup></td> <td>&nbsp;</td> <td>0 percent<sup>[4,6]</sup></td> <td>0 percent</td> <td>40 percent</td> <td> <p>&nbsp;</p> <p>Positive</p> </td> </tr> <tr> <td><strong>DTE</strong></td> <td>0 percent</td> <td>Rare</td> <td> <p>75 percent<sup>[5]</sup></p> 50 percent<sup>[4]</sup></td> <td>Diffuse 100 percent</td> <td>0 percent<sup>[3,4]</sup></td> <td>0 percent</td> <td> <p>12 percent<sup>[4]</sup></p> 100 percent<sup>[6]</sup></td> <td>100 percent</td> <td>0 percent</td> <td> <p>&nbsp;</p> <p>Negative &nbsp;</p> </td> </tr> <tr> <td><strong>Syringoma</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>100 percent<sup>[4]</sup></td> <td>33 percent</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>&nbsp;--</p> </td> </tr> <tr> <td><strong>SCC</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>38 percent<sup>[4]</sup></td> <td>&nbsp;</td> <td>0 percent<sup>[4]</sup></td> <td>&nbsp;</td> <td>0 percent<sup>[4]</sup></td> <td>0 percent</td> <td>12 percent</td> <td>&nbsp;--</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MAC: microcystic adnexal carcinoma; BCC: basal cell carcinoma; DTE: desmoplastic trichoepithelioma; SCC: squamous cell carcinoma.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Smith KL, Williams J, Corbett D, Skelton H. Microcystic adnexal carcinoma: An immunohistochemical study including markers of proliferation and apoptosis. Am J Surg Pathol 2001; 25:464.</LI>&#xD;&#xA;<LI>Vidal CI, Goldberg M, Burstein DE, et al. p63 Immunohistochemistry is a useful adjunct in distinguishing sclerosing cutaneous tumors. Am J Dermatopathol 2010; 32:257.</LI>&#xD;&#xA;<LI>Wick MR, Cooper PH, Swanson PE, et al. Microcystic adnexal carcinoma. An immunohistochemical comparison with other cutaneous appendage tumors. Arch Dermatol 1990; 126:189.</LI>&#xD;&#xA;<LI>Hoang MP, Dresser KA, Kapur P, et al. Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol 2008; 21:178.</LI>&#xD;&#xA;<LI>Krahl D, Sellheyer K. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol 2007; 34:782.</LI>&#xD;&#xA;<LI>Abesamis-Cubillan E, El-Shabrawi-Caelen L, Leboit PE. Merked cells and sclerosing epithelial neoplasms. Am J Dermatopathol 2000; 22:311.</LI>&#xD;&#xA;<LI>Evangelista MT, North JP. Comparative analysis of cytokeratin 15, TDAG51, cytokeratin 20 and androgen receptor in sclerosing adnexal neoplasms and variants of basal cell carcinoma. J Cutan Pathol 2015;42:824.&nbsp;&nbsp;&nbsp;</LI></OL></div><div id=\"graphicVersion\">Graphic 85945 Version 3.0</div></div></div>"},"85946":{"type":"graphic_table","displayName":"Histologic differential of microcystic adnexal carcinoma","title":"Histologic differential diagnosis of microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic differential diagnosis of microcystic adnexal carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Morpheaform basal cell carcinoma</td> </tr> <tr> <td>Desmoplastic squamous cell carcinoma</td> </tr> <tr> <td>Desmoplastic trichoepithelioma</td> </tr> <tr> <td>Syringoma</td> </tr> <tr> <td>Eccrine carcinoma</td> </tr> <tr> <td>Metastatic breast carcinoma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 85946 Version 1.0</div></div></div>"},"85947":{"type":"graphic_table","displayName":"Clinical differential of microcystic adnexal carcinoma","title":"Clinical differential diagnosis of microcystic adnexal carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical differential diagnosis of microcystic adnexal carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Basal cell carcinoma, infiltrative or morpheaform type</td> </tr> <tr> <td>Desmoplastic squamous cell carcinoma</td> </tr> <tr> <td>Scar</td> </tr> <tr> <td>Cyst</td> </tr> <tr> <td>Other adnexal carcinomas</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 85947 Version 1.0</div></div></div>"},"85948":{"type":"graphic_table","displayName":"Distinguishing Crohn versus intestinal TB","title":"Features that help distinguish between Crohn disease and intestinal tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features that help distinguish between Crohn disease and intestinal tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Crohn disease</td> <td class=\"subtitle1\">Intestinal tuberculosis</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Clinical manifestations</strong></td> <td> <ul> <li>Perianal disease </li> </ul> </td> <td> <ul> <li>High-swinging fever (&#62;38.5&#176;C) in absence of intraabdominal abscess </li> <li>Evidence of pulmonary TB on chest&nbsp;radiograph </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Radiographic findings&nbsp;(CT/MRI)</strong></td> <td> <ul> <li>Symmetrical bowel wall thickening </li> <li>Mesenteric fibrofatty proliferation (creeping fat) </li> <li>Mesenteric vascular engorgement (comb sign) </li> <li>Small homogenous pericecal lymph nodes </li> </ul> </td> <td> <ul> <li>Asymmetrical bowel wall thickening </li> <li>Inflammatory mass centered around the cecum and enveloping the terminal ileum </li> <li>Large mesenteric nodes with necrotic centers </li> <li>Ascites </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Endoscopic findings</strong></td> <td> <ul> <li>Longitudinal ulcers </li> <li>Aphthous ulcers </li> <li>Cobblestoned mucosa </li> <li>Preservation of ileocecal valve </li> <li>Multiple skip lesions </li> <li>Anorectal lesions </li> </ul> </td> <td> <ul> <li>Transverse ulcers </li> <li>Hypertrophic mucosa </li> <li>Scars/fibrous bands/inflammatory polyps </li> <li>Gaping/destruction of ileocecal valve </li> <li>Hyperemic nodules </li> </ul> </td> </tr> <tr> <td><strong>Histopathologic findings</strong></td> <td> <ul> <li>Single granulomas </li> <li>Architectural distortion distant from granulomatous inflammation </li> </ul> </td> <td> <ul> <li>Caseating granulomas or positive acid-fast bacilli staining* </li> <li>Confluent (&#8805;5/biopsy) and large (diameter &#62;200 micrometers) granulomas; submucosal granulomas </li> <li>Ulcers lined by epithelioid histiocytes </li> <li>Disproportionate submucosal inflammation </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TB: tuberculosis; CT: computed tomography; MRI: magnetic resonance imaging.<br />* Features pathognomonic for intestinal TB but present in &lt;30 percent of cases; no single variable described above is absolutely specific for either condition otherwise.</div><div id=\"graphicVersion\">Graphic 85948 Version 4.0</div></div></div>"},"85950":{"type":"graphic_figure","displayName":"Nondisplaced tibial shaft fracture","title":"Nondisplaced tibial shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nondisplaced tibial shaft fracture</div><div class=\"cntnt\"><img style=\"width:433px; height:602px;\" src=\"images/EM/85950_Nondistibishaffracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;nondisplaced, stable, distal tibial diaphyseal fracture (yellow arrow in images A and B) was treated nonoperatively. Weight bearing was started at 4 weeks and was full at 6 weeks. Union was uneventful (images C and D). A long leg cast was used for 4 weeks followed by a patellar-tendon bearing cast as shown here (image E).</div><div class=\"graphic_reference\">Reproduced with permission from: Petrisor BA, Bhandari M, Schemitsch E. Tibia and fibula fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Heckman JD, Court-Brown CM, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85950 Version 7.0</div></div></div>"},"85951":{"type":"graphic_diagnosticimage","displayName":"Displaced tibial shaft fracture","title":"Displaced tibial shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Displaced tibial shaft fracture</div><div class=\"cntnt\"><img style=\"width:504px; height:448px;\" src=\"images/EM/85951_Displactibshaffract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An anteroposterior (A)&nbsp;and lateral (B) radiograph of an unstable&nbsp;fracture of the tibial shaft are shown above.&nbsp;A fibular shaft fracture is also present. The tibial fracture&nbsp;was treated successfully with a locked reamed intramedullary nail (C and D). Yellow arrows indicate callus at the site of fracture healing.</div><div class=\"graphic_reference\">Reproduced with permission from: Petrisor BA, Bhandari M, Schemitsch E. Tibia and fibula fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Heckman JD, Court-Brown CM, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85951 Version 6.0</div></div></div>"},"85958":{"type":"graphic_movie","displayName":"Left ventricular apical thrombus without contrast","title":"Left ventricular apical thrombus without contrast","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Left ventricular apical thrombus without contrast</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/85958_LeftVATwocontrastvideo.mp4\" style=\"width:496px;height:352px\"></div><img style=\"width:571px; height:485px;\" src=\"images/CARD/85958_LeftVATwocontrastimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transthoracic echocardiogram in the apical four-chamber view demonstrating a mural thrombus filling the left ventricular apex.</div><div id=\"graphicVersion\">Graphic 85958 Version 1.0</div></div></div>"},"85959":{"type":"graphic_movie","displayName":"Left ventricular apical thrombus with contrast","title":"Left ventricular apical thrombus with contrast","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Left ventricular apical thrombus with contrast</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/85959_LeftVATwithcontrvideo.mp4\" style=\"width:496px;height:352px\"></div><img style=\"width:568px; height:490px;\" src=\"images/CARD/85959_LeftVATwithcontrimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transthoracic echocardiogram in the apical four-chamber view using an echocardiographic contrast agent that opacifies the blood pool. The mural thrombus is seen filling the left ventricular apex.</div><div id=\"graphicVersion\">Graphic 85959 Version 1.0</div></div></div>"},"85960":{"type":"graphic_diagnosticimage","displayName":"CT scan thymoma with atypical elements","title":"CT scan thymoma with atypical elements","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">CT scan thymoma with atypical elements</div><div class=\"cntnt\"><img style=\"width:598px; height:413px;\" src=\"images/RADIOL/85960_CT_scan_thymoma_atypical.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is a 56-year-old man who presented with an abnormal chest radiograph. The CT scan through the chest is projected in transverse plane (A) showing a mass with a calcification, magnified and highlighted in B (arrow). Image C shows regions of low density in the mass (double arrows) corresponding to lack of metabolic activity in D (double arrows) and likely reflecting necrosis. Pathology revealed type C thymoma of the WHO classification with multifocal invasion through the capsule and into the pericapsular adipose lung parenchyma and pericardium.</div><div class=\"graphic_footnotes\">CT: computed tomography; WHO: World Health Organization.</div><div class=\"graphic_reference\">Courtesy of Andrew Kriegel, MD.</div><div id=\"graphicVersion\">Graphic 85960 Version 4.0</div></div></div>"},"85961":{"type":"graphic_picture","displayName":"Clinical features T-PLL","title":"Clinical features of T cell prolymphocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clinical features of T cell prolymphocytic leukemia</div><div class=\"cntnt\"><img style=\"width:442px; height:513px;\" src=\"images/HEME/85961_Clin_feat_T_PLL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Nodular skin infiltration.<br />(B) Periorbital and conjunctival edema.</div><div class=\"graphic_reference\">This research was originally published in Blood. Dearden C. How I treat prolymphocytic leukemia. Blood 2012; 120:538. Copyright © 2012 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 85961 Version 1.0</div></div></div>"},"85962":{"type":"graphic_picture","displayName":"T-PLL morphology","title":"T cell prolymphocytic leukemia morphology","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">T cell prolymphocytic leukemia morphology</div><div class=\"cntnt\"><img style=\"width:504px; height:330px;\" src=\"images/HEME/85962_T_PLL_morphology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PB morphology from a typical case of T-PLL showing medium-sized lymphoid cells with a regular nuclear outline, single nucleolus, and intense basophilic cytoplasm. An occasional cell shows a cytoplasmic protrusion.</div><div class=\"graphic_reference\">This research was originally published in Blood. Dearden C. How I treat prolymphocytic leukemia. Blood 2012; 120:538. Copyright &#169; 2012 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 85962 Version 1.0</div></div></div>"},"85963":{"type":"graphic_figure","displayName":"T-PLL flow cytometry","title":"T cell prolymphocytic leukemia flow cytometry","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">T cell prolymphocytic leukemia flow cytometry</div><div class=\"cntnt\"><img style=\"width:646px; height:378px;\" src=\"images/HEME/85963_T_PLL_flow_cytometry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow cytometry in T-PLL showing negative membrane expression of CD3, strong expression of CD7 and CD5, and coexpression of CD4 and CD8.</div><div class=\"graphic_reference\">This research was originally published in Blood. Dearden C. How I treat prolymphocytic leukemia. Blood 2012; 120:538. Copyright &#169; 2012 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 85963 Version 1.0</div></div></div>"},"85964":{"type":"graphic_table","displayName":"Screening 13-item questionnaire for rTMS candidates","title":"Screening 13-item questionnaire for rTMS candidates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening 13-item questionnaire for rTMS candidates</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>1.</strong> Do you have epilepsy or have you ever had a convulsion or a seizure?</td> </tr> <tr> <td><strong>2.</strong> Have you ever had a fainting spell or syncope? If yes, please describe on which occasion(s).</td> </tr> <tr> <td><strong>3.</strong> Have you ever had a head trauma that was diagnosed as a concussion or was associated with loss of consciousness?</td> </tr> <tr> <td><strong>4.</strong> Do you have any hearing problems or ringing in your ears?</td> </tr> <tr> <td><strong>5.</strong> Do you have cochlear implants?</td> </tr> <tr> <td><strong>6.</strong> Are you pregnant or is there any chance that you might be?</td> </tr> <tr> <td><strong>7.</strong> Do you have metal in the brain, skull, or elsewhere in your body (eg, splinters, fragments, clips, etc)? If so, specify the type of metal.</td> </tr> <tr> <td><strong>8.</strong> Do you have an implanted neurotransmitter (eg, DBS, epidural/subdural, VNS)?</td> </tr> <tr> <td><strong>9.</strong> Do you have a cardiac pacemaker or intracardiac lines?</td> </tr> <tr> <td><strong>10.</strong> Do you have a medication infusion device?</td> </tr> <tr> <td><strong>11.</strong> Are you taking any medications? (please list)</td> </tr> <tr> <td><strong>12.</strong> Did you ever undergo TMS in the past? If so, were there any problems?</td> </tr> <tr> <td><strong>13.</strong> Did you ever undergo MRI in the past? If so, were there any problems?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">rTMS: repetitive transcranial magnetic stimulation; DBS: deep brain stimulation; VNS: vagus nerve stimulation; TMS: transcranial magnetic stimulation; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced from: Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Screening questionnaire TMS: An update. Clin Neurophysiol 2011; 122:1686. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 85964 Version 3.0</div></div></div>"},"85965":{"type":"graphic_table","displayName":"Causes of pediatric hyperkalemia","title":"Causes of hyperkalemia in children based on pathophysiology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hyperkalemia in children based on pathophysiology</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Cause</td> </tr> <tr> <td rowspan=\"3\">Increased potassium intake (rare cause of hyperkalemia with the exception of children with chronic kidney disease)</td> <td>Exposure to high potassium loads in intravenous fluids or medications</td> </tr> <tr> <td>Exposure to potassium-containing medications</td> </tr> <tr> <td>Massive transfusions of stored blood</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Transcellular potassium movement</td> <td>Structural cellular damage due to: <ul> <li>Hemolysis </li> <li>Rhabdomyolysis </li> <li>Tumor lysis </li> </ul> </td> </tr> <tr> <td>No structural cellular injury: <ul> <li>Metabolic acidosis </li> <li>Diabetic ketoacidosis </li> <li>Hyperkalemia periodic paralysis </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Abnormal renal potassium excretion</td> <td>Decreased effective circulating volume</td> </tr> <tr> <td>Decreased RAAS activity: <ul> <li>Congenital adrenal hyperplasia </li> <li>Adrenal insufficiency </li> <li>Drug effect (ACE inhibitor/ARB, eplerenone, spironolactone, or aliskiren) </li> </ul> </td> </tr> <tr> <td>Significant renal impairment with either acute or chronic loss of GFR</td> </tr> <tr> <td>Impaired tubular potassium secretion: <ul> <li>Reflux nephropathy </li> <li>Obstructive uropathy </li> <li>Sickle cell nephropathy </li> <li>Drug effect (amiloride, triamterene) </li> <li>Hypoaldosteronism (type IV renal tubular acidosis) </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Pseudohyperkalemia</td> <td>Hemolyzed specimen</td> </tr> <tr> <td>Leukocytosis or thrombocytosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RAAS: renin-angiotensin-aldosterone system; ACE inhibitor/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker; GFR: glomerular filtration rate.</div><div id=\"graphicVersion\">Graphic 85965 Version 2.0</div></div></div>"},"85966":{"type":"graphic_picture","displayName":"B cell leukemias morphology","title":"Peripheral blood morphology of four different B cell leukemias","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Peripheral blood morphology of four different B cell leukemias</div><div class=\"cntnt\"><img style=\"width:727px; height:521px;\" src=\"images/HEME/85966_B_cell_leuk_morph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) B-cell prolymphocytic leukemia, showing monomorphic prolymphocytes with condensed chromatin, prominent nucleolus, and scanty basophilic cytoplasm.<br />(B) Chronic lymphocytic leukemia with increased prolymphocytes, showing a single prolymphocyte, and several typical CLL cells, which are half the size of the prolymphocyte, have less cytoplasm and no nucleolus.<br />(C) Variant form of hairy cell leukemia, showing cells with condensed chromatin and a conspicuous single nucleolus, but with more abundant pale cytoplasm with cytoplasmic projections.<br />(D) Splenic marginal zone lymphoma showing lymphocytes with short polar villi and basophilic cytoplasm.</div><div class=\"graphic_reference\">This research was originally published in Blood. Dearden C. How I treat prolymphocytic leukemia. Blood 2012; 120:538. Copyright &copy; 2012 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 85966 Version 2.0</div></div></div>"},"85967":{"type":"graphic_picture","displayName":"B-PLL spleen histology","title":"Histology of the spleen in B cell prolymphocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology of the spleen in B cell prolymphocytic leukemia</div><div class=\"cntnt\"><img style=\"width:363px; height:513px;\" src=\"images/HEME/85967_B_PLLP_spleen_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low power view (original magnification x20) showing replacement of the white pulp and infiltration of the red pulp.<br />(B) High power view (original magnification x100) of the white pulp showing the typical prolymphocyte morphology with abundant cytoplasm, round nuclei, and a central eosinophilic nucleolus.</div><div class=\"graphic_reference\">This research was originally published in Blood. Dearden C. How I treat prolymphocytic leukemia. Blood 2012; 120:538. Copyright © 2012 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 85967 Version 1.0</div></div></div>"},"85968":{"type":"graphic_diagnosticimage","displayName":"MRI pubic ramus insufficiency fracture","title":"MRI pubic ramus insufficiency fracture","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">MRI pubic ramus insufficiency fracture</div><div class=\"cntnt\"><img style=\"width:563px; height:466px;\" src=\"images/RADIOL/85968_MRI_pubic_ramus_insuf_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The T1 weighted magnetic resonance imaging (MRI) sequence of the pelvis (A, B) reveals a right sided parasymphysial dark band suggesting edema (arrow). The STIR images (C) magnified and highlighted in D, confirm a faint fracture line (arrowhead) associated with the edema. These findings are consistent with an insufficiency fracture of the right side of the pubic symphysis.</div><div class=\"graphic_footnotes\">CT: computed tomography; STIR: Short-TI Inversion Recovery.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 85968 Version 3.0</div></div></div>"},"85969":{"type":"graphic_diagnosticimage","displayName":"Radiograph insufficiency fracture of the pubic ramus","title":"Radiograph insufficiency fracture of the pubic ramus","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Radiograph insufficiency fracture of the pubic ramus</div><div class=\"cntnt\"><img style=\"width:512px; height:518px;\" src=\"images/RADIOL/85969_Xray_insuf_frac_pubic_ramus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiograph of the pelvis is from a 95-year-old male who sustained minimal trauma and complained of left groin pain. Image A is magnified in B and reveals a nondisplaced fracture of the superior pubic ramus (arrow). A left inferior pubic ramus fracture is seen with difficulty in (C), and magnified and highlighted in D (arrowhead). These findings are consistent with insufficiency fractures of the superior and inferior pubic rami.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 85969 Version 3.0</div></div></div>"},"85971":{"type":"graphic_diagnosticimage","displayName":"CT scan insufficiency fracture of the pubic ramus","title":"CT scan insufficiency fracture of the pubic ramus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan insufficiency fracture of the pubic ramus</div><div class=\"cntnt\"><img style=\"width:440px; height:490px;\" src=\"images/RADIOL/85971_CTscan_insuf_frac_pub_ramus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The computed tomography (CT) scan of the pelvis is from a 95-year-old male who sustained minimal trauma and complained of left groin pain. The transverse images using bone windows reveal a nondisplaced fracture of the superior pubic ramus (A, green arrow) and a fracture through the inferior pubic ramus (B, red arrow) These findings are consistent with insufficiency fractures of the left pubic rami.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 85971 Version 2.0</div></div></div>"},"85972":{"type":"graphic_diagnosticimage","displayName":"MRI insufficiency fracture","title":"MRI insufficiency fracture","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">MRI insufficiency fracture</div><div class=\"cntnt\"><img style=\"width:543px; height:533px;\" src=\"images/RADIOL/85972_MRI_insufficiency_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The T1 weighted magnetic resonance imaging (MRI) sequence of the pelvis (A, B) reveals bilateral broad dark bands suggesting edema (arrows). The T2 weighted images (C, D) confirm dark fracture lines (arrowheads). These findings are consistent with bilateral insufficiency fractures of the sacral ala.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 85972 Version 3.0</div></div></div>"},"85973":{"type":"graphic_diagnosticimage","displayName":"Radiograph insufficiency fracture of the sacrum","title":"Radiograph insufficiency fracture of the sacrum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph insufficiency fracture of the sacrum</div><div class=\"cntnt\"><img style=\"width:434px; height:515px;\" src=\"images/RADIOL/85973_Xray_insuf_fracture_sacrum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiograph of the pelvis is from a 95-year-old male who sustained minimal trauma and complained of left groin pain. A fracture of the sacrum is not clearly visible on the first image (A) and perhaps a little more prominent on the magnified view (B) and best seen when highlighted and magnified on image C (arrow). Fractures of the left sided superior and inferior pubic rami are also present (double arrow). These findings are consistent with insufficiency fractures of the left sacral ala and pubic ramus.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 85973 Version 3.0</div></div></div>"},"85974":{"type":"graphic_diagnosticimage","displayName":"CT scan insufficiency fracture of the sacrum","title":"CT scan insufficiency fracture of the sacrum","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">CT scan insufficiency fracture of the sacrum</div><div class=\"cntnt\"><img style=\"width:598px; height:249px;\" src=\"images/RADIOL/85974_CTscan_insuf_frac_sacrum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The computed tomography (CT) scan of the pelvis reveals a subtle fracture of the left sacral ala&nbsp;(A, red arrow) and is magnified and highlighted in B.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 85974 Version 2.0</div></div></div>"},"85975":{"type":"graphic_figure","displayName":"Pathogenesis of CLL-SLL","title":"The pathogenesis of chronic lymphocytic leukemia / small lymphocytic lymphoma","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">The pathogenesis of chronic lymphocytic leukemia / small lymphocytic lymphoma</div><div class=\"cntnt\"><img style=\"width:527px; height:451px;\" src=\"images/HEME/85975_Pathogenesis_of_CLL-SLL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pathogenesis of CLL/SLL is complex, but appears to follow a two-step model of progression. First, monoclonal B cell lymphocytosis (MBL) develops as a result of genetic changes, some of which are thought to be the product of an abnormal response to antigenic stimulation. A second event, occurring at random rather than through cumulative damage, results in the accumulation of tumor cells and progression to CLL/SLL. Signs and symptoms are related to the accumulation of functionally incompetent lymphocytes in the bone marrow, lymph nodes, and other organs.</div><div class=\"graphic_footnotes\">MBL: monoclonal B cell lymphocytosis; CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma.</div><div id=\"graphicVersion\">Graphic 85975 Version 2.0</div></div></div>"},"85976":{"type":"graphic_table","displayName":"Further laboratory testing for pediatric hyperkalemia","title":"Initial diagnostic studies to assess unexplained hyperkalemia in a child","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial diagnostic studies to assess unexplained hyperkalemia in a child</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">In a child with no obvious risk factor for hyperkalemia and normal volume status, repeat testing of serum/plasma potassium from a free flowing venous sample to differentiate true significant hyperkalemia from pseudohyperkalemia</td> </tr> <tr> <td class=\"subtitle2_left\">In a child with unexplained&nbsp;true hyperkalemia based on repeated testing:</td> </tr> <tr> <td class=\"indent1\">Complete blood count, platelets, and serum lactic dehydrogenase (LDH) to assess for blood dyscrasia or hemolysis</td> </tr> <tr> <td class=\"indent1\">Serum creatine kinase (CK) to detect muscle injury</td> </tr> <tr> <td class=\"indent1\">Blood electrolytes (sodium, potassium, bicarbonate, chloride) to detect other electrolyte abnormalities such as metabolic acidosis </td> </tr> <tr> <td class=\"indent1\">Serum creatinine and blood urea nitrogen to assess renal function</td> </tr> <tr> <td class=\"indent1\">Urinalysis to detect renal disease</td> </tr> <tr> <td class=\"indent1\">Urine chemistries (urine should be obtained at same time or within a brief time of blood studies): <ul> <li>Urine potassium values should be greater than 20 mEq/L </li> <li>Urine sodium values less than 20 mEq/L suggest increased proximal sodium absorption and a decrease in sodium delivery in the distal tubule resulting in impaired potassium excretion due to limited availability of sodium for exchange </li> </ul> </td> </tr> <tr> <td class=\"indent1\">If there is a clinical concern for endocrinopathy, obtain serum aldosterone and plasma renin activity</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 85976 Version 2.0</div></div></div>"},"85977":{"type":"graphic_figure","displayName":"Positions for insertion of contraceptive devices","title":"Positions for insertion of contraceptive devices","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Positions for insertion of contraceptive devices</div><div class=\"cntnt\"><img style=\"width:476px; height:637px;\" src=\"images/OBGYN/85977_Positions-for-insertion-of-contraceptive-devices.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The woman should use&nbsp;the position that&nbsp;is most comfortable for her when inserting her diaphragm.</div><div id=\"graphicVersion\">Graphic 85977 Version 1.0</div></div></div>"},"85978":{"type":"graphic_table","displayName":"Pediatric hyperkalemia rapid overview","title":"Pediatric hyperkalemia management rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric hyperkalemia management rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td>Serum potassium<span style=\"color: black;\"> level&nbsp;5 to 7 mEq/L: Generally asymptomatic</span></td> </tr> <tr> <td><span style=\"color: black;\">Serum potassium level&nbsp;greater than&nbsp;7 mEq/L: Muscle weakness, paralysis, and cardiac changes on electrocardiography and arrhythmias. Sudden arrest may occur.</span></td> </tr> <tr> <td class=\"subtitle2_left\"><span style=\"color: black;\">Causes</span></td> </tr> <tr> <td><span style=\"color: black;\">Pseudohyperkalemia, usually due to hemolysis of the blood specimen, is the most likely cause of an elevated serum or plasma potassium level in children. It does not reflect true hyperkalemia and is not associated with cardiac conduction disturbances.</span></td> </tr> <tr> <td>The 2 major mechanisms of true hyperkalemia and their major causes are: <ul> <li>Increased potassium release from cells, most commonly due to rhabdomyolysis (eg, crush injury, prolonged seizure, hyperthermia, or exercise), tumor lysis syndrome, massive transfusion, and metabolic acidosis </li> <li>Reduced urinary potassium excretion, most commonly due to severe hypovolemia, impaired renal function, or hypoaldosteronism (eg, adrenal insufficiency) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory evaluation</td> </tr> <tr> <td>Laboratory tests are based upon probable etiology. All patients with true hyperkalemia should have the following tests obtained: <ul> <li>Blood urea nitrogen (BUN) </li> <li>Creatinine </li> <li>Blood glucose </li> <li>Serum electrolytes </li> <li>Urinalysis&nbsp; </li> <li>Urine electrolytes </li> </ul> <p>&nbsp;</p> In cases where rhabdomyolysis is suspected, the following studies are also indicated: <ul> <li>Serum creatine kinase and lactic dehydrogenase </li> <li>Urine for myoglobin </li> <li>Blood gas </li> </ul> <p>&nbsp;</p> In cases where adrenal insufficiency is suspected, additional testing includes: <ul> <li>Serum cortisol and ACTH (prior to administration of exogenous corticosteroids) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Electrocardiogram (ECG) changes*</td> </tr> <tr> <td class=\"indent1\">ECG findings commonly progress as follows: <ul> <li>Peaked T waves </li> <li>Prolonged PR and QRS intervals and small P waves </li> <li>Loss of P wave, further prolongation of QRS interval (\"sine wave\" pattern), and conduction delay that can manifest as bundle branch or atrioventricular (AV) nodal block </li> <li>Ventricular fibrillation or asystole </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Management</td> </tr> <tr> <td><strong>Confirm the patient is truly hyperkalemic</strong> (ie, exclude pseudohyperkalemia) by obtaining a venous or arterial blood sample that is not hemolyzed for rapid analysis</td> </tr> <tr> <td><strong>Obtain ECG and place patient on a cardiac monitor</strong></td> </tr> <tr> <td><strong>The following specific therapies are listed according to their effectiveness and rapidity of action, the choice of intervention is dependent upon the severity of ECG changes and muscle weakness:</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Stabilize cardiac membranes with calcium:</strong> <ul> <li>Give <strong>only</strong> for hyperkalemia with significant ECG findings (eg, widening of the QRS complex or loss of P waves, but <strong>not</strong> peaked T waves alone) or severe arrhythmias thought to be caused by hyperkalemia or in patients with a potassium level &#8805;7 mEq/L. </li> <li>For <strong>perfusing patients</strong>, give <strong>calcium gluconate 10% </strong>solution&nbsp;60 mg/kg; given as 0.6 mL/kg diluted in an equal volume of D5W or NS, maximum 2 g (20 mL, 4.5 mmol) per dose IV or IO&nbsp;over&nbsp;5 minutes. Time to onset of action is immediate. May repeat in 10 minutes as needed for persistent ECG changes or arrhythmias.<sup>&#182;</sup> </li> <li>For <strong>cardiac arrest</strong>, give <strong>calcium chloride 10% </strong>solution 20 mg/kg given as 0.2 mL/kg, maximum 2 g (20 mL, 14 mmol) per dose; dilute in an equal amount of D5W or NS and give slow IV via central venous access or IO push; repeat&nbsp;in 10 minutes&nbsp;as needed for persistent arrest, ECG changes, or arrhythmias.<sup>&#916;</sup> </li> <li><strong>Calcium gluconate <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #000000;\"></span></strong><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #000000;\">is a vesicant but can be safely administered through a free-flowing peripheral line in patients with life-threatening hyperkalemia at the dilution shown. </span>Peripheral administration of <strong>calcium chloride </strong>is <strong>not </strong>recommended. Sodium bicarbonate should not be administered in the same line as calcium solutions because of the potential for precipitation. </li> <li>Because&nbsp;the effect of calcium is transient, patients with hyperkalemia also require concomitant or immediate treatments to shift potassium into cells and to remove potassium. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Shift potassium into cells:</strong></td> </tr> <tr> <td class=\"indent2\"> <p><strong>Insulin and glucose:</strong> Onset of action is 10 to 20 minutes. Only give if significant ECG changes&nbsp;<strong>or</strong> confirmed serum potassium &#8805;7 mEq/L.</p> Give regular insulin (dose of 0.1 units per kg, maximum dose of 10 units) along with dextrose (glucose) dose of 0.5 g/kg over 30 minutes. The administration of dextrose is based upon the age of the patient as follows: <ul> <li>Children younger than 5 years of age: Give 10% dextrose (100 mg/mL) at a dose of 5 mL/kg </li> <li>Children 5 years of age and older: Give 25% dextrose (250 mg/mL) at a dose of 2 mL/kg </li> </ul> <p>&nbsp;</p> <p>For patients with severe acute symptoms, ECG changes, arrhythmias, or impending arrest: Larger doses of regular insulin (0.2 units/kg) and dextrose (1 g/kg, 10 mL/kg of 10% dextrose or 4 mL/kg of 25% dextrose) can be administered. </p> <p>Repeat dosing can be given after 30 minutes if needed. The major adverse effect is hypoglycemia, and serum glucose level should be monitored closely and additional dextrose administered as needed.</p> </td> </tr> <tr> <td class=\"indent2\"> <p><strong>Beta-2 agonist:</strong> Onset of action is 20 to 30 minutes.</p> Give nebulized albuterol (salbutamol) with dosing based upon patient weight as follows: <ul> <li>Neonates: 0.4 mg in 2 mL of saline </li> <li>Infants and small children &#60;25 kg: 2.5 mg in 2 mL of saline </li> <li>Children between 25&nbsp;and 50 kg: 5 mg in 2 mL of saline </li> <li>Older children and adolescents &#62;50 kg: 10 mg in 2 to 4 mL of saline (doses up to 20 mg have been used) </li> </ul> <p>&nbsp;</p> <p>Inhalation may be repeated after 20 minutes. Inhaled albuterol may also be administered by metered dose inhaler (MDI) as 4 to 8 puffs with spacer.</p> </td> </tr> <tr> <td class=\"indent2\"> <p><strong>Sodium bicarbonate:</strong> Onset of action is 15 minutes. Provides minimal effect on shifting potassium intracellularly and should <strong>not</strong> be the only therapy used in the management of hyperkalemia, even in acidotic children.</p> <p>Give 1 mEq/kg (1 mmol/kg). Maximum single dose of 50 mEq (50 mmol) which can be provided as 1 mL/kg of 8.4% solution or, for children less than 6 months of age, 2 mL/kg of 4.2% solution administered over 10 to 15 minutes.</p> <p>A repeat dose may be given 10 to 15 minutes after last administration. Do not give in the same IV line as calcium because of a risk of precipitation.</p> </td> </tr> <tr> <td class=\"indent1\"><strong>Remove potassium; since the effect of above therapies is transient, treatments to remove potassium are also required</strong></td> </tr> <tr> <td class=\"indent2\"><strong>Stop all potassium intake</strong></td> </tr> <tr> <td class=\"indent2\"><strong>Loop diuretic:</strong> Provides only limited short-term effect. Give furosemide 1 mg/kg IV (maximum single dose of 40 mg); higher dose may be required with renal insufficiency; fluid losses must be replaced unless the patient is volume expanded. The onset of effect is 1 to 2 hours. May be repeated after 6 hours.</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Cation exchange resin (sodium polystyrene sulfonate):</strong> Give sodium polystyrene sulfonate (without sorbitol) at a dose of 1 g/kg (maximum dose of 30 g) orally, through nasogastric tube, or as a retention enema. 1 g of resin will bind 1 mEq (mmol) of potassium. Onset is approximately 1 to 2 hours; may repeat dose after 4 to 6 hours based upon repeat serum potassium.</p> <p>Sodium polystyrene sulfonate should not be used in preterm neonates, term neonates with intestinal hypomotility and/or those at risk for necrotizing enterocolitis, postoperative patients, or those with bowel obstruction or ileus. Sorbitol can cause intestinal necrosis and should be avoided. A laxative that contains no magnesium or potassium (eg, lactulose) is an alternative to sorbitol use to prevent colonic impaction.</p> </td> </tr> <tr> <td class=\"indent2\"><strong>Hemodialysis:</strong> In children unresponsive to diuretic or cation exchange resin therapy, or with severe renal dysfunction, dialysis may be necessary to remove excess potassium from the body. Hemodialysis is the preferred modality to reduce potassium levels as it is the quickest and most controlled renal replacement treatment.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACTH: adrenocorticotrophic hormone; D5W: dextrose 5% solution in water; NS: normal saline; IV: intravenous; IO: intraosseus.<br />* Large interpatient variability exists in the relationship between the serum potassium and electrocardiogram (ECG) changes; at a given serum potassium, ECG changes are more common with acute elevations and less common with chronic elevations (eg, chronic kidney disease). Infants generally have a higher range of normal potassium levels, so ECG changes are usually observed at higher values.<br />¶ Conversions: 10% calcium gluconate = 100 mg/mL calcium gluconate = 9.3 mg/mL elemental calcium = 0.23 mmol/mL calcium; suggested dose of 60 mg/kg (perfusing patient) is equivalent to a dose of elemental calcium 5 mg/kg (0.15 mmol/kg) up to a&nbsp;maximum of 180 mg elemental calcium (4.5 mmol) per dose. <br />​Δ Conversions: 10% calcium chloride = 100 mg/mL calcium chloride = 27.3 mg/mL elemental calcium = 0.68 mmol/mL calcium; suggested dose of 20 mg/kg (cardiac arrest) is equivalent to a dose of elemental calcium 5 mg/kg (0.15 mmol/kg) up to a maximum of 540 mg elemental calcium (14 mmol) per dose. </div><div id=\"graphicVersion\">Graphic 85978 Version 9.0</div></div></div>"},"85980":{"type":"graphic_figure","displayName":"Mobilization of the hepatic flexure for colon cancer","title":"Mobilization of the hepatic flexure for colon cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mobilization of the hepatic flexure for colon cancer</div><div class=\"cntnt\"><img style=\"width:427px; height:460px;\" src=\"images/SURG/85980_Mobilization of the hepatic flexure for colon cancer.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 85980 Version 1.0</div></div></div>"},"85981":{"type":"graphic_figure","displayName":"Retroperitoneoscopic bilateral adrenalectomy position","title":"Retroperitoneoscopic bilateral adrenalectomy position","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Retroperitoneoscopic bilateral adrenalectomy position</div><div class=\"cntnt\"><img style=\"width:525px; height:334px;\" src=\"images/SURG/85981_Retro-bilateral-position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the patient in the prone position and endoscopic instrument placement for performing a retroperitoneoscopic bilateral adrenalectomy.</div><div id=\"graphicVersion\">Graphic 85981 Version 1.0</div></div></div>"},"85982":{"type":"graphic_figure","displayName":"Retroperitoneoscopic unilateral adrenalectomy position","title":"Retroperitoneoscopic unilateral adrenalectomy position","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Retroperitoneoscopic unilateral adrenalectomy position</div><div class=\"cntnt\"><img style=\"width:533px; height:336px;\" src=\"images/SURG/85982_Retro-unilateral-position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the optimal position of the patient on the operating room table&nbsp;for a unilateral retroperitoneascopic adrenalectomy.</div><div id=\"graphicVersion\">Graphic 85982 Version 2.0</div></div></div>"},"85983":{"type":"graphic_table","displayName":"Interactions between antiepileptic drugs and cytotoxic drugs","title":"Interactions between antiepileptic drugs and cytotoxic drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interactions between antiepileptic drugs and cytotoxic drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">AED</td> <td class=\"subtitle1\">CTDs that decrease AED concentration</td> <td class=\"subtitle1\">CTDs that increase AED concentration</td> <td class=\"subtitle1\">CTDs whose concentrations are lowered by AED</td> <td class=\"subtitle1\">CTDs whose toxicity is increased by AED</td> </tr> <tr class=\"divider_bottom\"> <td>Phenytoin</td> <td> <p>Nitrosourea</p> <p>Cisplatin</p> <p>Etoposide</p> <p>Dacarbazine</p> <p>Doxorubicin</p> <p>Carboplatin</p> <p>Vinblastine</p> <p>Methotrexate</p> <p>Bleomycin</p> Dexamethasone</td> <td> <p>5-FU</p> <p>Tegafur</p> <p>Tamoxifen</p> </td> <td> <p>Busulfan</p> <p>Vincristine</p> <p>Methotrexate</p> <p>Paclitaxel</p> <p>Topotecan</p> <p>Irinotecan</p> <p>9-Aminocampthotecin</p> <p>Teniposide</p> Dexamethasone</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Carbamazepine</td> <td> <p>Cisplatin</p> Doxorubicin</td> <td>&nbsp;</td> <td> <p>Vincristine</p> <p>Methotrexate</p> <p>Paclitaxel</p> <p>9-Aminocampthotecin</p> Teniposide</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Valproic acid</td> <td> <p>Methotrexate</p> <p>Cisplatin</p> Doxorubicin</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>Nitrosoureas</p> <p>Cisplatin</p> Etoposide</td> </tr> <tr> <td>Phenobarbital</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>Thiotepa</p> <p>Nitrosoureas</p> <p>Vincristine</p> <p>Methotrexate</p> <p>Paclitaxel</p> <p>9-Aminocampthotecin</p> <p>Teniposide</p> <p>Procarbazine</p> Prednisone</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AED: antiepileptic drugs; CTD: cytotoxic drugs.</div><div class=\"graphic_reference\">Reproduced from: DeAngelis LM, Posner JB, Neurologic Complications of Cancer, 2nd, Oxford University Press, New York, 2009; by permission of Oxford Universtiy Press, Inc. <a href=\"http://www.oup.com/\" target=\"_blank\">www.oup.com</a>. Copyright &copy; 2009.</div><div id=\"graphicVersion\">Graphic 85983 Version 8.0</div></div></div>"},"85984":{"type":"graphic_table","displayName":"Neuroleptic malignant syndrome diagnostic criteria","title":"Neuroleptic malignant syndrome diagnostic criteria: Expert panel consensus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuroleptic malignant syndrome diagnostic criteria: Expert panel consensus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"90%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Diagnostic criterion</td> <td class=\"subtitle1_single\">Priority score*</td> </tr> <tr> <td>Exposure to dopamine antagonist, or dopamine agonist withdrawal, within past 72 hours</td> <td>20</td> </tr> <tr> <td>Hyperthermia (&#62;100.4&#176;F or &#62;38.0&#176;C on at least 2 occasions, measured orally)</td> <td>18</td> </tr> <tr> <td>Rigidity</td> <td>17</td> </tr> <tr> <td>Mental status alteration (reduced or fluctuating level of consciousness)</td> <td>13</td> </tr> <tr> <td>Creatine kinase elevation (at least 4 times the upper limit of normal)</td> <td>10</td> </tr> <tr> <td>Sympathetic nervous system lability, defined as at least 2 of the following: <ul class=\"decimal_heading\"> <li>Blood pressure elevation (systolic or diastolic &#8805;25 percent above baseline) </li> <li>Blood pressure fluctuation (&#8805;20 mmHg diastolic change or &#8805;25 mmHg systolic change within 24 hours) </li> <li>Diaphoresis </li> <li>Urinary incontinence </li> </ul> </td> <td>10</td> </tr> <tr> <td>Hypermetabolism, defined as heart-rate increase (&#8805;25 percent above baseline) AND respiratory-rate increase (&#8805;50 percent above baseline)</td> <td>5</td> </tr> <tr class=\"divider_bottom\"> <td>Negative work-up for infectious, toxic, metabolic, or neurologic causes</td> <td>7</td> </tr> <tr> <td>&nbsp;</td> <td><strong>Total: 100</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">No threshold score has been defined and validated for us in making a diagnosis of NMS.</div><div class=\"graphic_footnotes\">* The mean priority score indexes each criterion according to its relative importance in making a diagnosis of neuroleptic malignant syndrome (NMS) according to an expert panel.</div><div class=\"graphic_reference\">Gurrera RJ, Caroff SN, Cohen A, et al. An International Consensus Study of Neuroleptic Malignant Syndrome Diagnostic Criteria Using the Delphi Method. The Journal of Clinical Psychiatry, Volume 72, Pages 1222-8, 2011. Copyright &copy; 2011, Physicians Postgraduate Press. Reprinted with permission.</div><div id=\"graphicVersion\">Graphic 85984 Version 5.0</div></div></div>"},"85990":{"type":"graphic_table","displayName":"Infant HIV prophylaxis regimen","title":"Infant antiretroviral prophylaxis to prevent perinatal HIV transmission in resource-rich settings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infant antiretroviral prophylaxis to prevent perinatal HIV transmission in resource-rich settings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"subtitle1_left\" colspan=\"4\">Selection of infant prophylaxis regimen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"2\">Treatment status of mother</td> <td class=\"subtitle2_left\" colspan=\"2\">Prophylaxis regimen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Mothers on antepartum ART with viral load &#8804;1000 copies/mL</td> <td colspan=\"2\">Zidovudine for 4 to 6 weeks*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Mothers who: <ul class=\"decimal_heading\"> <li>Received no antiretrovirals during pregnancy or </li> <li>Received only intrapartum antiretrovirals or </li> <li>Received antepartum ART but have viral load &#62;1000 copies/mL </li> </ul> </td> <td colspan=\"2\">Combination antiretroviral prophylaxis:<sup>&#182;</sup> <ul class=\"decimal_heading\"> <li><em>Three-drug regimen</em> <ul> <li>Zidovudine for 6 weeks plus </li> <li>Treatment-dose nevirapine for 2 to 6 weeks plus </li> <li>Lamivudine for 2 to 6 weeks </li> </ul> </li> </ul> OR <ul class=\"decimal_heading\"> <li><em>Two-drug regimen</em> <ul> <li>Zidovudine for 6 weeks plus </li> <li>Prophylaxis-dose nevirapine for three doses </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Drug dosing</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Agent</td> <td class=\"subtitle2_left\">Gestational age at birth</td> <td class=\"subtitle2_left\">Dose</td> <td class=\"subtitle2_left\">Duration</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #b6dde8;\"> <td class=\"subtitle2_left\" colspan=\"4\">For all HIV-exposed infants, to be initiated as soon after delivery as possible</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #b6dde8;\"> <td class=\"indent1\" rowspan=\"3\">Zidovudine</td> <td>&#8805;35 weeks</td> <td> <ul> <li>4 mg/kg orally twice daily </li> </ul> OR <ul> <li>Simplified weight band dosing (listed as volume of 10 mg/mL oral syrup twice daily) <ul> <li><em>2 to &#60;3 kg:</em> 1 mL </li> <li><em>3 to &#60;4 kg:</em> 1.5 mL </li> <li><em>4 to &#60;5 kg:</em> 2 mL </li> </ul> </li> </ul> </td> <td>Birth through 4 to 6 weeks*</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #b6dde8;\"> <td>&#8805;30 to &#60;35 weeks</td> <td> <ul> <li><em>Birth to age 2 weeks:</em> 2 mg/kg orally twice daily </li> <li><em>Age 2 to 6 weeks:</em> 3 mg/kg orally twice daily </li> </ul> </td> <td>Birth through 6 weeks</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #b6dde8;\"> <td>&#60;30 weeks</td> <td> <ul> <li><em>Birth to age 4 weeks:</em> 2 mg/kg orally twice daily </li> <li><em>Age 4 to 6 weeks:</em> 3 mg/kg orally twice daily </li> </ul> </td> <td>Birth through 6 weeks</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #fabf8f;\"> <td class=\"subtitle2_left\" colspan=\"4\">Additional prophylaxis (to add to zidovudine) for high risk infants: Three drug combination antiretroviral regimen option<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #fabf8f;\"> <td class=\"indent1\">Nevirapine (treatment dose)</td> <td>&#8805;34 weeks</td> <td> <ul> <li><em>Birth to age 4 weeks:</em> 6 mg/kg orally twice daily </li> <li><em>Age 4 to 6 weeks:</em> 200 mg/m<sup>2</sup> body surface area orally twice daily </li> </ul> </td> <td>Birth through 2 to 6 weeks</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #fabf8f;\"> <td class=\"indent1\">Lamivudine</td> <td>&#8805;32 weeks</td> <td> <ul> <li><em>Birth to age 4 weeks:</em> 2 mg/kg orally twice daily </li> <li><em>Age 4 to 6 weeks:</em> 4 mg/kg orally twice daily </li> </ul> </td> <td>Birth through 2 to 6 weeks</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #d3edbf;\"> <td class=\"subtitle2_left\" colspan=\"4\">Additional prophylaxis (to add to zidovudine) for high risk infants: Two drug NICHD-HPTN 040/PACTG 1043 Study regimen option<sup>&#182;</sup></td> </tr> <tr style=\"background-color: #d3edbf;\"> <td class=\"indent1\">Nevirapine (prophylaxis dose)</td> <td>N/A</td> <td> <ul> <li><em>Birth weight 1.5 to 2 kg:</em> 8 mg/dose orally </li> <li><em>Birth weight &#62;2 kg:</em> 12 mg/dose orally </li> </ul> </td> <td>Three doses in the first week of life: <ul class=\"decimal_heading\"> <li>Within 48 hours of birth </li> <li>48 hours after 1<sup>st</sup> dose </li> <li>96 hours after </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Infant antiretroviral prophylaxis should be initiated as soon after delivery as possible, ideally within 6 to 12 hours after.</div><div class=\"graphic_footnotes\">ART: antiretroviral treatment.<br />* Four weeks of zidovudine prophylaxis is reserved for infants of mothers who had a suppressed viral load throughout pregnancy and no adherence concerns.<br />&para; For most infants who warrant combination antiretroviral prophylaxis, we typically use the three-drug regimen in efforts to maximize prevention of transmission, although there are no comparative data evaluating its superiority over the two-drug regimen. The optimal duration is also uncertain. We typically administer it for six weeks, although an alternative approach if an HIV viral test at birth is negative is to discontinue nevirapine and lamivudine after two weeks and continue zidovudine alone for a total of six weeks.</div><div class=\"graphic_reference\">Adapted from: Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf</a> (Accessed March 16, 2017).</div><div id=\"graphicVersion\">Graphic 85990 Version 6.0</div></div></div>"},"85991":{"type":"graphic_picture","displayName":"ALCL small cell peripheral blood","title":"Peripheral blood ALK positive anaplastic large cell lymphoma, small cell variant","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Peripheral blood ALK positive anaplastic large cell lymphoma, small cell variant</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/HEME/85991_ALCLsmclperiphbld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear with numerous small lymphoma cells. Wright-Giemsa stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Ioachim’s Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85991 Version 6.0</div></div></div>"},"85992":{"type":"graphic_picture","displayName":"ALCL hallmark cells","title":"ALK positive anaplastic large cell lymphoma, classical variant ","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">ALK positive anaplastic large cell lymphoma, classical variant </div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/HEME/85992_ALCLhallmarkcells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lymphoma cells are large and anaplastic. Hallmark cells with horseshoe-shaped nuclei and perinuclear hofs are present (arrows). Hematoxylin-eosin stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Ioachim’s Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85992 Version 7.0</div></div></div>"},"85993":{"type":"graphic_picture","displayName":"ALCL immunohistochemistry","title":"ALK+ anaplastic large cell lymphoma immunohistochemistry","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">ALK+ anaplastic large cell lymphoma immunohistochemistry</div><div class=\"cntnt\"><img style=\"width:475px; height:364px;\" src=\"images/HEME/85993_ALCLimmunohistochem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunohistochemistry with hematoxylin counterstain.<br />(A) The lymphoma cells are strongly positive for ALK with a cytoplasmic pattern of staining.<br />(B) All of the neoplastic cells are strongly positive for CD30 in a membranous and paranuclear, dot-like pattern (target-like).<br />(C) The neoplastic cells are negative for CD3. Small reactive T cells are positive and serve as an internal control. <br />(D) The neoplastic cells are positive for EMA (MUC1).</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Ioachim’s Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85993 Version 6.0</div></div></div>"},"85995":{"type":"graphic_picture","displayName":"ALCL classical variant","title":"Anaplastic large cell lymphoma, classical variant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anaplastic large cell lymphoma, classical variant</div><div class=\"cntnt\"><img style=\"width:240px; height:181px;\" src=\"images/HEME/85995_ALCLclassvariant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Case of the common pattern of anaplastic large cell lymphoma shows cohesive clusters of large tumor cells with chromatin-poor nuclei and prominent nucleoli. Some tumor cells reveal the characteristic kidney-shaped nucleus (arrow). Hematoxylin and eosin, 40x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85995 Version 6.0</div></div></div>"},"85996":{"type":"graphic_picture","displayName":"ALCL small cell variant","title":"Anaplastic large cell lymphoma, small cell variant","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Anaplastic large cell lymphoma, small cell variant</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/85996_ALCLsmallcellvariant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Case of the small-cell pattern shows predominantly small tumor cells. Large tumor cells are concentrated around the blood vessels. Hematoxylin and eosin, 40x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85996 Version 6.0</div></div></div>"},"85997":{"type":"graphic_picture","displayName":"ALCL lymphohistiocytic variant","title":"Anaplastic large cell lymphoma, lymphohistiocytic variant","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Anaplastic large cell lymphoma, lymphohistiocytic variant</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/85997_ALCLlymphohistiovariant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Case of the lymphohistiocytic pattern reveals abundant histiocytes intermixing with ALCL tumor cells. Hematoxylin and eosin, 40x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85997 Version 6.0</div></div></div>"},"85998":{"type":"graphic_picture","displayName":"ALCL sinusoidal infiltration","title":"Anaplastic large cell lymphoma sinusoidal infiltration","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Anaplastic large cell lymphoma sinusoidal infiltration</div><div class=\"cntnt\"><img style=\"width:504px; height:370px;\" src=\"images/HEME/85998_ALCLsinusoidinfiltration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Case of common pattern demonstrates a sinusoidal infiltration pattern. Hematoxylin and eosin, 20x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 85998 Version 6.0</div></div></div>"}};